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Abstract
In epidemiological studies low birthweight predicts development of hypertension,
insulin resistance, glucose intolerance and dyslipidaemia (together described as the
'Metabolic Syndrome') and subsequent cardiovascular disease in adult life. The
mechanisms are unknown but may involve disturbances of the hypothalamic-
pituitary-adrenal (HPA) axis.
In animal models, manipulation of the in utero environment by maternal
undernutrition, treatment with dexamethasone or physical restraint, results in low
birthweight offspring with hypertension and insulin resistance in adult life. These
early life events have long-term effects on the HPA axis, resulting in elevated basal
and stress-induced glucocorticoid secretion and subtle changes in HPA axis
regulation. Glucocorticoid receptor (GR) and mineralocorticoid receptor expression
are decreased in the hippocampus, one of the most sensitive targets for
glucocorticoid negative feedback effects in rodents, but increased in the amygdala, a
site ofpositive modulation ofHPA axis activity.
Although the human evidence is limited, glucocorticoid excess (in Cushing's
syndrome) is associated with development of the Metabolic Syndrome and therefore
it is plausible that more subtle variations in glucocorticoid action contribute to the
pathogenesis of risk factors for cardiovascular disease. Moreover, in adult men,
higher fasting morning plasma Cortisol concentrations are associated with higher
blood pressure, plasma glucose and triglyceride concentrations, and lower
birthweight. These studies have led to the hypothesis that events in early life
permanently alter or 'programme' Cortisol secretion and that this leads to a high
prevalence of the Metabolic Syndrome and cardiovascular disease in adulthood. The
aim of this thesis was to study the HPA axis in detail, examining aspects of both
activity of the axis and Cortisol action, in order to determine variations that could
explain the link between low birthweight and subsequent development of
cardiovascular risk factors.
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The principal findings were that men aged 66-77 years, who were of low birthweight
and / or with the Metabolic Syndrome, have activation of the HPA axis with
increased Cortisol response to ACTH1.24 and increased urinary Cortisol metabolite
excretion. In contrast to rats programmed by dexamethasone administration during
pregnancy, there was no evidence of altered central feedback sensitivity to low dose
dexamethasone. However, dexamethasone may not cross the blood-brain barrier at
low doses in man, so that this only tests the pituitary component of the negative
feedback loop. Alternatively, rather than impaired central negative feedback, the
activation of the HPA axis could be due to increased forward drive to ACTH and
Cortisol secretion from higher centres. Consistent with this hypothesis there was lack
of habituation to the stress of repeated venepuncture in diabetic subjects.
In contrast to the central GR changes, peripheral (liver) GR expression is increased
in the rodent model. Tissue-specific differences in GR levels are a potential
mechanism whereby subtle abnormalities in Cortisol action could contribute to
variations in insulin sensitivity in the population. Using competitive quantitative
RT-PCR, GR mRNA levels were determined in total RNA extracted from skeletal
muscle biopsies from 23 men in Uppsala, Sweden who had been studied at age 70
years with an oral glucose tolerance test and a euglycaemic hyperinsulinaemic
clamp. Increased GR expression was associated with resistance to insulin-mediated
glucose uptake, independent of obesity. Using 5'-RACE-PCR (Rapid Amplification
of cDNA ends) it was demonstrated that one mechanism for tissue-specific
differences in GR is effects upon one or more multiple alternate promoters of the GR
gene.
Thus variations in HPA axis activity may be a key mechanism to explain the effects
of early life events on later cardiovascular disease and offers potential for new
therapeutic strategies to reduce cardiovascular risk. Understanding of the molecular
mechanisms involved in glucocorticoid programming and the consequences of
permanently altered glucocorticoid activity may provide novel insights into the
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Recent epidemiological studies have shown that events in early life are associated
with the development of subsequent cardiovascular disease and metabolic disorders.
It has been proposed that these associations arise as a result of the phenomenon of
'programming', whereby stimuli during crucial periods of development produce
permanent changes in cellular or tissue structure and function (Barker 1998).
Although the mechanisms are unknown, several hypotheses have been put forward to
explain the epidemiological associations. These include inadequate fetal nutrient
supply sufficient to reduce fetal growth (Hales and Barker 1992), certain genetic
factors (Dunger et al. 1998; Hattersley and Tooke 1999) and programming of major
endocrine axes controlling growth and development, particularly the hypothalamic-
pituitary-adrenal (HPA) axis (Edwards et al. 1993; Seckl 1998). There is growing
evidence from animal studies that adverse influences in prenatal or early post-natal
life permanently alter the biological and behavioural responses in the adult offspring
through long-term changes in the set-point of central and peripheral sensitivity to
glucocorticoid hormones. In humans, glucocorticoid excess in Cushing's syndrome
is associated with development of higher blood pressure, plasma glucose and
triglyceride concentrations (i.e. the Metabolic Syndrome), and therefore more subtle
variations in activity of glucocorticoids have been implicated in development of
these cardiovascular risk factors. Indeed, higher fasting morning plasma Cortisol
concentrations are associated with the Metabolic Syndrome and also with lower
birthweight (Phillips et al. 1998; Phillips et al. 2000). These preliminary studies
suggest that events in early life permanently alter or 'programme' Cortisol secretion
and that this may be a fundamental mechanism underlying the association between
low birthweight and the development of metabolic disorders and cardiovascular
disease in adult life. The aims of this thesis were to determine the aspects of the
HPA axis and Cortisol action which vary and the consequences of permanently
altered glucocorticoid activity, in humans of low birthweight and / or with the
Metabolic Syndrome.
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1.2 Early life events and disease in adulthood
1.2.1 The fetal origins hypothesis
An increasing number of epidemiological studies have shown events in early life are
associated with development of disease in adulthood. In population studies, low
birthweight or thinness at birth predicts subsequent Type 2 diabetes mellitus, insulin
resistance, hypertension, dyslipidaemia and ischaemic heart disease (Barker et al.
1993a; Barker et al. 1993b; Fall et al. 1995; Curhan et al. 1996; Forrester et al. 1996;
Leon et al. 1996; Barker 1998). This has led to the 'fetal origins' hypothesis which
proposes that adaptations made by the fetus in response to undernutrition lead to
permanent changes in physiology and metabolism which in turn predispose to
cardiovascular, metabolic and endocrine diseases in adult life. Environmental factors
acting at critical periods of development during which cells are rapidly dividing can
'programme' development of fetal tissues and organ structure and may alter
expression of the fetal genome. This leads to permanent effects on a wide range of
physiological processes, ultimately resulting in later dysfunction and disease (Barker
1998; Edwards et al. 1993).
1.2.1a Coronary heart disease
The proposal that the in utero environment could influence subsequent coronary
heart disease originated from observations of infant mortality rates among babies born
in Britain during the early 1900s. Neonatal death rates differed considerably across the
country, being highest in some of the northern industrial towns and the poorer rural
areas in the north and west. This geographical pattern closely resembles the variations
in death rates in adults from coronary heart disease, suggesting that similar factors
contribute to both newborn deaths and adult death rates from coronary artery disease.
Thus it was proposed that low rates of growth before birth are linked to the
development of coronary heart disease in adult life (Barker and Osmond 1986).
The early epidemiological studies linking the early environment to the aetiology of
coronary heart disease were based on studies ofmen and women in middle and late life
whose birthweight and body measurements at birth were routinely recorded. At the
turn of the 20th century, when perinatal mortality rates were high and there was
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concern about the physical deterioration of the British population, nurses were
trained to attend women in childbirth and to advise mothers on how to keep their
babies healthy. From 1911, midwives attended all pregnant women in Hertfordshire,
U.K., recording each baby's birthweight and notifying the births to the County
Medical Officer of Health. The local health visitor visited each baby at home at
intervals throughout infancy, recording its illnesses and development on a card.
When the baby was one year old and the visits ceased, the card was given to the
county health visitor and the details transferred to ledgers. In 1986, the MRC
Environmental Epidemiology Unit in Southampton discovered the East Hertfordshire
ledgers (which had been maintained until 1945) in the County Record Office. These
records were the largest set discovered in a systematic search for archives and records
in Britain.
The National Health Service Central Register at Southport was used to trace men and
women with intact birth records, who were born in Hertfordshire from 1911 to 1930.
Among 10 141 of these men, death rates from coronary heart disease fell progressively
with increasing birthweight and weight at 1 year of age (Barker et al. 1989). An
inverse relationship between low birthweight and coronary artery disease has
subsequently been confirmed in studies ofmen in Uppsala, Sweden (Leon et al. 1996);
Caerphilly, South Wales (Frankel et al. 1996); and Helsinki, Finland (Forsen et al.
1997); among 80 000 women in the American nurses study (Rich-Edwards et al. 1997);
and in men and women in Mysore, South India (Stein et al. 1996). These relationships
are strong and continuous, and represent birthweights within the normal range, not
just severely undersized babies (Barker et al. 1990; Curhan et al. 1996).
1.2.1b Glucose intolerance, hypertension and the Metabolic Syndrome
The trends in the association of cardiovascular disease and birth size are paralleled by
similar associations in two of the major risk factors for cardiovascular disease, Type 2
diabetes mellitus and hypertension. The trends are strong: in 370 Hertfordshire men,
aged 65 years, the prevalence of Type 2 diabetes mellitus and impaired glucose
tolerance (IGT) fell from 40% among men who weighed < 5.5 lb (2.54 kg), to 14%
among those who weighed > 9.5 lb (4.31 kg) (Hales et al. 1991). The trends are also
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consistent: the inverse relationship between birth size and altered glucose metabolism
has been demonstrated in 30 studies of adults throughout the world (Phillips et al.
1998; Law et al. 2001), while 70 studies, involving more than 440,000 individuals
have replicated the association between birth size parameters and hypertension (Law
and Shiell 1996; Huxley et al. 2000). Although it is not known at what age the
increased risk of disease appears, children of low birthweight have abnormalities in
glucose and insulin homeostasis at 4 and 7 years of age (Law et al. 1995; Yajnik et
al. 1995), and have higher blood pressure than their contemporaries at 8 years of age
(Moore et al. 1996).
Birthweight is a summary measure of fetal growth and development in utero. Where
data are available on other anthropometric measurements at birth, including body length
and head circumference, they show that suboptimal fetal growth, in particular thinness
at birth (that is a low ponderal index: birthweight/length ) or stunting of growth,
predicts atherosclerotic vascular disease in later life (Hales et al. 1991; Phillips et al.
1994a; Lithell et al. 1996; Forsen et al. 1997). Subjects with thinness at birth have a
higher prevalence of the 'Metabolic Syndrome' ('Insulin Resistance Syndrome' or
'Syndrome X'), the coexistence of glucose intolerance, hypertension and
dyslipidaemia (Reaven and Hoffman 1987; Barker et al. 1993b), suggesting that
these diseases result from a common intrauterine insult.
1.2.1c Potential confounding factors
It has been suggested that people who were exposed to an adverse environment in utero
and failed to grow, continue to be exposed to an adverse environment in childhood and
adult life, and it is this later adverse environment that produces the effects attributed to
programming in utero. But there is little evidence to support this argument. Rather,
associations between birthweight and raised adult blood pressure or glucose intolerance,
are found in each social group, and are independent of adult lifestyle influences such as
smoking, alcohol intake and obesity (Barker et al. 1995). Adult obesity does, however,
add to the intrauterine effects such that the highest prevalence of Type 2 diabetes
mellitus and IGT is seen in those people whom were small at birth but become obese as
adults (Hales et al. 1991; Lithell et al. 1996).
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1.3 Mechanisms linking birthweight to later disease
Despite the compelling epidemiological evidence, the molecular and cellular
mechanisms that explain a link between reduced fetal growth and later adult disease
are not understood.
1.3.1 Genes versus environment
It is conceivable that the link between low birthweight and disease in adulthood
reflects the effects of genes that reduce fetal growth and predispose the individual to
disease later in life. Insulin, for example, plays a key role in fetal growth and thus a
genetically determined impairment of insulin action could explain the association
between low birthweight and later diabetes (Hattersley and Tooke 1999). Diabetes
caused by a mutation of the glucokinase gene, encoding a glucose-sensing protein
expressed in the pancreas regulating insulin secretion, is associated with a 500 g
birthweight reduction (Hattersley et al. 1998). As well as genes modulating insulin
secretion, genes determining insulin resistance could also impair fetal growth, as has
been demonstrated in transgenic mice lacking key intermediates in the insulin
receptor signalling mechanism (Tamemoto et al. 1994). Common allelic variation at
the variable number of tandem repeat (VNTR) locus in the insulin promoter region of
the insulin gene, a polymorphism previously shown to be associated with insulin
resistance and Type 2 diabetes, is linked with a 200 g increase in birthweight
(Dunger et al. 1998). However, the influence of the polymorphism is much smaller
that the stronger birth size effect in the Hertfordshire cohort (Ong et al. 1999) and so
cannot explain all of the link between low birthweight and Type 2 diabetes.
Several sources of evidence suggest that it is the maternal environment, rather than
genetic factors, that is the dominant influence on birth size. The strong influence of
the mother is demonstrated in half-sibling studies showing a stronger correlation
between the birthweights of half-siblings sharing the same mother, than among those
sharing the same father (Morton 1955). The importance of the maternal environment
is also supported by animal cross breeding experiments and by embryo transfer
experiments; a fetus transferred to a larger uterus will attain a larger birth size (Snow
1989). In monozygotic twin studies, the twin who was lighter at birth is at the
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greatest risk of Type 2 diabetes mellitus (Poulsen et al. 1997). As these twins have
the same genetic background the difference in birthweight must be independent of
genetic factors. Further evidence against a genetic basis for the association between
low birthweight and adult disease is that prominent post-natal catch-up growth is
itself a risk factor for subsequent development of hypertension (Levine et al. 1994,
Eriksson et al. 1999), ischaemic heart disease (Osmond et al. 1993) and insulin
resistance (Leon et al. 1996), suggesting that smallness at birth due to intrauterine
environmental growth restraint, rather than genetic smallness, is important in
determining the risk of later disease. Moreover genetic factors play a minor role in
determining birth weight with up to 62% of the variation in birthweight between
individuals estimated as the result of the intrauterine environment (Penrose 1954).
1.3.2 Maternal undernutrition
In animal studies, poor maternal nutrition during crucial periods of fetal growth
impairs fetal growth and permanently affects the structure and physiology of several
organs and tissues. In rats, dietary restriction of protein during pregnancy lowers
birthweight and leads to subsequent glucose intolerance and hypertension in
adulthood (Langley and Jackson 1994; Hales et al. 1996). A reduced nutrient supply
to the fetal guinea pig induced by unilateral uterine artery ligation causes a lifelong
increase in blood pressure in the offspring (Persson and Jansson 1992). Thus in the
'thrifty phenotype hypothesis' (Hales and Barker 1992), the undernourished fetus
makes metabolic adaptations from which it benefits in the short term by increasing
fuel availability. These changes are permanently programmed and become
counterproductive in post-natal life when nutrition is not restricted.
The human evidence for the influence of maternal nutrition on the fetal origins of
adult disease is less clear. The Dutch famine from 1944 to 1945 was a natural
'experiment' of fetal undernutrition with a defined duration of exposure to famine.
Babies born to women starved during the famine in the last trimester of pregnancy
were of lower birthweight and developed glucose intolerance in adulthood (Ravelli et
al. 1998). This effect was independent of obesity. However, a cross-sectional study
of people born during and after the extreme siege of Leningrad in World War II
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showed no relationship between maternal undernutrition and subsequent diabetes
mellitus or hypertension (Stanner et al. 1997). Thus, maternal malnutrition seems
unlikely to be solely responsible for explaining the associations between birth weight
and subsequent adult disease. Moreover the importance of variations in maternal
nutrition within the 'normal range' as opposed to extreme starvation needs to be
established.
1.3.3 Glucocorticoids
An alternative mechanism by which reduced fetal growth could cause long term
effects is by either altering the set-point of hormonal axes that control growth and
development, or by changing the threshold of response of the tissue to the hormonal
stimulus. In response to undernutrition or other prenatal stressful stimuli, the fetus
reduces insulin secretion and increases secretion of several hormones that modulate
fetal and placental metabolism to increase fuel availability, redistribute blood flow,
and alter the rate and pattern of fetal growth. Levels of catabolic hormones such as
Cortisol, catecholamines and p-endorphins are increased, while concentrations of
anabolic hormones or growth factors including thyroxine, insulin, insulin-like growth
factors (IGFs) fall (Owens et al. 1989). Many of these hormones have well
characterised programming or imprinting effects, which occur during specific
developmental windows and persist throughout life. Recent studies have suggested
that the HPA axis plays a particularly important role and it has been proposed that
fetal exposure to glucocorticoids may link low birthweight and the predisposition to
diseases in adulthood (Edwards et al. 1993; Seckl 1998) (Figure 1.1). This
hypothesis is based on several pieces of evidence.
1.3.3a Steroids and programming
Steroid hormones have well-characterised programming effects. Neonatal androgen
secretion permanently programmes metabolic pathways in the liver, sexual
differentiation of the hypothalamus, and sexual behaviour, effects that persist
irrespective of subsequent sex steroid manipulations (Arai and Gorski 1968).













responses, effects largely mediated via altered expression of glucocorticoid receptors
in brain regions responsible for glucocorticoid feedback (Meaney et al. 1993).
1.3.3b Glucocorticoids and fetal growth
Glucocorticoids are essential for life, playing a key role in the regulation of fluid and
electrolyte homeostasis, blood pressure, the immune system, metabolism and
physiological responses to stress. During development, glucocorticoids are
important in regulating fetal growth and organ maturation (e.g. stimulating surfactant
production by the lungs), to prepare the fetus for extra-uterine life (Ballard 1979).
However, excessive fetal exposure to glucocorticoids causes growth retardation
(Reinisch et al. 1978) and human intrauterine growth retardation is associated with
elevated Cortisol levels (Goland et al. 1993). The fetus is normally protected from
high maternal levels of glucocorticoids by placental 11 P-hydroxysteroid
dehydrogenase type 2 (11 P-HSD2) (see 1.3.3c (iii)), which efficiently inactivates
most maternal Cortisol crossing the placenta (Benediktsson et al. 1993; Stewart et al.
1995). Activity of placental 11 P-HSD2 correlates with birthweight. The lowest
activity, exposing the fetus to increased glucocorticoid levels from the maternal
circulation, is seen in babies with the smallest birthweights (Stewart et al. 1995), thus
suggesting fetal glucocorticoid load is a critical factor during development.
The mechanisms by which glucocorticoids retard fetal growth are poorly understood
but are likely to involve other hormones and growth factors, particularly the IGFs.
Glucocorticoids inhibit IGF production (Luo et al. 1989; Price et al. 1992; Li et al.
1993) and increase IGF binding protein (IGFBP) expression (Luo and Murphy
1990), thereby antagonising IGF action and retarding fetal growth. Interestingly,
maternal high dose dexamethasone treatment induces fetal IGFBP-1 production
(Price et al. 1992) and transgenic mice overexpressing IGFBP 1 have low birthweight
and develop hyperglycaemia in adulthood (Rajkuhmar et al. 1995). Thus the IGF
system may be one pathway through which prenatal glucocorticoids could affect both
birthweight and control of glucose metabolism. This also could be a common
pathway for the programming effects of undernutrition as in sheep, maternal
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undernutrition elevates Cortisol (Fowden 1989) and suppresses fetal IGF-1 levels
(Oliver et al. 1993)
Indeed, it is possible that the effects of maternal undernutrition are partly mediated
by glucocorticoids. In the rat, maternal protein restriction attenuates placental 11 (3-
HSD2 activity (Langley-Evans et al. 1996), weakening the placental barrier and
significantly increasing fetal glucocorticoid load. Likewise, the hypertension
induced in the offspring by a maternal low protein diet is prevented by
pharmacological blockade of glucocorticoid biosynthesis and can be reintroduced by
replacement of corticosterone (Langley-Evans 1997).
Together this evidence suggests glucocorticoids play a central role in mediating
programming and that fetal glucocorticoid load is a critical factor in development.
Before examining the consequences of fetal over-exposure to glucocorticoids
(1.3.3f), the mechanisms of action of glucocorticoids will be described (1.3.3c). In
addition, through describing how glucocorticoids themselves induce insulin
resistance (1.3.3d) it will be seen that as well as mediating programming, variations
in action of glucocorticoids may be an important factor underlying the pathogenesis
ofmetabolic and cardiovascular disease (1.3.3e).
1.3.3c Mechanisms of glucocorticoid action
1.3.3c (i) The HPA axis (Figure 1.2)
Glucocorticoids (Cortisol in humans and other mammals, corticosterone in rats and
mice) are synthesized in the zona fasciculata/reticularis of the adrenal cortex under
the regulation of the HPA axis. Adrenocorticotrophic hormone (ACTH) produced by
corticotrophs in the anterior pituitary binds to adrenal cortex cell surface receptors
coupled to adenyl cyclase. This rapidly activates the first, and rate-limiting step in
the synthesis of steroid hormones i.e. removal of the cholesterol side-chain by side-
















Figure 1.2 The hypothalamic-pituitary-adrenal (HPA) axis
Schematic representation of the HPA axis showing factors determining Cortisol
action. Cortisol (F), secreted by the adrenal gland under regulation of CRH
(corticotrophin-releasing hormone) from the hypothalamus and ACTH
(adrenocorticotrophic hormone) from the pituitary circulates bound to CBG
(corticosteroid binding globulin). Free hormone diffuses into the target cell in which
interconversion of Cortisol and cortisone (E) by 11 |3-HSDs regulates access of
Cortisol to receptors (R) and subsequent regulation of target genes, including those
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ACTH is regulated by hypothalamic corticotrophin releasing hormone (CRH) and
arginine vasopressin (AVP). In the resting state, basal levels of CRH, AVP, ACTH
and Cortisol are released in a pulsatile and circadian fashion, regulated by the
suprachiasmatic nucleus of the hypothalamus, with plasma Cortisol levels peaking
prior to activity (i.e. in the morning in humans) and in response to 'stress'.
Glucocorticoid secretion is auto-regulated by a negative feedback loop whereby
glucocorticoids feedback to regulate secretion of CRH and ACTH at the level of the
hypothalamus and pituitary respectively (Orth et al. 1992; Chrousos 1995). Higher
centres, particularly the hippocampus, also play an important role in the negative
feedback inhibition of glucocorticoid secretion (Feldman and Conforti 1980;
Jacobson and Sapolsky 1991).
Circulating glucocorticoids are predominantly protein bound (Orth et al. 1992) to
corticosteroid binding globulin (CBG) (70-75%) and albumin (15-20%), while 5-
10% circulate as free steroid. Protein binding limits the concentration of free
biologically active hormone and protects the hormone against degradation by P-450
enzymes in the liver.
1.3.3c (ii) Steroid receptors
As with other members of the steroid hormone family, glucocorticoids exert their
actions by binding to intracellular receptors (Reviewed by Bamberger et al. 1996).
Glucocorticoids bind with differing affinity to two types of receptor. The low
affinity Type 2 or glucocorticoid receptor (GR) is widely distributed in brain and
periphery, while the Type 1 or mineralocorticoid receptor (MR) has a high affinity
for glucocorticoids but is more restricted in anatomical localization e.g. to distal
nephron, colon and sweat glands.
GR and MR belong to the structurally-related nuclear receptor superfamily, which
includes thyroid, retinoic and vitamin D receptors and a large group of orphan
receptors for which no specific ligand has been identified. Nuclear receptors are
highly specialised ligand-dependent transcription factors, which interact with specific
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cis-acting elements to enhance or repress target gene expression. GR can also
modulate gene expression by physically interacting with other transcription factors
such as AP-1 and NF-kB.
1.3.3c (iii) 11 P-hydroxysteroid dehydrogenase enzymes (11 p-HSDs)
Access to steroid receptors is regulated by local activity of the 11 P-hydroxysteroid
dehydrogenase enzymes (11 P-HSDs). These enzymes catalyse the interconversion
of physiologically active glucocorticoids (Cortisol in humans, corticosterone in rats)
to inert 11-keto products (cortisone and 11-dehydrocorticosterone, respectively)
(Murphy et al. 1974; Lopez-Bernal et al. 1980; Seckl 1993). 11 P-HSD2 in kidney
inactivates Cortisol, thus protecting MR from Cortisol (Edwards et al. 1988; Funder et
al. 1988; Brown et al. 1996). In contrast 11 P-HSD1 reactivates Cortisol from
inactive cortisone in many sites, ensuring adequate activation of GR (Jamieson et al.
1995).
1.3.3d Mechanisms of glucocorticoid induced insulin resistance
There are numerous potential sites of action for glucocorticoids to affect insulin
sensitivity (Reviewed by Andrews and Walker 1999). The principal effects of
glucocorticoids are to oppose the actions of insulin in the regulation of carbohydrate,
lipid and protein metabolism by effects on the three main target tissues of liver,
skeletal muscle and fat. Glucocorticoids increase blood glucose by mobilising
substrates for hepatic gluconeogenesis. They stimulate release of amino acids from
skeletal muscle, fatty acids and glycerol from adipose tissue, and increase expression
of gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase (PEP-CK)
(Hanson and Reshef 1997), so enhancing gluconeogenesis in the liver.
Glucocorticoids also stimulate glycogen synthesis by activating glycogen synthase
and inactivating the glycogen-mobilising enzyme glycogen phosphorylase.
Peripheral glucose uptake and utilization is inhibited by glucocorticoids, partly due
to decreased translocation of glucose transporters (GLUT 4) to the cell surface
(Dimitriadis et al. 1997). The acute effects of glucocorticoids on fat metabolism are
to stimulate lipolysis, providing gluconeogenic substrates (Boden 1997).
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In addition to the metabolic effects of glucocorticoids on peripheral glucose uptake,
glucocorticoids inhibit glucose-stimulated insulin secretion from pancreatic P-cells
(Delauney et al. 1997). Non-metabolic effects of glucocorticoids include impairment
of endothelium-dependent vasodilatation (Mangos et al. 2000), which is a potential
mechanism to alter regional blood flow and thereby reduce glucose delivery to
skeletal muscle.
The influence of glucocorticoids on insulin sensitivity is most apparent in clinical
syndromes of Cortisol excess or deficiency. In Cortisol deficiency (hypopituitarism
or hypoadrenalism (Addison's disease)), tissue sensitivity to insulin is increased. In
contrast in Cortisol excess (Cushing's syndrome), patients develop glucose
intolerance, hypertension and central obesity, i.e. the cluster of risk factors for
cardiovascular disease together described as the 'Metabolic Syndrome' (Reaven and
Hoffman 1987). It is therefore an attractive idea that less profound disturbances of
the HPA axis might underlie the Metabolic Syndrome and its link with obesity. Thus
it has been proposed that excessive activity of glucocorticoids within the 'normal'
physiological range, may contribute to the pathogenesis of insulin resistance and the
development of cardiovascular risk factors (Bjorntorp et al. 1999).
1.3.3e Glucocorticoid activity in subjects with the Metabolic Syndrome
The hypothesis that Cortisol contributes to the pathogenesis of essential hypertension
and Type 2 diabetes mellitus was rejected by many on the basis of small case-control
studies with very limited measurements ofCortisol secretion (Huther and Sholz 1970;
Vermeulen and Van der Straeten 1963). More recently, a series of studies have
examined the relationship between aspects of Cortisol secretion and tissue action and
cardiovascular risk factors. In case-control and cross-sectional studies higher blood
pressure, glucose intolerance, insulin resistance and hyperlipidaemia are associated
with elevated Cortisol concentrations in blood, saliva and urine (Watt et al. 1992;
Filipovsky et al. 1996; Stolk et al. 1996; Phillips et al. 1998; Rosmond et al. 1998;
Walker et al. 1998b; Fraser et al. 1999; Phillips et al. 2000) or impaired peripheral
inactivation ofCortisol (Walker et al. 1993; Soro et al. 1995; Walker et al. 1998b).
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Men with cardiovascular risk factors also have altered peripheral sensitivity to
glucocorticoids. Tissue sensitivity to Cortisol is partly determined by the density of
GR expression and can be assessed indirectly by measuring the intensity of dermal
blanching after topical administration of synthetic glucocorticoids. The dermal
vasoconstrictor response to glucocorticoids is increased in men with relative glucose
intolerance and insulin resistance (Walker et al. 1998b), and also in men with
essential hypertension (Walker et al. 1996), or with a familial predisposition to
hypertension (Walker et al. 1998a). This response is also enhanced in healthy
subjects who carry a polymorphism located with the restriction enzyme Bel I within
a non-coding part of the GR gene (Panarelli et al. 1998) which is associated with a
familial predisposition to hypertension (Watt et al. 1992) and with greater
hyperinsulinaemia (Weaver et al. 1992).
Together this evidence suggests that alterations in activity of the HPA axis whether
by increased circulating levels of Cortisol, increased GR sensitivity to Cortisol or
altered Cortisol metabolism, may contribute to the pathogenesis of insulin resistance
and the development of cardiovascular risk factors. Given the evidence from the
epidemiological studies showing an association between low birthweight and the
development of these cardiovascular risk factors, it has been proposed that
glucocorticoids are a key link between low birthweight and the predisposition to
diseases in adult life (Edwards et al. 1993; Seckl 1998). This hypothesis is supported
by animal data and accumulating evidence from human studies.
1.3.3f Programming of the HPA axis
In rats, prenatal exposure to excess exogenous (dexamethasone) or endogenous
(inhibition of 11-PHSD2 by carbenoxolone) glucocorticoids results in offspring of
low birthweight and permanently elevated blood pressure and glucose and insulin
levels in adulthood (Benediktsson et al. 1993; Lindsay et al. 1996). Such
manipulations of the early environment 'programme' permanent changes in HPA
axis regulation. These animals have impaired central negative feedback with
decreased GR expression in the hippocampus, one of the most sensitive targets in
rodents for glucocorticoid central negative feedback effects, resulting in increased
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basal or stress-induced plasma glucocorticoid levels (Langley and Jackson 1994;
Benediktsson et al. 1993; Levitt et al. 1996; Nyirenda et al. 1998). In contrast to the
decreased central GR expression, peripheral (hepatic) GR expression is increased in
association with up-regulation of the gluconeogenic enzyme PEP-CK (Nyirenda et
al. 1998). One mechanism for tissue-specificity which allows differential GR
regulation, is the use ofmultiple and tissue-specific promoters. In rat, the GR gene
contains 8 coding exons (2-9) and at least 11 alternate untranslated exon 1 sequences
(1 i-l ii), some of which are tissue-specific (McCormick et al. 2000). Importantly,
tissue-specific first exon usage is altered by perinatal environmental manipulations
(McCormick et al. 2000).
The evidence for programming of the HPA axis in humans is more limited. In a
study of 64 year old men born in Hertfordshire, those who had lower birthweight had
raised concentrations of fasting Cortisol, a crude measure of Cortisol secretion
(Phillips et al. 1998). Mean fasting plasma Cortisol concentrations fell progressively
from 408 nmol/1 among those whose birthweights were < 5.5 lb (2.5 kg) to 309
nmol/1 among those who weighed > 9.5 lb (4.31 kg) at birth. Elevated plasma
Cortisol concentrations were also associated with higher blood pressure, plasma
glucose and triglyceride concentrations (Phillips et al. 1998). These associations are
also observed in men and women in early adult life and middle-age (Phillips et al.
2000) (Figure 1.4), and children and adolescents with lower birthweight have been
reported to excrete more Cortisol or its metabolites in urine (Clark et al. 1996;
Harlandeta/. 1997).
These preliminary observations from human population studies, together with the
data from animal studies, raised the possibility of an important link between birth
size and adrenocortical activity in adult life. It has been proposed that events in early
life permanently alter or 'programme' Cortisol secretion and that this, together with
increased obesity, leads to a high prevalence of the Metabolic Syndrome and
cardiovascular disease in adult life. The aims of this thesis were to examine the
aspects of the HPA axis and glucocorticoid action involved in programming and also
the consequences ofpermanently altered glucocorticoid activity.
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1.4 Aims of thesis
A detailed study of the HPA axis was conducted in order to determine mechanisms
underlying the elevated 0900 h plasma Cortisol in men with low birthweight and/or
the Metabolic Syndrome. Studies were designed to elucidate whether the elevated
plasma Cortisol was due to impaired central negative feedback, increased drive to
Cortisol secretion and / or delayed clearance of Cortisol.
Feedback is traditionally tested using the dexamethasone suppression test, which
assesses central negative feedback suppression of ACTH and Cortisol secretion
(Liddle 1960). Chapter 2 explores the use of this test with a very low dose of
dexamethasone in order to reveal subtle variations in central feedback sensitivity,
and investigates whether the test could be combined with measurement of salivary
Cortisol, which might be preferable as an epidemiological tool.
In Chapter 3 the responses of the HPA axis to dynamic testing, and whether the
responses are linked with blood pressure or glucose intolerance are investigated in
the Hertfordshire population in whom the original observations of an association
between elevated 0900 h Cortisol and low birthweight were made. Central negative
feedback was tested using the very low dose dexamethasone suppression test
described in Chapter 2 and responsiveness of the HPA axis to stimulation was tested
using a very low dose short synacthen test. In addition, excretion of Cortisol and its
metabolites in urine was measured as an indication of clearance of Cortisol.
Although the mechanisms underlying variations in plasma Cortisol in subjects with
the Metabolic Syndrome are unknown, it is known that plasma Cortisol levels fall
during an oral glucose tolerance test (OGTT) (Rodman and Bleicher 1973; Sober et
al. 1977), and so this may be a useful tool for further determining acute differences
in HPA axis activity in subjects with the Metabolic Syndrome. However, it is not
known whether the fall in plasma Cortisol reflects the circadian fall in circulating
hormone or whether ingestion of glucose affects the response. In Chapter 4 this is
determined in a placebo-controlled study of the effect of oral glucose on circulating
plasma Cortisol, in both glucose intolerant subjects and normal controls. The
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findings of Chapter 4 enable interpretation of further measurements of Cortisol during
OGTTs in a larger cohort in Chapter 5. Here, whether the associations between
Cortisol and the Metabolic Syndrome are the same in women as in men are explored
and the confounding effect of obesity is examined.
Little is known about peripheral sensitivity to glucocorticoids in vivo in man, partly
due to limited accessibility of tissue for studying. Chapter 6 describes design of a
novel competitive quantitative RT-PCR assay for measuring GR mRNA levels. This
assay was used to quantitate GR expression in a rare collection of human skeletal
muscle biopsies from the Uppsala Longitudinal Study of Adult Men (McKeigue et
al. 1998), and to examine whether changes in GR expression in skeletal muscle were
associated with features of the Metabolic Syndrome.
Finally, a potential mechanism for differential and tissue-specific regulation of GR
expression (as has been observed in rats programmed by dexamethasone
administration in utero) was examined in Chapter 7 by looking for alternate
promoters of the human GR gene.
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Chapter 2
Validation of the overnight very low dose dexamethasone suppression test
2.1 Introduction
Subtle increases in the circulating concentrations of glucocorticoids have been
implicated in the aetiology of several common disorders including central obesity
(Ljung et al. 1996), depression (Carroll et al. 1981), the Metabolic Syndrome
(Bjorntorp 1993) and coronary artery disease (Brunner 1997). These changes in
glucocorticoid exposure may be mediated by alterations in the sensitivity of the
central feedback control of the HPA axis. These are demonstrable by administration
of the synthetic glucocorticoid, dexamethasone at night, which results in the
suppression of plasma Cortisol concentrations the following morning.
The conventional protocol for the overnight dexamethasone suppression test (DST)
(Liddle 1960) depends on the administration of between 1 and 2 mg dexamethasone
and is designed to identify patients with Cushing's Syndrome. However, the use of a
much lower dexamethasone dose, e.g. 0.25 mg (Best et al. 1997) may be more
informative in distinguishing physiological variations in HPA axis activity. Recently
it has been suggested that the very low dose test could be further refined by
measuring the overnight suppression of salivary rather than plasma Cortisol.
Measurement of salivary Cortisol levels offers several potential advantages enabling
it to become a useful epidemiological tool for population studies of HPA axis
function (Landon et al. 1982). These include simplicity of sample collection
allowing the test to be performed at home, the avoidance of venepuncture which
results in stress-induced hypercortisolaemia and that salivary measurements reflect
free plasma Cortisol levels which are less influenced by changes in CBG. Therefore,
before conducting the field study of the HPA axis in Hertfordshire, the
reproducibility of the very low dose DST was assessed by comparing Cortisol




The study group consisted of 29 healthy subjects, 14 men and 15 women. None had
a history of endocrine disease, or had received systemic or topical steroid treatment
within the previous 6 months. The study was approved by the Southampton and
South West Hampshire Health Authority and University of Southampton Joint
Ethical Committee.
In each subject two very low dose DSTs were performed at least one week but no
more than ten weeks apart. On the first day the subjects attended after fasting for 12
h and saliva and blood samples were collected at 0830 h. Between two and four ml
of saliva was collected into a salivette tube (Sarstedt Ltd., Leicester, U.K.). The
subjects took 0.25 mg dexamethasone at 2200 h the same night and attended the
following morning after a further 12 h overnight fast for collection of saliva and
blood samples at 0830 h. Plasma and saliva samples were separated by
centrifugation and stored at -80° C until analysis. The subjects also completed the 10
item General Health Questionnaire (cut off score for depression = score > 5) a
previously validated questionnaire for detecting depression (Yesavage et al. 1983 and
see Appendix Al question 9).
2.2b Anthropometry
The subjects' height was measured with a portable stadiometer (CMS weighing
equipment, Camden, London, U.K.) to the nearest 0.1 cm, avoiding digit-preference.
Subjects were measured standing upright and without shoes, with head placed in the
Frankfurt Plane, such that an imaginary line joining the upper margin of the external
auditory meatus and the lower border of the orbit of the eye was horizontal. Weight
was measured with a portable SECA scale (SECA Ltd., Birmingham, U.K.), without
shoes and in lightweight clothing, to the nearest 0.1 kg. Body mass index (BMI) was
calculated as the weight (kg) divided by the height (m) squared.
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Waist and hip circumferences were measured with a steel tape measure. Waist was
measured with the individual standing in the upright position, in a horizontal plane
midway between the superior iliac crest and the ribcage in the mid-axillary line, at
the end of normal expiration, to the nearest 0.1 cm. Hip circumference was measured
as the largest horizontal circumference at the maximum protrusion of the buttocks
with the feet together. The waist to hip ratio (WHR) was calculated as a measure of
central obesity.
2.2c Laboratory measurements
Cortisol was measured in plasma by radioimmunoassay (Guildhay antisera, Moore et
al. 1985). Cortisol and cortisone were measured in saliva by time-resolved
immunofluorescent assay ('DELFIA', Wood et al. 1997). The coefficients of
variation (CV) were 6.3% at 300 nmol/1 for plasma and 8.5% at 12 nmol/1 for saliva
assays.
2.2d Statistical analysis
As the distributions of Cortisol measurements were highly skewed, loge-transformed
values were used in all analyses. Bland-Altman plots (the differences between two
repeated measurements for each subject against the mean of those measurements)
were produced for post dexamethasone plasma and salivary Cortisol measures (Bland
and Altman 1986). From these the 95% range for the differences about their mean
was calculated and this used as an indication of repeatability. Fractional suppression
of Cortisol in plasma and saliva was calculated as (day 1 sample - day 2 sample) /
day 1 sample (%). Analysis advised by statistician HE Syddall, Southampton.
2.3 Results
The subjects were aged 24 - 54 (mean 35.1) years with BMI ranging from 17.9 to
31.3 (means 27.1 in men vs. 23.5 in women, p=0.001) kg/m2 and WHR ranging from
23
0.82 to 1.20 (mean 0.94) in men and 0.67 to 0.81 (mean 0.74) in women. None of
the subjects was depressed as indicated by the General Health Questionnaire. Table
2.1 shows the baseline and post dexamethasone suppression concentrations of
Cortisol measured in plasma and saliva.
Table 2.1. Mean (95% confidence interval) fasting plasma Cortisol and salivary
Cortisol concentrations before and after suppression with 0.25 mg dexamethasone in
duplicate tests carried out in 29 subjects at least one week apart
Baseline First phase Second phase
Mean Range Mean Range Mean Range













15.3 4.4-34.4 8.6 1.6-29.2 7.3 1.6-23.8
(nmol/1) (13.11,17.94) (6.65,11.08) (5.45,9.82)
The basal plasma Cortisol concentrations ranged from 232 to 958 nmol/1 (mean 270.4
nmol/1) and tended to be lower in the men than the women (371.4 vs 485.6 nmol/1,
p=0.06). The mean concentration of Cortisol measured after dexamethasone
suppression was similar for both tests as assessed by plasma (270.4 vs 265.1 nmol/1)
or saliva measurements (Cortisol 8.6 vs. 7.3 nmol/1, total Cortisol + cortisone, 37.6 vs.
29.4 nmol/1). Also the fractional suppression of plasma Cortisol, which was similar
on the two study phases (30.6% and 30.4%), was somewhat but not significantly
greater than the fractional Cortisol suppression measured in saliva (27.3% and
28.8%). Neither the fractional suppression nor the post dexamethasone Cortisol
measurements differed according to sex, age, BMI orWHR.
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The reproducibility of the post dexamethasone Cortisol concentrations obtained from
the two tests is illustrated by the Bland-Altman plots in Figures 2.1 and 2.2 (showing
the differences in Cortisol concentration at the two study phases plotted against the
mean). For plasma (Figure 2.1), the mean difference did not differ significantly from
zero (mean 0.02, p = 0.80). 95% of differences were within 0.78 loge units from the
mean (-0.76 to +0.80) indicating that a repeated plasma measurement could be
approximately half as small or twice as large as the first. For saliva (Figure 2.2), the
mean also did not differ significantly from zero (mean 0.16, p = 0.29), but 95% of
differences were within 1.64 loge units from the mean (-1.48 to +1.80), thus
indicating that a repeated saliva measurement could be approximately five times as
small or five times as large as the first. Saliva repeatability was no better when
cortisone was considered, either alone, when as a total of salivary Cortisol and
cortisone, or as a ratio ofmeasurements.
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Figure 2.1 Differences in loge (post-dexamethasone plasma Cortisol) concentrations
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Figure 2.2 Differences in loge (post dexamethasone salivary Cortisol) concentrations

































The results suggest that the use of salivary Cortisol measurement in the analysis of a
very low dose overnight DST is less reproducible than plasma Cortisol measurement.
For saliva the repeated measurement was as much as five times as small or five times
as large as the first for 95% of the time, while for plasma a repeated measurement
was only half as small or twice as large as the first.
Although the DST has gained increasing importance in studies examining the role of
abnormalities of the HPA axis in pathogenesis of several common diseases, there is
surprisingly little information on the reproducibility of the test. Charles et al. (1982)
showed similar levels ofHPA axis suppression in 17 of 19 depressed patients studied
on two occasions after the administration of 1 mg dexamethasone. A similar
conclusion was reached by Greden et al. (1983), who showed that 9 of 13 subjects
studied on two occasions had the same abnormal response to 1 mg dexamethasone,
defined by a threshold level of plasma Cortisol suppression. However, in these
studies of subjects with clear evidence of disease, no data was given on the
reproducibility of the test within individuals. Importantly the use of such a high dose
of dexamethasone would be expected to completely suppress the axis and hence be
more likely to result in reproducibly undetectable Cortisol levels. This contrasts with
this study where post dexamethasone Cortisol levels were well within the detection
limits of the assay showing an approximately 30% suppression and hence a greater
within-subject variability.
The poorer performance of the 0.25 mg DST based on salivary measurements is
difficult to explain. It was not due to assay imprecision as the 'DELFIA' assay used
has been shown to be reproducible over a wide range of Cortisol concentrations and
the assays for saliva and plasma had similar CVs. In addition, previous studies have
shown that saliva quantitatively reflects free plasma Cortisol, and therefore might be
expected to be a better index of dexamethasone suppression. Also, although salivary
Cortisol is converted to cortisone by 11P-HSD2 (Walker and Best 1995) the salivary
results were not significantly improved when the total of Cortisol and cortisone
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concentrations was considered. Thus the reason for the poor reproducibility of the
saliva measurement is unclear but may include sampling problems (e.g. variable
salivary flow rates) or a poor correlation between salivary and plasma Cortisol
concentrations at low (post dexamethasone) concentrations.
These data imply that the intrinsic variation in salivary Cortisol levels has been
underestimated. Because of the poorer repeatability of salivary measurements as
compared to plasma it was elected to measure Cortisol concentrations in plasma
following dexamethasone suppression in the field study.
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Chapter 3
Dynamic testing of the HPA axis in men with low birthweight and
cardiovascular risk factors
3.1 Introduction
The mechanisms underlying the association of Type 2 diabetes mellitus, raised blood
pressure and dyslipidaemia (i.e. the Metabolic Syndrome), and their exacerbation by
obesity, are not known, but are important in our understanding of the
pathophysiology of atheromatous disease. Since patients with Cushing's syndrome
develop these clinical features, it is an attractive idea that less profound disturbances
of the HPA axis might underlie the Metabolic Syndrome and its link with obesity.
In animal models, manipulation of the early environment 'programmes' permanent
changes in HPA axis regulation: rats exposed to glucocorticoids in utero have
impaired central negative feedback with decreased hippocampal GR expression and
increased basal or stress-induced plasma glucocorticoid levels (Levitt et al. 1996). In
studies of adult men higher fasting morning plasma Cortisol concentrations, a crude
measure of Cortisol secretion, are associated with higher blood pressure, plasma
glucose and triglyceride concentrations, and lower birthweight (Phillips et al. 1998;
Phillips et al. 2000). These studies have led to the hypothesis that events in early life
permanently alter or 'programme' Cortisol secretion and that this, together with
increased obesity, leads to a high prevalence of the Metabolic Syndrome and
cardiovascular disease in adult life.
The aim was to test this hypothesis in the Hertfordshire population in whom the
observations of an association between elevated 0900h plasma Cortisol and low
birthweight and / or the Metabolic Syndrome were made. The study was designed to
characterise abnormalities ofCortisol secretion in relation to features of the Metabolic




In 1991, 370 men born between 1920 and 1930 in East Hertfordshire, and still
resident there, underwent 75-g oral glucose tolerance tests (OGTTs) and blood
pressure measurements as part of a study examining the relationships between early
life events and subsequent glucose tolerance (Hales et al. 1991). Plasma Cortisol was
analysed in the fasting samples from this study in 1997 (Phillips et al. 1998). In
1997, the General Practitioners of the surviving 245 men were approached and asked
if they would be willing for their patients to be contacted again. Subjects were
contacted by letter and invited to take part in a cross-sectional study examining the
relationship between the early environment and the HPA axis. Subjects with clinical
evidence of pituitary or adrenal disease and those who had received oral
glucocorticoids in the previous 3 months were excluded. 205 men were suitable and
agreed to take part. Ethical approval was obtained from the East and North
Hertfordshire Health Authority Local Research Ethics Committee and written
informed consent was obtained from each subject.
3.2b Interview
The subjects were visited at home by one of four trained MRC nurses who
administered a questionnaire (see Appendix A 1). Information about medical and
social history, family history of diabetes and hypertension, smoking habits, alcohol
consumption and current medication was recorded. Mood was assessed by the 10
item General Health Questionnaire (Yesavage et al. 1983). The subjects were then
invited to attend a morning clinic at Hertford County Hospital for dynamic
suppression and stimulation tests of the HPA axis. They were given a tablet of 0.25
mg dexamethasone with instructions to take this at 2200 h on the night before the




Having taken 0.25 mg dexamethasone at 2200 h and fasted overnight, subjects
attended clinic the following morning. At 0830 h, a 21-gauge butterfly cannula was
inserted in an antecubital fossa vein. After 30 min rest, a baseline 10 ml venous
blood sample was collected into a lithium heparin vacutainer before 1 pg of freshly
diluted ACTH,_24 (tetracosactrin, Synacthen, Alliance, Chippenham, U.K.) was
injected as a bolus with a 10 ml 0.9% NaCl flush. The dilute solution of synacthen
was prepared by adding 250 pg to 50 ml of 0.9% NaCl in a 50 ml syringe. The
resulting solution (5 pg/ml) was mixed and used immediately after preparation. 10
ml venous blood samples were collected through the cannula at 20, 30, 40 and 60
min after ACTH,_24 administration. Samples were centrifuged immediately at 3,000
rpm for 20 min and plasma stored at -80°C for subsequent hormone analysis.
Dexamethasone (0.25 mg) and ACTH]_24 (1 pg) doses were selected to provide an
average 50-75% of maximal suppression or stimulation, respectively, with a wide
range (Best et al. 1997; Daidoh et al. 1995). More conventional doses (e.g. 1 mg
dexamethasone or 250 pg ACTH,.24) would be expected to produce maximal effects
in all of these otherwise healthy participants and would not detect subtle alterations
in the control of Cortisol secretion.
(ii) 24 h urine collection
At the preliminary interview, subjects were given written and oral instructions for a
24 h urine collection to be collected a week before or after the
dexamethasone/ACTH,.24 test. Standard bottles (of known weight) were issued and
collected by the nurses at a pre-arranged date. The urine collection was weighed, the
weight of the bottle subtracted and the total volume recorded in ml. Two 20 ml
aliquots were labelled and stored at -20°C for analysis of Cortisol and its metabolites.
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3.2d Anthropometry
Anthropometric measurements were recorded at the end of the clinic. As previously
described (Chapter 2.2b), height was measured using a portable stadiometer and
weight was measured with a portable SECA scale. BMI was calculated as the weight
(kg) divided by the height (m) squared. Waist and hip circumferences were
measured with a steel tape measure and WHR calculated as a measure of central
obesity.
Two inter/intra-observer studies for recording height, weight, waist and hip
measurements were conducted before and between clinics to ensure repeatability of
these measurements, both between and within individual staff. 12 subjects were
measured twice by each of the 4 nurses, who were blinded to their own and others'
measurements of each subject. There were no significant differences in the height,
weight, waist or hip measurements made between nurses.
3.2e Laboratory meaurements
(i) Plasma analysis
Plasma Cortisol was measured by RIA as before (see 2.2c) in samples at all time
points (T = 0, 20, 30, 40 and 60 min). RIAs were used to measure corticosteroid-
binding globulin (CBG) (Medgenics Diagnostics, Fleurus, Belgium) and
dexamethasone levels (enzyme-linked immunosorbent assay adapted from Cozart
Biosciences Ltd., Abingdon, Oxford) in the first sample (T = 0). In a subgroup of
men with contrasting birthweight (>9.5 lb (4.31 kg) or <6.5 lb (2.92 kg), n=12 in
each group), plasma dehydroepiandrosterone (Diagnostic Systems Laboratories, Inc.,
Webster, Texas, USA), 17-a-hydroxyprogesterone (in-house RIA) and progesterone
("Immulite" analyser, Diagnostic Products Ltd, Gwynedd, Wales) were measured.
Measurements of glucose, triglyceride and insulin concentrations which have been
reported previously (Hales et al. 1991) were used in the analysis.
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(ii) Urine analysis
Cortisol, cortisone and their metabolites (see Figure 3.1) were measured in urine by
gas chromatography/electron impact mass spectrometry following Sep-pak CI8
extraction, hydrolysis with [^-glucuronidase, and formation of the methoxime-
trimethylsilyl derivatives. Epi-cortisol and epi-tetrahydrocortisol were used as
internal standards (Best et al. 1997; Best and Walker 1997). Total Cortisol and
metabolite excretion was calculated as tetrahydrocortisols (THFs) +
tetrahydrocortisone (THE) + cortols + cortolones. Ratios of urinary metabolites were
used to infer relative activation of the principle enzymes metabolising Cortisol.
Relative reduction by 5a- and 5p-reductases was inferred from the 5p-THF/5a-THF
ratio. Total A-ring reduction of Cortisol was inferred from the ratio of cortisol/THFs
and 5p-reductase activity from the ratio of cortisone/THE. Whole-body equilibrium
between Cortisol and cortisone, determined by the balance of tissue-specific activities
of 11 P-reductase and 11 P-dehydrogenase activities, was inferred from the ratio of
THFs/THE. Renal 11 P-dehydrogenase activity was inferred from the urinary free
cortisol/cortisone ratio.
Urine creatinine was measured using the Jaffe reaction on the Bayer PLC (Newbury,
UK) "Advia" analyser.
3.2f Statistical analysis
To obtain normally distributed variables, measurements of glucose, triglycerides,
urinary Cortisol metabolites, peak Cortisol following ACTH,.24, and area under the
curve after ACTH,.24 for dehydroepiandrosterone and 17-a-hydroxyprogesterone,
were loge-transformed. Geometric means and sds are therefore presented for these
variables. Associations between continuously distributed variables were assessed by
the Pearson correlation coefficient, and associations between continuous and
categorical variables by the Mann-Whitney U-test or the two-sample t-test as
appropriate. Multiple linear regression was then used to explore the relationship
between continuously distributed response variables and possible explanatory
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used to analyse binary response variables. In addition to analysing the peak Cortisol
response to ACTH,.24 using the methods described above, a longitudinal analysis of
the Cortisol response to ACTH^ was also conducted. The longitudinal approach
considers the full series of Cortisol data for each subject and models the average
response during the test in relation to the factors of interest, taking into account the
effects of time, and the autocorrelation of Cortisol measurements within each subject
(Zeger and Liang 1996). All statistical analysis was carried out by statistician HE
Syddall, Southampton, using STATA, release 5; the xtgee feature was used to
implement the longitudinal analysis (Statacorp 1997, Stata Statistical Software
Release 5, College Station, TX: Stata Corporation).
3.3 Results
3.3.1 Subject characteristics andpotential confounders
The men were aged between 66 and 77 (mean 70.9, sd 3.1) years with a mean BMI of
26.9 (sd 3.7) kg/m2. Fifteen men had Type 2 diabetes mellitus (2 h glucose > 11.1
mmol/1) and 33 had impaired glucose tolerance (IGT) (2 h glucose 7.8 to 11.0
mmol/1). Mean systolic blood pressure was 161.5 mmHg (sd 22.1 mmHg) and 73
men were receiving treatment with antihypertensive drugs. Two subjects were
excluded from analysis of plasma Cortisol concentrations because of extreme values:
one had a vaso-vagal event after intravenous cannulation and the other was receiving
ethinyloestradiol treatment. Six men had missing values for glucose measurements.
None of the measurements of Cortisol in plasma or urine correlated with age or
differed in subjects receiving topical or inhaled corticosteroid therapy (n=l 6). None
of the differences in plasma Cortisol described below were accounted for by variation
in plasma CBG or dexamethasone concentrations.
3.3.1a Obesity
Obesity, reflected in increased BMI, was associated with higher blood pressure
(r=0.18, p=0.04), hypertriglyceridaemia (r=0.28, p=0.0001) and glucose intolerance
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(r=0.16, p=0.02). Obesity was also associated with a linear increase in total urinary
Cortisol metabolite excretion (r=0.19, p=0.006) but did not predict plasma Cortisol
after dexamethasone or ACTH,_24. Central obesity, reflected in increased WHR, was
associated with similar trends. In addition, increased WHR predicted marginally
lower plasma Cortisol following 0.25 mg dexamethasone (r=-0.13, p=0.06) and
disproportionately higher excretion of 5a- rather than 5(3-reduced metabolites of
Cortisol (r=-0.14, p=0.05). Obesity was not associated with altered ratios of
cortisol/cortisone metabolites. Increased lean body mass, as judged by urinary
creatinine excretion (Malina 1986) was also associated with higher total urinary
Cortisol metabolites (r=0.23, p=0.001). Neither the effects of obesity nor urinary
creatinine were independent predictors of total urinary metabolite excretion in
multiple regression analysis. Urinary creatinine was not associated with plasma
Cortisol concentrations.
3.3.1b Depression and social class
Men with a current or previous history of depression (n=12) had greater peak plasma
Cortisol concentrations after ACTH,_24 (474.0 (sd 1.1) versus 428.7 (sd 1.2) nmol/1,
p=0.03) and higher total urinary Cortisol metabolites (median (inter-quartile range)
22.4 (16.3, 48.2) versus 17.8 (11.3, 24.8) mg/24h, p=0.04). Men with manual
occupations (class IIIM-V, n=134) had no difference in plasma Cortisol
concentrations, but excreted less total Cortisol metabolites than men with non-manual
occupations (class I-IIIN, n=69) (15.9 (sd 2.1) versus 20.8 (1.8) mg/24h, p=0.008).
3.3.2 Associations with birthweight
Table 3.1 shows relationships between birthweight and Cortisol and its metabolites.
Lower birthweight was associated with a greater rise in plasma Cortisol
concentrations after ACTH,.24 and a later peak time (Figure 3.2), but no difference in
plasma Cortisol after dexamethasone. The inverse relationship between birthweight
and adrenal ACTH,.24 responsiveness remained after exclusion ofmen with IGT and
Type 2 diabetes mellitus and/or treated hypertension, and was not confounded by
obesity.
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Plasma Cortisol profiles during dexamethasone/ACTHi.24 test according to
birthweight
£>=0.03 from longitudinal analysis, interaction of Cortisol response by birthweight with time
• birthweight < 6.51b (2.92kg); ▲ -7.51b (3.41kg); ▼ - 8.51b (3.86kg); ★ - 9.51b (4.31kg);
• >9.51b (4.31kg)
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Differences in adrenocortical responses to ACTH,^ in a subgroup of men with
contrasting birthweight (>9.5 lb (4.31 kg) or <6.5 lb (2.92 kg), n=12 in each group)
were further explored by measurement of other ACTH-dependent adrenal steroids in
plasma. Men with lower birthweight also had higher levels of
dehydroepiandrosterone (mean area under curve: birthweight <6.5 lb 6.5 (sd 2.2)
nmol/l.hrs; >9.5 lb 4.9 (sd 1.5) nmol/l.hrs), 17-a-hydroxyprogesterone (birthweight
<6.5 lb 9.7 (sd 1.3) nmol/l.hrs; >9.5 lb 8.1 (sd 1.3) nmol/l.hrs) and progesterone
(birthweight <6.5 lb 3.6 (sd 0.5) nmol/l.hrs; >9.5 lb 3.1 (sd 0.7) nmol/l.hrs) indicating
that no common biosynthetic defect, such as 21-hydroxylase deficiency, accounts for
the difference in Cortisol response.
Total urinary Cortisol metabolite excretion was higher in men with the lowest and
highest birthweights (p=0.03 for quadratic trend). Although higher birthweight men
were not more obese, they were taller and heavier as adults (r=0.23, p=0.001) and
excreted more creatinine in urine (r=0.20, p=0.006), which could confound the
relationship with urinary glucocorticoid excretion. After adjustment for urinary
creatinine and obesity (either BMI or WHR) an inverse linear relationship, rather
than a quadratic trend, was evident such that low birthweight men excreted more
urinary Cortisol metabolites (r=-0.29, p=0.04). Birthweight was not associated with
Cortisol metabolite ratios.
3.3.3 Associations with features ofthe Metabolic Syndrome
Table 3.2 shows relationships between plasma Cortisol and urinary Cortisol
metabolites with blood pressure, glucose tolerance and fasting plasma triglyceride
concentrations, after correction for the potential confounding effects of obesity,
depression, social class, and urinary creatinine where appropriate. Plasma Cortisol
concentration at 0900 h following dexamethasone was not associated with
cardiovascular risk factors. However, peak plasma Cortisol concentration following
ACTHj.24 was higher in men with higher blood pressure and higher fasting plasma
triglyceride concentrations and tended to be higher in men with higher post-glucose
plasma glucose concentrations. Likewise, in a longitudinal analysis of the Cortisol
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profiles there were similar positive associations between mean plasma Cortisol
concentration and these features, with or without adjustment for potential
confounding factors. In men with all three features of the Metabolic Syndrome
(previously defined (Barker et al. 1993b) as systolic blood pressure >160 mmHg or
subject receiving anti-hypertensive therapy (n=120); the presence of IGT or Type 2
diabetes mellitus (n=48); fasting plasma triglyceride >1.4 mmol/1 (n=101)), peak and
mean plasma Cortisol concentration over time were significantly elevated. Total
urinary Cortisol metabolite excretion also tended to be greater in men with these
cardiovascular risk factors.
3.3.4 Predictors of the Metabolic Syndrome
Having examined individual features of the Metabolic Syndrome, logistic regression
modelling was then performed to identify predictors of combined features of the
Metabolic Syndrome (as defined above). Potential variables included age, social
class, birthweight, WHR, BMI, plasma Cortisol after dexamethasone, peak plasma
Cortisol after ACTH,_24, total urinary Cortisol metabolite excretion, and ratio of 5p-
/5a-reduced metabolites of Cortisol. The best fitting model identified effects ofBMI
(p=0.003), peak plasma Cortisol after ACTHj.24 (p=0.03) and birthweight (p=0.02).
The effect of birthweight was more significant when peak plasma Cortisol was
excluded (p=0.008), and the effect of peak plasma Cortisol was more significant
when birthweight was excluded (p=0.02) (see Figure 3.3). The estimated odds ratios
(95% CI) for the 'Metabolic Syndrome' are 1.18 (1.06-1.32) for a unit increase in
BMI, 1.55 (1.09-2.21) for a one pound decrease in birthweight, and 1.28 (1.02-1.61)
for a 50 nmol/1 increase in peak Cortisol concentration. Effects ofWHR were similar
to BMI.
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Figure 3.3
Relative risk of the Metabolic Syndrome according to current body mass index









* Relative to lowest peak and lowest BMI group
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3.4 Discussion
The principal findings are that men with low birthweight and features of the
Metabolic Syndrome have enhanced responsiveness of plasma Cortisol to ACTH^
and increased total urinary Cortisol metabolite excretion, but normal plasma Cortisol
after dexamethasone. Indeed, plasma Cortisol after ACTH,_24 accounts for much of
the effect of birthweight on features of the Metabolic Syndrome. These findings are
consistent with the hypothesis that low birthweight is associated with increased
activity of the HPA axis, and that this could contribute to the Metabolic Syndrome
and attendant risk of cardiovascular disease.
By contrast with Cortisol measurements in low birthweight men, these data show that
obesity was associated with lower plasma Cortisol following dexamethasone and no
difference in responses to ACTH,_24, in the face of increased urinary Cortisol
metabolite excretion, especially of 5a-reduced metabolites of Cortisol. The lower
plasma Cortisol may be explained by increased peripheral metabolism of Cortisol by
5a-reductases (Andrew et al. 1998). Indeed, increasing obesity and its associated
increase in lean body mass (reflected in higher creatinine excretion) amongst high
birthweight men confounded the relationship between birthweight and urinary
Cortisol metabolite excretion. This confounding effect resulted in a U-shaped
unadjusted relationship between birthweight and Cortisol metabolites, as described
previously (Clark et al. 1996).
The explanation for activation of the HPA axis in men with lower birthweight and
features of the adult Metabolic Syndrome remains unclear. Rats exposed to
glucocorticoids in utero have increased plasma glucocorticoid levels and lower levels
of GR in brain and pituitary gland, which may impair negative feedback control of
CRH and ACTH secretion (Levitt et al. 1996). If the same 'programming' of GR
expression occurred in man, then suppression of plasma Cortisol by dexamethasone
would be expected to be impaired in men with lower birthweight, but in this study it
was preserved. Indeed, since fasting plasma Cortisol is higher in low birthweight
men without dexamethasone (Phillips et al. 1998; Phillips et al. 2000), but not
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different post dexamethasone, the incremental effect of dexamethasone may be
greater. However, in mice the entrance of low doses of synthetic glucocorticoids
such as dexamethasone into the brain is blocked by a drug-exporting mdrla encoding
P-glycoprotein in the blood-brain barrier (Meijer et al. 1998). As mdr-1 is expressed
in endothelial cells of human capillary blood vessels at the blood-brain barrier
(Cordon-Cardo et al. 1989), P-glycoprotein could also regulate entrance of synthetic
glucocorticoids into the central nervous system in man (Karssen et al. 2001).
Therefore this low dose DST may only have tested the pituitary component of the
negative feedback loop.
Another possibility is that increased Cortisol secretion could result from increased
adrenocortical sensitivity to ACTH. The measurements of other ACTH-dependent
steroids exclude variance in Cortisol response due to sub-clinical 21-hydroxylase
deficiency (New 1998). Other corticosteroid biosynthetic defects which have been
proposed as being important in hypertension, such as 11 P-hydroxylase deficiency,
predict lower rather than higher Cortisol responses. Alternatively, the pattern of
Cortisol response to synacthen in low birthweight subjects with both an increased
peak and a slower decline raises the possibility that they may have impaired plasma
clearance of Cortisol not revealed by 24 hour urinary Cortisol analysis. Finally,
elevated plasma Cortisol may result from enhanced drive to CRH, ACTH and Cortisol
secretion from higher centres manifest as an increase in plasma Cortisol when
stressed on first sampling. Preliminary evidence supporting this proposal will be
discussed in Chapter 4.
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Chapter 4
Measurements of plasma Cortisol during oral glucose tolerance tests:
a preliminary study
4.1 Introduction
The mechanisms underlying the activation of the HPA axis in subjects with the
Metabolic Syndrome (as in Chapter 3) are unknown. Obese subjects also have
activation of the HPA axis (Marin et al. 1992; Pasquali et al. 1993; Andrew et al.
1998), but in contrast to the elevated plasma Cortisol in subjects with the Metabolic
Syndrome (Phillips et al. 1998; Phillips et al. 2000; Walker et al. 2000), plasma
Cortisol concentrations are low in obesity (Ljung et al. 1996; Walker et al. 2000). In
obesity, increased peripheral clearance of Cortisol may account for the compensatory
activation of the HPA axis (Andrew et al. 1998). Alternatively, a number of
metabolic responses to feeding may interact with the HPA axis, and be altered in the
Metabolic Syndrome. It is known that plasma Cortisol levels fall during an OGTT
(Rodman and Bleicher 1973; Sober et al. 1977) and rise during a protein meal
(Gibson et al. 1999). In the extreme, adrenal hypersensitivity to gastric inhibitory
peptide can result in 'food-induced Cushing's syndrome' (Lebrethon et al. 1998).
Therefore measurements of plasma Cortisol during OGTTs may be a useful tool for
revealing altered control of the HPA in the Metabolic Syndrome. However, it is not
known whether the fall in plasma Cortisol during the OGTT reflects the circadian fall
in circulating hormone or whether ingestion of glucose affects the response. The aim
was to determine this by performing the first placebo-controlled cross-over study of
the effect of oral glucose on circulating plasma Cortisol before measuring changes in
plasma Cortisol during OGTTs in a larger number of subjects (see Chapter 5). To
further explore the associations between Cortisol and glucose tolerance, both subjects




40 participants from the dexamethasone/ACTH,.24 study were invited to take part in a
further study of Cortisol dynamics during OGTTs. These men were selected by their
previous glucose tolerance data from 1991 with the aim of studying equal numbers
with glucose intolerance and normal controls.
Following an overnight fast, subjects attended a clinic at Hertford County Hospital at
0830 h for OGTTs. A 21-gauge butterfly cannula was inserted in an antecubital
fossa vein and after 30 min rest, a baseline blood sample was obtained. Subjects then
drank either 75 g oral glucose (as 389 ml Traditional Lucozade Sparkling Glucose
Drink) or placebo (identical in appearance and taste to Lucozade but containing no
glucose, supplied by SmithKline Beecham). They returned a week later for a repeat
test with the alternative solution in a single-blind crossover design. Venous blood
was sampled from the cannula at 30, 60, 90 and 120 min for measurement of plasma
glucose and insulin concentrations, following the glucose or placebo load. 29
subjects (17 glucose intolerant, 12 controls) received glucose in the first phase, while
10 subjects (5 glucose intolerant, 5 controls) received placebo first. Placebo and
glucose phases were separated by at least one week.
4.2b Laboratory measurements
Blood samples were centrifuged, processed immediately and stored at -80°C for
subsequent analysis. Plasma Cortisol was measured by RIA as before (see 2.2c).
Plasma glucose was measured by the hexokinase method and insulin by a two-site
immunometric assay with either 12T or alkaline phosphate labels.
4.2c Statistical analysis
As the distributions of Cortisol measurements were skewed, loge transformed
variables were used in all analyses. Independent 2-sample t-tests were used to
compare Cortisol concentrations for control compared with glucose intolerant
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subjects. ANOVA for repeated measures was used to analyse the plasma Cortisol
measurements during the glucose tolerance test. All analysis was conducted using
Statistica 6.0 1997. Methods were checked by statistician HE Syddall, Southampton.
4.3 Results
One subject completed only one phase of the study and was therefore excluded from
analysis. Using plasma glucose measurements following the 75 g oral glucose load,
22 subjects were defined as glucose intolerant (either IGT or Type 2 diabetes
mellitus, defined as in 3.3.1), and 17 subjects as normal controls.
4.3.1 Differences in plasma Cortisol between controls and glucose intolerant
subjects without glucose
In all subjects plasma Cortisol concentrations declined over the 120 min of the test
following placebo. Glucose intolerant subjects had significantly higher Cortisol
concentrations following placebo than controls (p=0.001) (Figure 4.1). This
difference was most marked at baseline and during the first 90 min of the test but was
no longer present at 120 min. The differences in Cortisol between glucose intolerant
subjects and controls were not accounted for by variations in CBG.
4.3.2 Effect of treatment with glucose on plasma Cortisol
Figure 4.2 shows that treatment with an oral glucose load blunted the circadian fall in
plasma Cortisol in both controls and glucose intolerant subjects (p=0.002). There was
no significant difference in the effect of the glucose load in controls compared with
those with glucose intolerance (controls p=0.02, glucose intolerant p=0.04,
interaction p=0.50).
4.3.3 Order of test: habituation to venepuncture
0900 h plasma Cortisol concentrations were significantly higher in the first phase of
the study than in the second phase in controls (p=0.01) (Figure 4.3). However, in
glucose intolerant subjects, 0900 h plasma Cortisol concentrations in the two study
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Figure 4.3
Effect of order of study phase on 0900 h plasma Cortisol in glucose intolerant
and control subjects
First phase, black columns', second phase, white columns
p = 0.01 for effect of order in control subjects; no significant order effect in glucose
intolerant subjects.
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phases were not different (p=0.18) as this measurement did not fall in the second
study phase.
4.3.4 Effect of treatment with glucose and order of test on plasma glucose and
insulin concentrations
Both plasma glucose and insulin concentrations were higher after treatment with
glucose than placebo (p<0.001) and were significantly higher in glucose intolerant
subjects than controls. In contrast to the plasma Cortisol concentrations, plasma
glucose and insulin concentrations were no different in the two study phases in either
glucose intolerant subjects or controls.
4.4 Discussion
Treatment with an oral glucose load blunted the normal circadian fall in plasma
Cortisol in both subjects with glucose intolerance and in normoglycaemic controls.
However, subjects with glucose intolerance had higher Cortisol concentrations
following placebo, suggesting that their normal diurnal fall in plasma Cortisol
differed from controls. Baseline plasma Cortisol concentrations were higher during
the first phase of the study in control subjects suggesting a stress response associated
with the novelty of first clinic attendance. In addition, subjects with glucose
intolerance had high plasma Cortisol concentrations at the second clinic attendance
suggesting a lack of habituation to repeated measurement of plasma Cortisol.
It is not known whether the fall in Cortisol during an OGTT reflects the circadian fall
in plasma Cortisol or whether glucose ingestion affects the response. These studies
were performed in the morning when any alterations in circadian rhythm should be
most clearly demonstrated. Indeed, subjects with glucose intolerance had higher
plasma Cortisol than controls during the first 90 min of the placebo phase of the
study. Altered diurnal rhythms of salivary Cortisol in subjects with glucose
intolerance have been reported (Rosmond et al. 1998), and this finding is consistent
with the associations between 0900 h plasma Cortisol and glucose intolerance
(Phillips et al. 1998; Phillips et al. 2000).
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Despite the differences in circadian fall of plasma Cortisol, the effect of glucose
ingestion was to raise plasma Cortisol in both normal and glucose intolerant subjects.
Plasma and salivary Cortisol concentrations rise following a meal (Rosmond et al.
1998), particularly if the meal is of high protein content (Gibson et al. 1999), as
protein ingestion stimulates pituitary ACTH secretion (Al-Damluji et al. 1987).
Although it has previously been suggested that carbohydrate ingestion has little effect
on the HPA axis (Ishizuka et al. 1983), this study now demonstrates that an oral
glucose load raises plasma Cortisol. It remains unknown whether this is a
consequence of the glucose load itself, or whether the associated insulin release
affects Cortisol metabolism. For example, insulin may modulate adrenal
steroidogenesis by inhibiting 17,20-lyase thereby favouring Cortisol synthesis in
preference to dehydroepiandrosterone and androstenedione (Nestler et al. 1992).
Insulin may also affect Cortisol metabolism by decreasing the activity of lip-HSDl
which acts primarily as a reductase mediating conversion of inactive cortisone to
active Cortisol (Jamieson et al. 1995). Insulin may also act centrally on the HPA axis
regulating drive, although results of studies to date are conflicting, either showing a
decreased Cortisol response to CRH following insulin infusion (Walker et al. 1994),
or increased ACTH secretion following supraphysiological hyperinsulinaemia
(Fruehwald-Shultes et al. 1999). However, as the effect of treatment with the
glucose load did not differ between glucose intolerant subjects and controls, it would
appear less likely that the hyperglycaemia or changes in insulin concentrations
associated with glucose intolerance influenced the fall in Cortisol concentrations
during the test.
An alternative hypothesis to explain the elevated plasma Cortisol during the glucose
tolerance test is a response to stress. To reduce any effect of stress the study was
conducted the study in familiar surroundings, with staff previously known to the
subjects. Yet fasting plasma Cortisol measured at the first phase attendance, and so
arguably the most stressful visit, was significantly higher than that at the second
phase in control subjects. Elevated plasma and salivary Cortisol concentrations are
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observed in situations of increased perceived stress (Rosmond et al. 1998) and the
stress of venepuncture is known to raise plasma Cortisol (Meeran et al. 1993). The
effect of psychosocial stress on raising Cortisol has also been reported to be greater
after a glucose load (Kirschbaum et al. 1997).
Most interestingly, glucose intolerant subjects also had high baseline plasma Cortisol
concentrations in the second phase of the study, indicating a lack of habituation to
repeated stress. A similar lack of habituation of blood pressure and heart rate
responses to repeated restraint stress is seen in spontaneously hypertensive rats
compared with normal controls (McDougall et al. 2000). As discussed in Chapter 3,
subjects with glucose intolerance and /or low birthweight have evidence of activation
of the HPA axis, which was not accounted for by differences in central feedback
sensitivity. The elevated plasma Cortisol from stress of repeated venous sampling
seen in this study would be consistent with the hypothesis that the activation of the




Predicting cardiovascular risk factors from plasma Cortisol measured during oral
glucose tolerance tests
5.1 Introduction
The findings in Chapter 3 show that there is activation of the HPA axis in the
Metabolic Syndrome, although the underlying mechanisms remain unclear. The data
also show that activation of the HPA axis is predicted by low birthweight, supporting
the hypothesis that it may result from permanent alteration in the central control of
the HPA axis as a result of events in early life (Seckl 1998). Indeed the findings in
Chapter 4 are consistent with increased central drive to Cortisol secretion. However,
in Chapter 4, plasma Cortisol following an oral glucose load did not differ in subjects
with glucose intolerance compared with normoglycaemic controls. Also, in another
study plasma Cortisol measured 2 hours following an oral glucose load was less
predictive of cardiovascular risk than the fasting measurement (Walker et al. 2000),
suggesting that the fall in Cortisol might be less in subjects with the Metabolic
Syndrome.
Most of the published cross-sectional studies relating Cortisol levels to cardiovascular
risk factors have been performed in men, whereas most of the case-control studies of
Cortisol in obese subjects have included women. Therefore it is not known whether
the associations of Cortisol with the Metabolic Syndrome are the same in women and
the extent to which these relationships are confounded by obesity. The aim therefore
was to measure plasma Cortisol during OGTTs in a larger number of both men and
women to determine correlates of changes in plasma Cortisol with features of the





The Hertfordshire cohort has been previously described (Chapter 3.2a). 370 of these
men underwent 75-g OGTTs in 1991. Measurements of blood pressure and height,
weight, waist and hip circumferences were recorded (Hales et al. 1991). The other
subjects were participants from another epidemiological study conducted by the
MRC Environmental Epidemiology Unit in Southampton. Between 1935 and 1943,
a standardised record form was kept for each woman admitted to the Sharoe Green
Hospital in Preston, Lancashire, England. This record included the date of the
mother's last menstrual period and the baby's birthweight, placental weight (both
recorded in pounds), and length from crown to heel and head circumference (both
recorded in inches). The National Health Service central register was used to trace
503 people born in the hospital between 1935 and 1943, and still living in
Lancashire. In 1993, 266 men and women living in or close to Preston attended
Sharoe Green Hospital for a 75-g OGTT. Anthropometric measurements and blood
pressure were recorded (Phipps et al. 1993).
5.2b Laboratory measurements
Plasma Cortisol was assayed by RIA in the fasting, 30 min and 120 min samples from
the OGTT (see 2.2c). There was sufficient plasma for complete Cortisol results from
339 men in the Hertfordshire cohort and 254 subjects (135 men, 119 women) in the
Preston cohort. None of the subjects had pituitary or adrenal disease and two
subjects on oral prednisolone treatment were excluded from the Preston analysis.
5.2c Statistical analysis
The area under the Cortisol curve (Cortisol AUC) was used as a summary
measurement of plasma Cortisol during the OGTT by calculating the area under the
trapezium described by the Cortisol measurements at baseline, 30 min and 120 min
(units h.nmol/1). Likewise the areas under the glucose (glucose AUC) and insulin
(insulin AUC) curves during the OGTT were calculated. In addition, the percentage
decline in Cortisol from baseline to 120 min during the OGTT was calculated as
100*( (logecortisol 0 min-logecortisol 120 min) / logecortisol 0 min). The insulin
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increment, a previously validated index of insulin secretion (Phillips et al. 1994b),
was calculated from the plasma measurements during the OGTT as loge((insulin 30
min - insulin 0 min)/(glucose 30 min - glucose 0 min)). The distributions of
measurements of blood pressure, triglycerides, cholesterol, Cortisol, glucose, insulin
and AUCs were loge-transformed and geometric means and sds are presented. As the
distribution of BMI was positively skewed in the Preston data set but was not
satisfactorily transformed by the loge transformation, Fisher-Yates normal-scores for
BMI were used as a measure of obesity. Pearson correlation coefficients were
computed to examine the pair-wise associations between variables. Associations
between Cortisol, BMI and glucose and insulin measurements during the OGTT were
investigated by multiple linear regression. All statistical analysis was conducted by
statistician HE Syddall, Southampton.
5.3 Results
5.3.1 Subject characteristics
Table 5.1 shows the characteristics of the participants and the measurements of
plasma glucose, insulin and Cortisol during the OGTT. The Hertfordshire men were
older but of similar BMI to the Preston men. The Preston men and women were of
similar ages but the men were of higher BMI (p=0.01) and WHR (pO.OOOl). The
Preston men had higher glucose AUC (p<0.001 unadjusted, p=0.002 adjusted for
BMI) and tended to have higher insulin AUC during the OGTT (p=ns) than the
women. Blood pressure was higher in men than in women.
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Table 5.1 Characteristics of participants
Hertfordshire Preston Preston
Mean (sd)a men men women
(n=339) (n=135) (n=119)
Age (y) 64.6 (3.2) 51.8 (2.2) 51.3 (2.4)
BMI (kg/m2) 26.9 (3.6) 25.7 (3.4) 24.7 (4.4)
WHR 0.9(0.1) 0.9(0.1) 0.8(0.1)
Number with IGT/Type 2 DM n=84 n=14 n=20
Plasma glucose (mmol/l)
Fasting 6.1 (1.2) 5.8(1.1) 5.4(1.1)
30 min 9.4(1.2) 9.0(1.3) 7.5 (1.3)
120 min 6.6 (1.4) 5.5 (1.3) 5.8 (1.3)
Glucose AUC (h.mmol/1) 16.0(1.3) 14.7(1.2) 13.4(1.3)
Plasma insulin (pmol/l)
Fasting 43 (1.9) 45(1.7) 42(1.6)
30 min 275 (1.9) 288 (1.7) 249(1.7)
120 min 150(2.4) 147 (2.2) 178 (2.0)
Insulin AUC (h.pmol/1) 425 (1.8) 439 (1.6) 420(1.6)
Insulin increment (pmol/mmol) 70.5 (2.3) 81.4 (2.2) 94.2 (2.1)
Plasma Cortisol (nmol/l)
Fasting 320(1.4) 427 (1.3) 403 (1.4)
30 min 349 (1.5) 425 (1.5) 362 (1.4)
120 min 259 (1.4) 276(1.4) 245 (1.4)
Cortisol AUC (h.nmol/1) 634(1.4) 749(1.4) 656 (1.3)
Systolic blood pressure (mmHg) 164(1.2) 138(1.2) 130(1.2)
Diastolic blood pressure (mmHg) 90(1.1) 78 (1.1) 73 (1.2)
Triglycerides (mmol/l) 1.4(1.7) 1.4(1.7) 1.1(1.6)
HDL cholesterol (mmol/l) 1.2(1.3) 1.2(1.3) 1.5 (1.3)
LDL cholesterol (mmol/l) 4.7(1.3) 4.4(1.3) 4.3 (1.3)
aValues are geometric mean (sd) for all variables except age and WHR for which
arithmetic means (sd) are given, and BMI for which the arithmetic mean (sd) is given
for Hertfordshire, and the median (and inter-quartile range) is given for Preston.
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5.3.2 Plasma Cortisol concentrations during the OGTT
In all subjects plasma Cortisol concentrations fell during the OGTT (pO.OOOl).
Table 5.2a shows the associations between Cortisol AUC and clinical features of the
metabolic syndrome. In men and women, higher Cortisol AUC was associated with
higher glucose AUC and higher systolic blood pressure. Higher Cortisol AUC was
associated with reduced insulin increment in men, but higher 2 h insulin and insulin
AUC in women. Table 5.2b shows the associations between the change in plasma
Cortisol following the oral glucose load and clinical features of the metabolic
syndrome. The only statistically significant associations were in the Preston men
where a smaller decline in plasma Cortisol was associated with higher 2 h glucose
and glucose AUC, lower systolic blood pressure, higher HDL cholesterol and
reduced insulin increment.
5.3.3 Obesity
Obesity, as measured by BMI, was associated with both lower fasting Cortisol
(Hertfordshire p=0.02; Preston p=0.04 unadjusted, p=0.02 adjusted for gender) and a
lower Cortisol AUC (Hertfordshire p=0.0001; Preston p=0.05 unadjusted, p=0.01
adjusted for gender), but not with the percentage decline in Cortisol. Tables 5.2a and
5.2b show that after adjustment for the confounding effect of obesity, the
associations between Cortisol AUC or percentage decline in plasma Cortisol and
clinical features of the metabolic syndrome were strengthened.
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5.3.4 Independent effects ofplasma Cortisol and obesity on plasma glucose
The independent effects of plasma Cortisol and obesity on plasma glucose are
illustrated in Tables 5.3a and 5.3b. In both cohorts at any BMI, higher Cortisol AUC
was associated with higher glucose AUC, while at any Cortisol AUC, higher BMI
was associated with higher glucose AUC. Thus, the highest glucose AUC was
observed in subjects with highest Cortisol AUC and highest BMI, and the lowest in
those with lowest Cortisol AUC and least BMI. In a multiple regression analysis with
glucose AUC as the dependent variable and Cortisol AUC, BMI, age and gender as
independent variables, Cortisol AUC (p=0.001), BMI (p<0.001), and age (p=0.01)
were all significant predictors of glucose AUC in Hertfordshire, and Cortisol AUC
(p<0.001), BMI (p<0.001) and gender (p=0.03, women with lower glucose AUC
than men) were strongest predictors of glucose AUC in Preston. There was no
significant interaction between Cortisol AUC and obesity in either cohort
(Hertfordshire p=0.99, Preston p=0.73). The association between glucose AUC and
both Cortisol AUC and obesity was also observed after exclusion of the 84
Hertfordshire and 34 Preston subjects with IGT or Type 2 diabetes mellitus, although
the strengths of the associations were reduced.
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Table 5.3a Effects of Cortisol AUC and BMI on glucose AUC in Hertfordshire
Hertfordshire Tertiles ofBMI (kg/m")c
Men
Mean" (n) Lowest Middle Highest All
Lowest 13.8 15.6 16.3 15.4
(n=27) (n=42) (n=44) (n=113)
Tertiles of Middle 15.2 15.5 17.0 15.9
Cortisol AUC (n=42) (n=36) (71=36) (n=114)
(h.nmol/l)b Highest 16.2 16.2 18.7 16.9
(n=44) (n=36) (n=32) (n=112)
All 15.3 15.8 17.2 16.0
(n=113) (n=114) (n=l 12) (n=339)
a Geometric mean of glucose AUC. The geometric sd ranged between 1.2 and 1.4
b Tertiles of Cortisol AUC (h.nmol/1): < 552, -720, >720
c Tertiles ofBMI (kg/m2): < 25.5, -28.0, > 28.0
Table 5.3b Effects of Cortisol AUC and BMI on glucose AUC in Preston
Tertiles ofBMI (kg/m")
Preston
Men and Women Lowest Middle Highest All
Mean"' b (n)
Lowest 12.8 13.5 14.1 13.4
(n=27) (n=29) (n=25) (n=8I)
Tertiles of Middle 13.5 13.7 14.2 13.8
Cortisol AUC (n=33) (n=22) (n~27) (n=82)
(h.nmol/lf Highest 14.2 14.5 16.9 14.8
(n=40) (n=25) (n=l8) (n=83)
All 13.6 13.9 14.8 14.0
(n=100) (n=76) (n=70) (n=246)
a Geometric mean of glucose AUC. The geometric sd ranged between 1.1 and 1.3
b Results in Table 5.3b combined for men and women
Effect is the same if analysed separately but results for women are weaker
c Tertiles ofCortisol AUC (h.nmol/1):
Preston men < 635, -841, >841
Preston women < 573, -740, >740
d Tertiles ofBMI (kg/m2):
Preston men < 27, -27, > 27
Preston women < 24, -26, > 26
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5.3.5 Association ofplasma Cortisol and birthweight
Table 5.4 shows the associations between Cortisol AUC and birthweight. In the
Hertfordshire men low birthweight was associated with higher Cortisol AUC
(p=0.006 unadjusted, p=0.03 adjusted for BMI). In the Preston cohort low
birthweight was associated with higher Cortisol AUC (p=0.03 adjusted for gender,
p=0.04 adjusted for gender and BMI). The association was stronger in women than
men but there was no statistically significant interaction between gender and
birthweight as predictors of Cortisol AUC (p=0.44 for interaction). Addition of
birthweight into the above multiple regression model revealed low birthweight was
also a significant predictor of high glucose AUC and did not reduce the strength of
effects of the other predictors (Cortisol AUC p<0.001, BMI p<0.001, gender p=0.02,
birthweight p=0.002). There were no significant interactions between birthweight
and Cortisol AUC or birthweight and BMI. Birthweight was not associated with
percentage decline in Cortisol following the glucose load.
Table 5.4 Associations of Cortisol AUC (h.nmol/1) during OGTTa
and birthweight
Hertfordshire men Preston men Preston women
Birthweight lb n Cortisol AUC n Cortisol
AUC
n Cortisol AUC
- 6.5 56 682 (1.4) 44 785 (1.4) 38 713 (1.3)
-8.5 209 641 (1.4) 49 716(1.3) 46 627(1.4)
>8.5 74 581 (1.4) 42 751 (1.4) 35 636 (1.3)






Values are geometric means and standard deviations








adjusted for gender and BMI
fPreston men and women together, no significant interaction between gender and birthweight, p=0.44
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5.4 Discussion
In both of these populations in whom raised fasting plasma Cortisol is associated with
clinical features of the Metabolic Syndrome (Phillips et al. 1998; Phillips et al.
2000), high Cortisol AUC during the OGTT also predicts cardiovascular risk.
Likewise, in addition to the previously described association between low
birthweight and elevated fasting plasma Cortisol, low birthweight was associated with
higher Cortisol AUC.
The associations are sex-specific: higher Cortisol AUC was associated with higher
systolic blood pressure in both sexes. In women, high Cortisol AUC was also
associated with high glucose and insulin AUCs. However, in men high Cortisol AUC
was associated with high glucose AUC but not with hyperinsulinaemia, suggesting
insulin deficiency rather than insulin resistance. Consistent with this, high Cortisol
AUC was associated with reduced insulin increment, a good correlate of first phase
insulin secretion (Phillips et al. 1994b), which is interesting as glucocorticoids can
directly inhibit insulin release from pancreatic P-cells (Delauney et al. 1997).
However, the decline in plasma Cortisol after glucose administration was poorly
predictive of features of the Metabolic Syndrome, being weakly significant only in
the Preston men. This may not be surprising in light of the findings of Chapter 4,
and in other studies plasma Cortisol measured 2 hours following a glucose load has
been less predictive of cardiovascular risk than the fasting measurement (Walker et
al. 2000). The fall in plasma Cortisol following an oral glucose load is influenced by
the diurnal fall in Cortisol secretion, which is altered in glucose intolerant subjects
(Rosmond et al. 1998; Chapter 4), and also by the effect of oral glucose to raise
plasma Cortisol (Chapter 4).
This study also confirms the previously reported contrasting effects of obesity and
Cortisol on glucose intolerance (Walker et al. 2000). Several studies have shown that
regulation of the HPA axis is altered in obesity (Marin et al. 1992; Pasquali et al.
1993; Andrew et al. 1998), notably that obesity is associated with lower plasma
Cortisol concentrations (Ljung et al. 1996) and increased peripheral clearance of
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Cortisol (Strain et al. 1980; Andrew et al. 1998). Consistent with the hypothesis that
elevated plasma Cortisol and obesity represent different mechanistic pathways to
cardiovascular risk, the effect of BMI and plasma Cortisol in this study, as in a
previous study (Walker et al. 2000) were independent and additive. Thus, increasing
BMI strengthened the associations between Cortisol and glucose intolerance such that
the highest glucose AUC was observed in subjects with the combination of obesity
and high plasma Cortisol concentrations.
The OGTT is commonly used in epidemiological studies of cardiovascular risk and
also provides a dynamic test of the HPA axis since oral glucose raises plasma
Cortisol levels. However, although measurement of plasma Cortisol during the
glucose tolerance test reinforces the interpretation of the relationships between
fasting plasma Cortisol and cardiovascular risk factors (Phillips et al. 1998; Phillips et
al. 2000), it did not offer additional value over measurement of fasting Cortisol.
While subtle differences in diurnal variation of plasma Cortisol and in response to
oral glucose might have obscured each other, it seems unlikely that altered HPA




Measuring peripheral glucocorticoid receptor expression in skeletal muscle
from men with cardiovascular risk factors
6.1 Introduction
The findings from the clinical studies are consistent with the hypothesis that
activation of the HPA axis (Chapter 3), with increased drive to Cortisol secretion
from higher centres (Chapter 4) leads to differences in insulin sensitivity and
cardiovascular risk factors in the population. An alternative mechanism leading to
variations in Cortisol action is of altered tissue responsiveness to glucocorticoids.
Tissue sensitivity to Cortisol is largely determined by the density of GR expression.
In man, the dermal vasoconstrictor response to topical steroids, an indirect measure
of tissue sensitivity to Cortisol, is increased in men with glucose intolerance and
insulin resistance (Walker et al. 1998b), and also in men with essential hypertension
(Walker et al. 1996), or with a familial predisposition to hypertension (Walker et al.
1998a). This response is also enhanced in healthy subjects who carry a
polymorphism within a non-coding part of the GR gene (Panarelli et al. 1998) which
is associated with a familial predisposition to hypertension (Watt et al. 1992) and
with greater hyperinsulinaemia in obese subjects (Weaver et al. 1992).
Little is known about GR expression in man in vivo, partly due to problems of tissue
accessibility. Skeletal muscle is a major determinant of insulin-stimulated glucose
disposal and a primary site of insulin resistance, and moreover is a suitable tissue to
biopsy. A collaboration with Professor Paul McKeigue, London School of Hygiene
& Tropical Medicine, Keppel Street, London, WC1E 7HT, allowed access to a
valuable resource of skeletal muscle biopsies from men from the Uppsala
Longitudinal Study of Adult Men (McKeigue et al. 1998). The aim was to examine
whether there was a relationship between skeletal muscle GR expression and features
of the Metabolic Syndrome. In order to determine changes in GR mRNA levels in
small sample sizes, a quantitative competitive reverse transcriptase (RT)-PCR assay




From the Uppsala Longitudinal Study of Adult Men (McKeigue et al. 1998), a
sample of 99 men were selected who had been studied at age 70 and for whom
muscle biopsy specimens were available. These men were part of a cohort of men
born between 1920 and 1924 and living in Uppsala, Sweden, whose birthweights
were known, and who had participated in a health investigation from 1970 to 1973.
At a follow-up study in 1991, when the men were aged 70 years they underwent a
75g OGTT and euglycaemic hyperinsulinaemic clamp. Height, weight, waist and
hip circumferences were measured, and 24 h ambulatory blood pressures recorded.
On a separate day they attended after an overnight fast for a muscle biopsy. A
biopsy of approximately 100 mg of muscle was taken from the vastus lateralis
muscle via an 8 mm incision through the skin and fascia, using a Bergstrom needle
under local anaesthesia. Biopsies were divided in half, snap frozen in liquid nitrogen
and stored at -80°C. One half of each sample was used for RNA preparation. GR
mRNA levels were determined using the competitive quantitative RT-PCR assay
described below.
6.2b Competitive quantitative RT-PCR assay
Competitive quantitative RT-PCR is the most sensitive technique for measuring
mRNA copy numbers (Clementi et al. 1993). Although there are several different
methods for competitive RT-PCR, use of a synthetic RNA competitor, especially one
possessing sequences nearly identical to the target RNA, controls for the efficiencies
ofboth reverse transcription and amplification.
b(i) Tissues
Total RNA was extracted from vastus lateralis skeletal muscle biopsies using the
TRIzol method (Appendix A 3.2). Integrity of RNA was verified by denaturing
agarose gel electrophoresis (Appendix A 3.1b). Of the 99 available samples, RNA
suitable for use in the assay was made from 24 samples. 23 samples were too small
to yield RNA (either because samples were too small to yield RNA or the muscle
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was attached to connective tissue or fat), and in 52 the extracted RNA was degraded
and RT-PCR did not yield detectable bands for GR and 18S.
b(ii) Competitors
RNA competitors for human GR mRNA and human 18S mRNA (used as an internal
control for variability in target RNA) were synthesised separately but under the same
conditions (Benchmarks 1994, Appendix A 3.4.l(i)). Both competitors contain 83
base pair (bp) deletions to distinguish the PCR products derived from endogenous
and synthetic RNAs.
b(iii) Assay
Competitive quantitative RT-PCR was carried out using 100 ng total target RNA in
the assay (Appendix A 3.4.1(h)). Because of small sample size, the competitive
quantitative RT-PCR was performed once for each sample and only repeated if the
competitive reaction was unsatisfactory (correlation less than 0.9). The inter-assay
coefficient of variation was 12%. As an additional internal control to ensure inter-
th
assay repeatability a liver sample was included after every 4 muscle sample in the
experiment. PCR products were size separated by agarose gel electrophoresis (see
Figure Appendix A 3.1) and band intensities determined using a phosphorimager and
AIDA package (Appendix A 3.4.1 (ii)c).
6.2c Statistical analysis
Insulin sensitivity was calculated from the glucose infusion rate (g / min) between 60
and 120 min of the euglycaemic clamp, dividing this infusion rate by body weight
(kg) and mean insulin level (mU /1). As the distributions of plasma glucose, insulin
and triglycerides measurements were skewed, loge transformed variables were used
in all analyses. All associations with GR were adjusted for 18S. To discount the
effect of antihypertensive therapy, associations with 24 h mean ambulatory blood
pressure were examined by censored normal regression, with the 6 men on
antihypertensive therapy and the 3 with untreated values above 150 mmHg allocated
to the top fertile (Statacorp 1997, Stata Statistical Software Release 5, College
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Station, TX: Stata Corporation).. Statistical methods were advised by Professor P
McKeigue, London School ofHygiene & Tropical Medicine.
6.3 Results
Results are shown in Table 6.1 and Figure 5.1. Increased skeletal muscle GR mRNA
levels were significantly associated with higher insulin levels after a glucose load
and raised blood pressure but not with plasma lipids, glucose or obesity.
Associations with insulin sensitivity and fasting insulin levels were in the same
direction but did not reach statistical significance in this small sample. There were
also no associations between muscle GR mRNA levels and birthweight. In multiple
regression analyses relationships with insulin sensitivity and blood pressure were
independent of obesity.









Tasting plasma glucose (mM) 5.5 (0.9) -0.05 0.80 0.58
Tasting plasma insulin (pM) 10.6(8.2) 0.41 0.06 0.09
aInsulin lh post glucose (pM) 74.2 (46.9) 0.53 0.01 0.02
bM/I (mg.min '.kg '.fmU/l)"1) 5.2 (2.0) -0.36 0.10 0.05
c24 h systolic blood pressure 142 0.05 0.05
(mmHg)
"Triglycerides (mM) 1.2 (0.9) 0.26 0.24 0.30
BMI (kg.m"2) 26.3 (3.3) 0.16 0.46 -
WHR 0.95 (0.05) 0.14 0.53 0.91
Birthweight (g) 3585 (423) 0.12 0.57 0.82
a variables loge-transformed for analysis
bglucose infusion rate (g.min"1) between 60 and 120 min of the euglycaemic clamp
divided by body weight (kg) and mean insulin level (mU.f1)
c median presented; using censored normal regression no partial correlation
coefficient can be calculated
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Figure 6.1
Associations of skeletal muscle GR mRNA levels with
plasma insulin levels and blood pressure
partial correlation coefficient = 0.53
p=0.01 adjusted for 18S, p=0.02 adjusted for BMI
p=0.05 adjusted for 18S, p=0.05 adjusted for BMI
6.4 Discussion
These data suggest that men with insulin resistance and hypertension have increased
GR mRNA levels and, by inference, increased numbers of GR in skeletal muscle.
This is consistent with a recent report, as yet published only as an abstract, in skeletal
muscle myoblasts cultured from biopsies obtained from men with insulin resistance
(Whorwood et al. 1998). GR mediate diverse effects on insulin sensitivity (in liver,
adipose tissue, and skeletal muscle) and blood pressure (in kidney, blood vessels, and
brain). Increased receptor number in these sites could contribute to the association
between features of the Metabolic Syndrome, and thus may explain previous
observations of enhanced in vivo responsiveness to glucocorticoids (Walker et al.
1998b). This could be an important mechanism underlying the pathophysiology of
insulin resistance and larger studies will be needed to determine whether the
observations extend to subjects of low birthweight.
It may seem surprising that despite the previously observed modestly elevated
circulating glucocorticoids in subjects with the Metabolic Syndrome (Phillips et al.
1998; Phillips et al. 2000), and the findings of Chapter 3, peripheral GR expression
was elevated in men with hypertension and dyslipidaemia, since GR levels are often
negatively auto-regulated by circulating glucocorticoids. Indeed, if receptor
expression were similarly increased in central negative feedback sites, lower
circulating Cortisol levels to compensate for peripheral hypersensitivity would be
expected. However, it appears likely that the dysregulation of GR expression is
tissue-specific. For example, Cortisol levels are higher, not lower, in subjects with
the Metabolic Syndrome (Phillips et al. 1998; Phillips et al. 2000), and there were no
differences in central feedback sensitivity demonstrated in men with the Metabolic
Syndrome in Chapter 3. In addition, not all aspects of Cushing's syndrome are
recapitulated in men with increased expression of GR in muscle; these men are not
obese and do not have fasting hyperglycaemia, suggesting perhaps that the adipose
tissue and liver are spared from this effect. Finally, the findings of increased
peripheral GR but no change in central GR somewhat parallel the animal model of
insulin resistance induced by prenatal exposure of rats to dexamethasone, where
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dysregulation of GR expression is indeed tissue-specific, with increased GR mRNA
in liver but decreased GR mRNA in central negative feedback sites (Nyirenda et al.
1998).
There are several potential mechanisms for dysregulation of GR expression.
Polymorphisms of the GR gene have been associated with in vivo responsiveness to
glucocorticoids (Panarelli et al. 1998) and with insulin resistance (Weaver et al.
1992) and may be in allelic association with variations in the tissue-specific promoter
regions (Walker et al. 1998). One mechanism allowing differential regulation of GR
expression is effects upon one or more multiple alternate promoters of the GR gene
as occurs in rat and mouse (McCormick et al. 2000). Moreover, tissue-specific exon
1 usage is altered by perinatal environmental manipulations (McCormick et al.
2000). Whether the human GR gene is also regulated by more than one promoter is
explored in Chapter 7.
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Chapter 7
Multiple alternate first exons of the human GR gene:
a mechanism for tissue-specific regulation of GR expression
7.1 Introduction
Thus far the results suggest that in men with the Metabolic Syndrome sensitivity to
glucocorticoids is not the same in all tissues. Glucocorticoid sensitivity is increased
in peripheral tissues (e.g. in skeletal muscle, Chapter 6) due to increased GR
expression, but not in central tissues responsible for negative feedback (there was no
difference in plasma Cortisol following dexamethasone suppression, Chapter 3).
Likewise in the offspring of rats treated with dexamethasone in utero, there is a
similar pattern of tissue-specific GR expression, namely increased peripheral
(hepatic) GR expression (Nyirenda et al. 1998) but decreased central (hippocampal)
GR expression (Levitt et al. 1996). One mechanism for tissue-specificity, which
allows differential GR regulation and has been reported for other members of the
steroid receptor family, is the use ofmultiple and tissue-specific promoters (Kastner
et al. 1990; Kwak et al. 1993; Flouriot et al. 1998; Zennaro et al. 1996).
The GR gene spans at least 110-kb and contains 8 coding exons (exons 2-9) and a
non-coding exon 1 (Hollenberg et al. 1985; Encio and Detera-Wadleigh 1991; Zong
et al. 1990). The human (Encio and Detera-Wadleigh 1991; Zong et al. 1990),
mouse (Strahle et al. 1992; Cole 1992; Chen et al. 1999a; Chen et al. 1999b), and rat
(Gearing et al. 1993; McCormick et al. 2000) GR gene promoter regions have been
cloned and partially characterised. Rat GR mRNA exhibits considerable
heterogeneity at the 5' ends (Gearing et al. 1993; McCormick et al. 2000). At least
11 alternate exon 1 sequences (li-ln), are present in the rat GR gene (Gearing et al.
1993; McCormick et al. 2000); 5 of these correspond to those identified in the mouse
GR gene (Strahle et al. 1992, Cole 1992) and one corresponds to that published for
the human GR gene (Zong et al. 1990). Each alternate exon 1 is spliced from a fixed
3' donor site to the same 5' acceptor site in exon 2. The amino acid sequence of GR
itself is unaffected by splicing of alternate exons 1 as there is an in-frame stop codon
immediately upstream of the translation initiation site in exon 2. This complex
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organisation of the 5'-end of the GR gene may reflect the need for diverse tissue-
specific regulation and allows differential regulation ofGR in specific cell types.
The use of alternative promoters in gene regulation provides an efficient and flexible
means of controlling complex patterns of gene expression and thus is a potential
mechanism for programming of gene expression. In rat tissues, two of the alternate
exons (exons 16 and 110) are expressed in all tissues examined, and are together
present in 77-87% of total GR mRNA (McCormick et al. 2000). The remaining GR
mRNA transcripts contain tissue-specific alternate first exons. Tissue-specific first
exon usage is altered by perinatal environmental manipulations. Postnatal handling
of pups before weaning, which permanently increases hippocampal GR and
attenuates stress responses (Francis et al. 1996; Liu et al. 1997), selectively elevates
GR mRNA containing the hippocampus-specific exon % (McCormick et al. 2000).
In prenatal glucocorticoid exposure, although total hepatic GR expression is
increased (Nyirenda et al. 1998), the proportion of hepatic GR mRNA containing the
predominant exon 110 falls, suggesting that one or more of the minor exon 1
containing species is programmed to increase by the manipulation in early life.
Most of the alternate exons 1 in the rat GR gene lie within a 3-kb CpG island,
upstream of exon 2, that exhibits substantial promoter activity in transfected cells.
As this region is highly conserved between rat and human (Zong et al. 1990;
Govindan et al. 1991), it is likely that the human GR gene also uses alternate
promoters. Indeed recent evidence suggests the existence of at least two other
alternate exons 1 within the human GR gene (Breslin and Vedeckis 1998; V Lyons &
K Chapman, personal communication). Therefore the aim was to investigate
whether human GR mRNA also exhibits 5'-heterogeneity.
7.2 Methods
7.2a 5 '-RACE (RapidAmplification ofcDNA Ends)-PCR
5'-RACE is a procedure for amplification of nucleic sequences from a messenger
RNA template between a defined internal site and unknown sequences at the 5'-end
of the mRNA (Frohman 1993).
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5'-RACE-PCR was performed using a commercial kit (Life Technologies Ltd.)
according to the manufacturer's instructions with minor modifications (Appendix A
3.4.2) on total RNA isolated from human liver and peripheral blood mononuclear
cells (Appendix A 2.7).
First strand cDNA synthesis of total RNA was carried out using a primer
complementary to exon 2 of the human GR gene (GSP1) (Appendix A 3.4.2a). The
first strand product was purified from unincorporated dNTPs and GSP1 (Appendix A
3.4.2b). TdT (terminal deoxynucleotidyl transferase) was used to add a
homopolymeric dC tail to the 3' ends of the cDNA (Appendix A 3.4.2c). Tailed
cDNA was then amplified by 35 cycles of PCR amplification (Appendix A 3.4.2d)
using a nested gene-specific primer (GSP2) which anneals 3' to GSP1 (Appendix A
2.6a) and an 'anchor' primer (allowing amplification from the homopolymeric tail,
supplied with the kit). To increase specificity a nested PCR was carried out on the
products of the first PCR reaction, under the same conditions but using a 'universal
anchor primer' (from kit) and GSP3 primer, which anneals 3' to GSP2 (Appendix A
2.6a). PCR products from nested PCR reactions were cloned into pGEM-T easy
(Appendix A 3.3c), and sequenced using GSP3 (Appendix A 3.4.5).
7.2b RLM-RACE (RNA Ligase Mediated RapidAmplification ofcDNA Ends)
The major limitation of the above procedure is that there is no selection for
amplification of fragments corresponding to the actual 5' ends of mRNA: all cDNAs
are acceptable templates in the reaction. Additionally the PCR step favours
amplification of less than full-length products, and thus usually produces a
heterogeneous population of amplified products. RNA Ligase Mediated Rapid
Amplification of cDNA Ends (RLM-RACE) is an improvement to the classic RACE
technique as it is designed to amplify cDNA only from full-length capped mRNA
(Shaefer 1995).
Because of this, 5'-RACE-PCR was also performed on the human liver RNA using a
First Choice RLM-RACE kit (Ambion Inc.) according to manufacturer's instructions
(Appendix A 3.4.3).
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RNA was firstly treated with calf intestinal phosphatase (CIP) to remove 5'
phosphates from molecules such as ribosomal RNA, fragmented mRNA, tRNA and
contaminating genomic DNA (Appendix A 3.4.3(i)a). The RNA was then treated
with Tobacco Acid Pyrophosphatase (TAP) to remove the cap structure from full-
length mRNA, leaving a 5' monophosphate (Appendix A 3.4.3(i)b). A synthetic
RNA adapter, that can ligate only to decapped (full-length) RNA molecules with a 5'
phosphate end, was ligated to CIP/TAP-treated RNA (Appendix A 3.4.3(i)c).
Reverse Transcription (RT) of ligated RNA was carried out (Appendix A 3.4.3(h).
Two rounds of 35 cycles of PCR amplification were performed (Appendix A
3.4.3(iii)). In the first 'outer' PCR, lpl RT product was used in a reaction containing
outer RNA adapter primer (from kit), and outer gene specific primer (GSP2
Appendix A 2.6a). A second 'inner' PCR was carried out on the products of the first
PCR reaction, under the same conditions but with primers inner RNA adapter primer
(from kit) and inner gene specific primer (GSP3 Appendix A 2.6a). PCR products
from 'inner' nested PCR reactions were cloned and sequenced as above (and
Appendices A 3.3c and A 3.4.5).
7.2c Reverse Transcription-PCR (RT-PCR)
To identify other novel human exon 1 species RT-PCR was performed on total RNA
extracted from human liver, brain, fat and muscle (Appendix A 2.7) using primers
corresponding to sequences predicted to be present based on sequence comparison
with the rat GR gene (Appendix A 2.6d and see Figures 7.1a and 7.1b).
RT was performed using a commercial kit (Promega U.K. Ltd.) (Appendix A 3.4.4a).
35 cycles of PCR amplification of the RT product were performed (Appendix A
3.4.4b) using a 5'-primer (i.e. primers corresponding to rat exons I4, 15, U, I7, lio,
Appendix A 2.6a) and a 3'-primer complementary to exon 2 (GSP3 Appendix A























































Figure 7.1a Sequence of 5'-DNA flanking exon 2 of the human GR gene
Showing position of exons 1
Nucleotides are numbered as in published sequence
(Accession no. M32284, Zong et al. 1990)
Nucleotides in Bold italic font represent position of primers
Nucleotides which are underlined indicate corresponding sequence in rat GR











4 5 0 GGGGCGAACGCGGCGCACCGGGCGGGGCGGCCACCGAGGGGACGCGGCG
500 TGCAGGCGCAGTCGGGGCCGGGGTGGCGGGGCCCGCGCGGAGGGCGTGG



















15 0 0 CCCCCTAGTGTCCCCTTTCCTCCAAGGGGGTCGCCCGACACCCGTTTTC
1550 GTGGTGAACGCT.AAGCCGCGTCTGAATTTTACTCGCCCGAATATTGTG
1 1600 CACGCCACCCCGCGGCGCCCGAGCGCGAGCCCGGG
Figure 7.1b Sequence of 5'-DNA flanking exon 2 of the human GR gene
showing positions of exons 1
Nucleotides are numbered as in published sequence
(Accession no. S68374 Govindan et al. 1991)
Nucleotides in Bold italic font represent position of primers
Nucleotides which are underlined indicate corresponding sequence in rat GR




In the majority of products identified by 5'-RACE-PCR, the 5'-end was located in
exon 2. Some products contained exon 1 sequence in addition to that of exon 2. Of
these, two independent 5'-RACE products were obtained from liver and peripheral
blood mononuclear cells RNA, and one from brain, deriving from independent
cDNAs generated in the initial reverse transcription reactions. The 5'-ends of the
cDNAs terminated at different positions in exon 1, indicating that they are unlikely
to be generated by PCR from the same initial tailed cDNA. Clones from liver,
peripheral blood mononuclear cells and brain contained the exon 1 sequence
previously identified in human GR mRNA (now termed human 1C, Breslin and
Vedeckis 1998) and which corresponds to exon li0 of the rat and exon 1C of the
mouse GR gene. In addition, clones from liver and peripheral blood mononuclear
cells contained exon 1 sequence corresponding to exon U of the rat and exon IB of
the mouse GR gene, and hence termed human exon IB (Breslin and Vedeckis 1998).
7.3.2 RLM-RACE
Sequence analysis of individual clones revealed the presence of exons 1
corresponding to published human exon 1C (equivalent to rat exon 1 io) in liver. The
exon 1C clones differed in length suggesting alternate transcription start sites. The
most 5'-sequence obtained corresponds to nucleotide position -950 according to the
published human GR cDNA sequence (see Figure 7.1b), and is further 5' than the
published 1C sequence (Govindan et al. 1991).
7.3.3 RT-PCR
Exons 1 corresponding to rat exons U, 15> and l7j and human exons IB and 1C
(equivalent to rat exons le and lio) were identified in RNA extracted from human
liver, skeletal muscle, fat and brain. Figure 7.2 shows a representative agarose gel of
novel exons 1 identified in skeletal muscle. Figure 7.3 summarises these results
showing a schematic representation of the human GR gene promoter region as
compared with the published rat and mouse GR gene promoter regions.
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Figure 7.2 Representative agarose gel showing novel human exons 1 identified
by RT-PCR in total RNA isolated from human skeletal muscle
RAT
17
o^ 6 ^ 8 Is 1-10 l11
MOUSE
HUMAN
Figure 7.3 Schematic representation (not to scale) of the human GR gene
promoter.
Figure shows published human exons IB and 1C (Encio and Detera-
Wadleigh 1991, Zong et al. 1990) and novel exons 1 identified
compared with the published rat (McCormick et al. 2000) and mouse
(Strahle et al. 1992, Cole 1992) GR gene promoter regions.
The Bel I restriction fragment-length polymorphism (Panarelli et al.
1998) associated with abdominal obesity, insulin resistance and
elevated blood pressure, lies within intron 1 i.e. upstream of exon 2
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7.4 Discussion
The findings show that there is more than one exon 1 in the human GR gene.
Sequence analysis of individual clones generated from the 5'-RACE-PCR
experiments, revealed the presence of exon 1 sequences previously identified in
human GR mRNA as exon IB (Breslin and Vedeckis 1998) and exon 1 (Encio and
Detera-Wadleigh 1991; Zong et al. 1990), now designated exon 1C (Breslin and
Vedeckis 1998) (equivalent to rat exons U and 1 io) in liver and peripheral blood
mononuclear cells. Exon 1C was also identified in the brain tissue. Previous work
from the laboratory has identified exons IB and 1C in GR mRNA from human
peripheral blood mononuclear cells (V Lyons & K Chapman, personal
communication). Human exon IB is homologous to the rat exon 16 (Gearing et al.
1993; McCormick et al. 2000) and mouse exon IB (Strahle et al. 1992; Cole 1992)
and is present in the published human GR gene sequence at position -873 to -925
(Zong et al. 1990). Human exon 1C is homologous to rat exon lio (Gearing et al.
1993; McCormick et al. 2000) and mouse exon 1C (Strahle et al. 1992; Cole 1992)
and is present in the published human GR gene sequence at position -1111 to -1035
(Govindan et al. 1991). Other novel exons 1 were identified by RT-PCR using
primers corresponding to sequences predicted to be present based on sequence
comparison with the rat GR gene. Thus exons 1 corresponding to rat exons U, I5, and
l7j and human exons IB and 1C (equivalent to rat exons U and 110) were identified in
all tissues examined (see Figure 7.2).
GR is expressed in virtually all cell types, but levels of GR vary between tissues,
within tissues and during development. This is important as the level of GR
expression is key in determining glucocorticoid action. The wide variation in GR
expression both spatially and temporally suggests complex regulation of the GR
gene. Use of alternative promoters in gene regulation provides an efficient means of
controlling complex patterns of gene expression. Thus alternate promoter usage may
be a key mechanism underlying tissue-specific responses to hormone, and is also a
potential mechanism for programming of gene expression. In addition, production of
mRNAs with different untranslated 5'-leader sequences by alternative promoter
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usage can affect gene expression by variations in stability or translation efficiency of
these mRNAs (Kozak 1991).
The standard 5'-RACE-PCR method has limitations. As there is no selection for
amplification of fragments corresponding to the actual 5' ends ofmRNA, all cDNAs
are acceptable templates in the reaction. Additionally, the PCR step selects the most
efficient (smallest) amplicons, favouring amplification of less than full-length
products. Indeed most of the transcripts generated by this method were short, only
extending into exon 2. The alternative method of RLM-RACE, is designed to
amplify cDNA only from full-length capped mRNA. Any first strand cDNA
molecules that do not extend all the way to the 5' end of the adapter will not yield a
product in the PCR (since these targets lack the adapter-specific primer binding
sites). Use of this technique generated exon 1C clones of differing length. Although
shorter transcripts could represent truncated artifacts of reverse transcription and
amplification, it is most likely that they represent alternate transcription start sites.
CpG islands are frequently associated with multiple transcription initiation sites
(Roller et al. 1991; Ye et al. 1993) and at least four transcription start sites have been
mapped for the published human exon 1 (Zong et al. 1990; Encio and Detera-
Wadleigh 1991). The regions flanking exon 1 may be important in determining
differential promoter activity as they contain multiple GC boxes, the recognition site
of the SP1 transcription factor (Zong et al. 1990; Encio and Detera-Wadleigh 1991).
The region of the CpG island in which 8 of the 11 alternate exons 1 of the rat GR
gene lie shows moderate conservation with the corresponding human GR gene
sequence (-70% identity over the CpG island; nucleotides -1600 to -4220) (Zong et
al. 1990; Govindan et al. 1991). It seems likely that more alternative exons 1 could
exist within the CpG island.
In rat tissues, the abundance of alternate promoters varies in different tissues
allowing tissue-specific regulation of GR gene expression. Although the alternate
promoters are ubiquitously expressed in human tissues, further work will establish




The role of the HPA axis in programming of adult disease
The idea that stimuli or insults during critical or sensitive periods in early life have
lifelong consequences is well established in developmental biology and has been
termed 'programming'. Recently the phenomenon of programming has been used to
explain the epidemiological data showing that small size at birth or in infancy is
associated with an increased risk of adverse health outcomes in adult life including
diabetes, hypertension and ischaemic heart disease. Such observations have led to
the 'fetal origins hypothesis' whereby environmental factors acting in utero or in the
early postnatal period permanently alter the development of organs and lead to later
organ dysfunction and disease (Barker 1998). Despite early criticisms, the
associations between parameters of early growth and adult disease have been
reproduced throughout the world, and research is now centred on identifying the
underlying factors that are involved in programming of disease.
Recent studies suggest the HPA axis plays an important role. In animal studies
adverse influences in prenatal or early post-natal life permanently alter the biological
and behavioural responses in the adult offspring through long-term changes in central
and peripheral sensitivity to glucocorticoids (Benediktsson et al. 1993; Langley and
Jackson 1994; Levitt et al. 1996; Nyirenda et al. 1998). In humans, glucocorticoid
excess (in Cushing's syndrome) is associated with the Metabolic Syndrome and
subsequent cardiovascular disease and therefore it is plausible that more subtle
variations in glucocorticoid activity contribute to the pathogenesis of risk factors for
cardiovascular disease in the population. Indeed, higher fasting morning plasma
Cortisol concentrations are associated with higher blood pressure, plasma glucose and
triglyceride concentrations, and also with lower birthweight (Phillips et al. 1998;
Phillips et al. 2000). These preliminary studies led to the hypothesis that events in
early life permanently alter or 'programme' Cortisol secretion and that this may be a
fundamental mechanism underlying the association between low birthweight and the
development ofmetabolic disorders and cardiovascular disease in adult life.
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The data in Chapter 3 show that an underlying mechanism mediating the association
between elevated fasting plasma Cortisol and low birthweight and / or the Metabolic
Syndrome is activation of the HPA axis with increased Cortisol response to
exogenous ACTH1.24 and increased excretion of urinary Cortisol metabolites. This
activation of the HPA axis has now been observed in a population of younger
individuals of known birthweight and early clinical features of the Metabolic
Syndrome (Levitt et al. 2000).
Animals prenatally exposed to dexamethasone have elevated basal and stress-
induced plasma glucocorticoid levels (Benediktsson et al. 1993; Langley-Evans et al.
1994; Levitt et al. 1996; Nyirenda et al. 1998) and subtle changes in HPA axis
regulation. GR and MR expression are decreased in the hippocampus (Levitt et al.
1996), one of the most sensitive targets for glucocorticoid negative feedback effects
in rodents, but increased in the amygdala (Welberg et al. 2000), a site of positive
modulation of HPA axis activity. In contrast in humans there was no evidence of
altered central feedback sensitivity to low dose dexamethasone in men with low
birthweight or the Metabolic Syndrome (Chapter 3). However, at low doses
dexamethasone has limited access to the brain and so may only test the pituitary
component of the negative feedback loop. Further studies are needed to explore the
use of alternative glucocorticoids such as prednisolone or hydrocortisone in feedback
regulation. Moreover, while the role of hippocampal MR in HPA axis regulation has
been well established in rodents (de Kloet et al. 1998), little is known about its
relevance in humans, although MR is known to be located in the human
hippocampus (Seckl et al. 1991). Evidence supporting a physiological role for MR
in human central feedback includes the observations that administration of MR
antagonists (potassium canrenoate or spironolactone) increase plasma Cortisol
concentrations (Dodt et al. 1993; Young et al. 1998; Heuser et al. 2000; Arvat et al.
2001) whereas fludrocortisone suppresses plasma Cortisol in healthy adults (Mangos
et al. 2000). It remains possible that glucocorticoid feedback occurs via a centrally
mediated MR mechanism and responses to MR antagonists such as spironolactone to
increase HPA drive should be tested.
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Alternatively, rather than impaired central negative feedback, the activation of the
HPA axis could be due to increased forward drive to ACTH and Cortisol secretion
from higher centres. The lack of habituation to the stress of repeated venepuncture
observed in diabetic subjects in Chapter 4 is consistent with this explanation.
Interestingly recent rodent studies suggest habituation may be MR mediated (Cole et
al. 2000). Such alterations in the central regulation of the HPA axis may be key in
the development of glucose intolerance. Lack of habituation to stress and increased
activation of the HPA axis in subjects with glucose intolerance also supports the
hypothesis that chronic stress in man leads to development of cardiovascular risk
factors. Similar variations in HPA axis activity may contribute to the observed
relationships between psychosocial stress and subsequent cardiovascular disease
(Brunner 1997). Methods which have been employed to test feed forward of the
HPA axis (e.g. Trier Psychosocial Stress Test (Kirschbaum et al. 1993), combined
dexamethasone-CRH test (Heuser et al. 1994)) may be useful in furthering
understanding of activation of the HPA axis.
An alternative mechanism whereby alterations in glucocorticoid activity may
contribute to the pathogenesis of risk factors for cardiovascular disease is through
altered tissue responsiveness to glucocorticoids. In Chapter 6 increased expression
of GR mRNA in skeletal muscle was associated with insulin resistance suggesting
that this may be a key underlying mechanism. Further studies are needed to see
whether increased peripheral sensitivity to glucocorticoids is also apparent in
subjects of low birthweight.
Together the animal studies and results of Chapters 3 and 6 suggest that GR
expression is tissue-specific. The finding of alternate promoters of the human GR
gene in Chapter 7 provides a mechanism for tissue specific regulation of GR
expression. Further work is needed to see whether levels of the different promoters
vary in different tissues. This could provide a novel mechanism for tissue-specific
manipulations of target organ response and drug design. Certainly therapeutic
manipulation of the HPA axis itself is not an attractive target to improve insulin
sensitivity. Unacceptable side effects similar to Addison's disease would be
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anticipated if plasma Cortisol was lowered due to the ubiquitous expression of steroid
receptors. However, specificity of effects for drugs acting at other steroid receptors
has been achieved. An example is raloxifene, a 'selective oestrogen receptor
modulator' (SERM), which acts as an oestrogen antagonist in breast and
endometrium but as an agonist in bone (MacGregor and Jordan 1998). Further
understanding the tissue-specificity of Cortisol action will be important in drug
design to minimize the risk of adverse effects.
Data in this thesis suggest that in humans programmed changes in the regulation of
the HPA axis with activation of the HPA axis and increased tissue sensitivity to
glucocorticoids may have long term adverse effects. This is particularly important as
glucocorticoids have extensive therapeutic use prenatally. For example they are used
to accelerate lung maturation in pre-term labour (Crowley et al. 1990). In addition,
glucocorticoids are used for prenatal therapy for fetuses at risk of congenital adrenal
hyperplasia (Speiser and New 1994). Low birthweight has been reported in these
babies (Pang et al. 1992), and problems with social and emotional behaviour in
children treated with dexamethasone in utero have been observed (Trautman et al.
1995). It remains to be seen whether such manipulations also carry a risk of




Questions 1-9 used in the study of dynamic testing of the HPA axis in Hertfordshire
(Chapter 3); Question 9 used in the validation of the overnight low dose dexamethasone
suppression test (Chapter 2)
I would like to ask you a few questions about any illnesses you may have suffered since
we saw you last.
1 .a Have you ever been told by a doctor that you have diabetes?
1 .b At what age was it diagnosed?




2.a Have you ever been diagnosed by a doctor as having
a heart attack?
2,b Have you ever been diagnosed by a doctor as having angina?
2.c Have you ever had an operation to clear the arteries in your
heart (coronary artery bypass graft or angioplasty)?
2.d If yes, in what year?
3. Have you ever been diagnosed by a doctor as having a stroke?
4. have you ever been treated by a doctor for high blood pressure?
5. Have you had any other illness since we interviewed you last?









6. What regular medicines/pills/tablets/skin creams are you using?
In particular:
have you taken any oral steroids, used steroid inhalers or used
steroid containing creams or eye drops in the last year? Yes/No
if yes, please give details below
have you ever taken HRT? Yes/No
if yes, what preparation?
and when did you take it?
PLEASE USE BLOCK CAPITALS












7. I'd like to ask you whether you have drunk different types of alcoholic drinks in
the last 12 months. I do not need to know about non-alcoholic drinks.
Do you ever drink alcohol? 0. No Go to Q8
1. Yes ask 7a) etc
a) How often do you currently drink
Shandy or Low Alcohol Beer/Lager/Cider FFQ 1-7 >xl
When you drink these how many pints would you normally have?
(if range give code mid-point; 1 average can =0.8 pints)
b) How often do you currently drink
Beer/Stout/Lager/Cider FFQ 1-7 >xl
When you drink these how many pints would you normally have?
(if range give code mid-point)
c) How often do you currently drink
Low alcohol wine FFQ 1-7 >xl
When you drink these how many glasses would you normally have?
(if range give code mid-point)
d) How often do you currently drink
Wine/Sherry/Martini/Cinzano FFQ 1-7 >xl
When you drink these how many glasses would you normally have?
(if range give code mid-point)
e) How often do you currently drink
Spirits/Liqueurs FFQ 1-7 >xl
When you drink these how many measures would you normally have?
(if range give code mid-point)
8.a Have you ever smoked regularly? (ie at least once a day for a year or more)
1. Yes - ask question 8 .b
0. No
8.b How old were you wen you first smoked regularly?


















How old were you when you last smoked regularly?
Some of the tests we are doing at the clinic are affected by how you are feeling
so I just need to ask you some questions about this:
Are you basically satisfied with your life? YES/NO
Have you dropped many of your activities and interests? YES/NO
Do you feel that your life is empty? YES/NO
Do you often get bored? YES/NO
Are you in good spirits most of the time? YES/NO
Are you afraid that something bad is going to happen to you? YES/NO
Do you feel happy most of the time? YES/NO
Do you often feel helpless? YES/NO
Do you prefer to stay at home, rather than going out and
doing new things? YES/NO
Do you feel you have more problems with memory than most? YES/NO
Do you think it is wonderful to be alive now? YES/NO
Do you feel pretty worthless the way you are now? YES/NO
Do you feel full of energy? YES/NO
Do you feel that your situation is hopeless? YES/NO
Do you think that most people are better off than you are? YES/NO
Have you needed to see your doctor because of depression
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A 2.2 Buffers and solutions
Unless stated solutions were prepared with distilled water,










5 M potassium acetate
0.2 M NaOH, 1% SDS. Freshly
prepared before use.
15 g Amberlite ion exchange resin
(BDH. Lutterworth, UK) mixed with
150 ml formamide for 1 h, then filtered
twice to remove Amberlite
ultrapure water (500 ml) mixed with
diethylpyrocarbonate (DEPC; 5 drops)
and left for 1-24 h before autoclaving
0.25% (w/v) bromophenol blue, 0.25%
(w/v) xylene cyanol, 25% Ficoll made
up in DEPC-treated water
800 ml water added to 186.1 g
Na2EDTA.2H20. pH adjusted to 8.0
with NaOH, volume adjusted to 1 litre
0.34% (w/v) bromophenol blue, 0.03%
(w/v) xylene cyanol, 20 mM EDTA in
deionised formamide
50 mM glucose, 25 mM Tris-HCl, 10
mM EDTA, pH 8.0
0.2M 3-[N-morpholino]propanesulfonic
acid, 50 mM Na acetate, 5 mM EDTA,
pH 7.0
245.6 g potassium acetate dissolved in
300 ml water. Volume adjusted to 500
ml by adding 57.5 ml glacial acetic acid




1M Tris-HCl, pH 8.0
108.9 g Tris, 55.7 g boric acid, 20 ml
0.5 M EDTA, volume adjusted to 1 litre
with water
10 mM Tris-HCl (pH 8.0), 1 mM EDTA
121.1 g Tris base in 800 ml water. pH
adjusted to 8.0 with concentrated HC1
and volume adjusted to 1 litre
A 2.3 Bacterial media
Luria-Bertoni (LB) broth
LB-agar
10 g bactotryptone, 5 g yeast extract, 5
g NaCl made up to 1 litre with distilled
water and autoclaved immediately
3 g agar added to 300 ml LB broth
before autoclaving. For plates, LB-agar
melted in a microwave oven, cooled
until warm, 100 pg/ml ampicillin added,
and poured into 100 mm petri dishes.
A 2.4 Plasmids
pGEMT-easy
E. coli JM109 cells
Promega U.K. Ltd.,
Delta House, Chilworth Research
Centre, Southampton SO 16 7NS
Promega U.K. Ltd.
A 2.5 Enzymes and buffers
SP6, T7, Sail, Ncol, EcoRl
and lOx restriction buffers Promega U.K. Ltd.
High activity 74 DNA ligase and 1 Ox buffer Roche Diagnostic Ltd., Bell Lane,
Lewis, East Sussex BN7 1LG
Taq polymerase and lOx buffer Roche Diagnostic Ltd.
LagBead™ hot start polymerase wax beads and
Thermophilic DNA polymerase lOx reaction buffer, Mg-ffee Promega UK Ltd.
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A 2.6 Oligonucleotides
A 2.6a 5'-RACE-PCR Oswel DNA Service, University of




A 2.6b Primers usedfor construction of 'competitor' template and used in
competitive quantitative RT-PCR assay
Operon Technologies, Inc., 1000
Atlantic Avenue, Alameda, CA 94501
(i) GR primers
5' primer hGR-1 5 '-GAC ATT TTG CAG GAT TTG GAG-3'
3' primer hGR-2 5'-GCT TAC ATC TGG TCT CAT GCT-3'
3' linker hGR-3 5'-TGG TCT CAT GCT CTT GGC ACC TAT TCC AAT T-3'
(ii) 18Sprimers
5' primer hl8S-l 5'-CGG AAC TGA GGC CAT GAT TA-3'
3' primer hl8S-2 5'-GGA CAT CTA AGG GCA TCA CA-3'
3' linker hl8S-3 5'-GGG CAT CAC ACG TAA CTA GT-3'
A 2.6c Sequencing
SP6 5' -TGT AAT ACG ACT CAC TAT AG-3'
77 5'-TGT AAT ACG ACT CAC TAT AG-3'
A 2.6d RT-PCR VH Bio Ltd. P.O Box 7, Gosforth,
(See also Figure 7.1a and 7.1b) Newcastle upon Tyne, NE 3 4DB
Exon 14 5'-TAA ACC CAC ACA GCA CAA CC-3'
Exon 15 5'-TCG CTG GAG GTT TTG CAT TTG-3'
Exon IB 5'-CAG ATG ATG CGG TGG T-3'
Exon l7 5'-GAA ACT GGA GAA ACT CGG TGG-3'
Exon 1C 5' -TGC GTT CAC AAG CTA AGT TG-3'
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A 2.7 RNA
Total RNA isolated from human liver (supplied by V. Lyons, isolated from tissue
freshly obtained by P. Hadoke from the Liver Transplant Programme, Edinburgh).
Total RNA isolated from human peripheral blood mononuclear cells (supplied by V.
Lyons, prepared from buffycoat from Blood Transfusion Service, Edinburgh).
Total RNA isolated from human brain (supplied by D. Brown, prepared from post¬
mortem specimen).
Subcutaneous adipose tissue supplied by P. Hadoke. RNA prepared by TRIzol
method (A 3.2).




First-strand cDNA synthesis kit
First choice RLM-RACE Kit
Genius Thermal Cycler
GlassmaxDNA isolation system
Hybaid Recovery DNA Purification Kit II
Microcon centrifugal filter device
5'-RACE system version 2.0
Reverse Transcription System
RiboProbe In Vitro Transcription Systems
Thermo Sequenase Radiolabeled
Terminator Cycle Sequencing Kit
H.A.West Ltd.
Amersham Pharmacia Biotech UK Ltd.
Ambion, Inc.
Thistle Scientific Ltd.,
Unit 48, Greenhill Business Centre
Coltswood Road, Coatbridge ML5 2AA
Life Technologies Ltd.
Hybaid Ltd.,
Action Court, Ashford Road, Ashford,
Middlesex TW15 1XB
Millipore Corp.,








A 3.1 Gel electrophoresis
a) Agarose gels
Agarose gels were prepared by adding solid agarose (for analysis of PCR products)
or low melting point agarose (to gel purify DNA fragments) to 0.5x TBE 0.8-2.5%
(w/v), boiling in a microwave oven, and adding 0.5 pg/ml ethidium bromide. The
gel was poured into a gel mould with an appropriate comb and once set, submerged
in 0.5x TBE buffer in an electrophoresis tank; Horizon 58 (50 ml gel) or Horizon
11.54 (100 ml gel) (Life Technologies Ltd.). lkb DNA markers and samples
containing 1 pi DNA loading buffer were loaded into the wells and electrophoresed
at 140V. DNA was visualised by UV transillumination at X = 254 nm, imaged using
an Appligene Imager and recorded on Seikosha video printer paper.
b) RNA gels
Integrity of total RNA was confirmed by denaturing agarose gel electrophoresis.
Before use, gel trays, tanks and combs were scrubbed in hot soapy water, soaked in
0.1 M NaOH for 30 min and rinsed with ultrapure water. A 1% (w/v) gel was
prepared by melting 0.25 g agarose in 18 ml DEPC water in a microwave oven for 30
s. Once cooled slightly, 40% (w/v) formaldehyde (2 ml) and lOx MOPS buffer (10
ml) were added and the mixture poured into a gel mould with appropriately sized
combs in place. Once set, the gel was aged by submerging in an electrophoresis tank
in lx MOPS buffer for 15 min. RNA (20 pg) was prepared for electrophoresis by
adding 40% (w/v) formaldehyde (2.5 pi), lOx MOPS buffer (2.5 pi) and deionised
formamide (10 pi) in a total volume of 25 pi. The sample was mixed and RNA
denatured by incubating at 65° C for 15 min. Ethidium bromide was added to the
loading buffer (1 pi per 50 pi loading buffer) and 2 pi of this mix added to each
sample of denatured RNA. The RNA was loaded onto the wells on the gel and
electrophoresed for 20-30 min at 100V. RNA was visualised by UV
transillumination (k = 254 nm) and photographed as before.
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c) Sequencing gels
Prior to use, two glass plates (45 cm x 35 cm) were scrubbed with detergent and
rinsed with distilled water and then absolute ethanol. 0.3 mm spacers were inserted
between the two clean plates, the edges clamped with bulldog clips and sealed with
2% agarose (w/v). 42 g urea was dissolved in 15 ml 40% acylamide:bisacrylamide
(19:1) and 4 ml 20x glycerol tolerant buffer. The solution was made up to 100 ml
with distilled water and filtered through Whatman #1 filter paper. 600 pi 10%
ammonium persulphate (w/v) was added and mixed. 40 pi TEMED was added and
the gel mix cast immediately and left overnight to polymerise. The gel was
assembled into the electrophoresis tank (Kodak Biomax STS 451) using 0.8x glycerol
tolerant buffer as running buffer. The gel was pre-run at 1800 V for 30 min and the
wells flushed with buffer before loading the samples, which had been denatured in
formamide loading buffer at 95°C for 3 min. Gels were typically run at 1800 V and
then transferred to Whatman 3MM paper and vacuum-dried at -80°C (BioRad 583
gel drier). The gel was exposed to autoradiographic film overnight and then
developed.
A 3.2 Ribonucleic acid (RNA) preparation
Total RNA was extracted using the TRIzol method. Tissue was disrupted by grinding
in a pestle and mortar under liquid nitrogen. 1 ml TRIzol reagent was added to up to
100 mg ground tissue. Samples were further disrupted using syringes with needles
of decreasing gauge (19-, 23- and 25- gauge) and then incubated for 5 min at room
temperature. 0.2 ml chloroform was added, samples incubated at room temperature
for 3 min and centrifuged in a microcentrifuge at 14,000 rpm for 15 min at 4°C. The
aqueous phase was transferred to a fresh eppendorf tube and the RNA precipitated by
addition of 0.5 ml isopropanol, incubation at room temperature for 10 min and
centrifugation at 4°C for 10 min at 14,000 rpm. The supernatant was removed with a
drawn-out glass pasteur pipette and pellets washed with 1 ml cold (4°C) 75%
ethanol. After vortexing, samples were centrifuged at 4°C for 5 min at 7,500 rpm.
The supernatant was removed and pellets air-dried for 5 min at room temperature.
Pellets were re-suspended in 20 pi DEPC water by incubating at 65°C for 15 min and
vortexing vigorously.
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A 3.3 Manipulation ofDNA
a) Restriction digests
Plasmid DNA was digested with the appropriate restriction enzyme (10 U) in lx
restriction enzyme buffer in a total volume of 10-40 pi for 1-2 h at 37°C (or 40°C
depending on enzyme). Digestion of the DNA was confirmed by agarose gel
electrophoresis, comparing against uncut plasmid.
b) DNA fragment recovery
DNA fragments were purified using a commercially available kit (Hybaid Recovery
DNA Purification Kit II). Fragments were firstly resolved on a 1-2 % low melting
point agarose gel run at 90V, visualised under UV light (X = 365 nm) (to prevent
damage to DNA) and then excised from the gel using a scalpel. Gel slices were
placed in a spin filter, 400 pi of resuspension binding buffer added, the sample
placed at 55°C for 5 min, and then centrifuged for 30 s at 14,000 rpm. 500 pi Wash
Solution was added to the spin filter and centrifuged as before. This wash step was
repeated, the pellet dried by a further 1 min centrifugation and the spin filter
transferred to a new catch tube. 20 pi Elution Solution was added, the binding
matrix/DNA re-suspended by flicking and DNA recovered by centrifugation as




Fragments recovered from low melting point agarose gels were ligated using 1-5 U
T4 DNA ligase in 2x supplied buffer in a final volume of 10 pi (typically using 2-4
pi (approximately 50 ng) of insert DNA, and 0.5-1 pi (approximately 100 ng) vector
DNA). Reactions were incubated at room temperature for 1 h before transforming
into commercially prepared competent JM109 E. coli.
(ii) Transformations
JM109 cells were removed from storage at -80°C and allowed to thaw on ice. 50 pi
cells was transferred to a pre-chilled 1.5 ml glass test tube, 200-500 ng DNA added
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and the mixture gently flicked to mix. The reaction was placed on ice for 10 min,
heat-shocked at 42°C for 50 s and allowed to recover on ice for 2 min. 200 pi of LB
was added, the cells placed in a rotating incubator at 37°C for 30 min and plated on
LB agar (containing 40 pi 50 mg/ml X-GAL, 40 pi 0.1M 1PTG and 100 pg/ml
ampicillin). The plates were incubated upside down at 37°C overnight.
(iii) Screening ofclones
(iii)a Minipreps
A single transformed bacterial colony was selected and incubated overnight in a
rotating incubator at 37°C in 2 ml LB containing 100 pg/ml ampicillin. Cultures
were centrifuged at 14,000 rpm for 1 min in a microcentrifuge and the pellets re-
suspended in 100 pi cold GTE buffer. 200 pi fresh alkaline SDS was added,
vortexed and placed on ice for 10 min. 150 pi cold 5M potassium acetate (pH 4.8)
was added, vortexed and placed on ice for a further 10 min. Following
centrifugation at 14,000 rpm for 5 min, the supernatant was transferred to fresh
eppendorf tubes. 225 pi chloroform and 225 pi Tris-HCl saturated phenol were
added, the mixture vortexed and centrifuged for 2 min. The supernatant was
transferred to a fresh eppendorf tube, 2 volumes of absolute ethanol added, vortexed
and incubated at room temperature for 5 min. After centrifugation at 14,000 rpm for
5 min, the supernatant was removed with a drawn-out glass pasteur pipette and the
pellet left to air dry for 10 min. The pellet was re-suspended in 50 pi TE containing
50 ng RNase A and stored at -20°C.
(iii)b Large scaleplasmidDNA preparation
Single colonies of transformants containing the required plasmid were added to 500
ml LB containing 100 pg/ml ampicillin and incubated overnight at 37°C in a shaking
incubator. Cultures were centrifuged at 6,000 rpm for 5 min at 4°C in a Beckman
J14 rotor, and the supernatant discarded. The cell pellet was re-suspended in 12 ml
cold GTE buffer, mixed with 24 ml fresh alkaline SDS, and placed on ice for at least
10 min. 16 ml of cold 5 M potassium acetate was added, mixed gently, and placed
on ice for a further 10 min prior to centrifugation at 6,000 rpm for 10 min at 4°C in a
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Beckman J14 rotor. The supernatant was filtered through sterile gauze to remove the
precipitate. 32 ml isopropanol was added to the filtrate and the mixture left at room
temperature for 30 min to precipitate the DNA. The DNA was pelleted by
centrifugation at 10,000 rpm for 3 min at 4°C in a Beckman J14 rotor, and the
supernatant discarded. The DNA pellet was air-dried and re-suspended in 2.2 ml TE
buffer. 3 g CsCl was added, dissolved and 100 pi of ethidium bromide (10 mg/ml)
added. The DNA solution was transferred to a 3 ml Beckman Quickseal
ultracentrifuge tubes, tubes topped up with CsCl/TE solution and centrifuged for
either 4 h at 100,000 rpm, or for 16 to 20 h at 70,000 rpm in a TLA100.3 rotor in a
Beckman Optima TLX Ultracentrifuge. The plasmid DNA band was removed using
a needle and syringe through the tube wall and transferred to a fresh tube. CsCl/TE
was added to fill the tube and the tube was centrifuged as before. The plasmid DNA
band was again removed and the ethidium bromide removed by extracting repeatedly
with isopropanol until the pink colour disappeared. Plasmid DNA was then dialysed
against three changes of 2 1 TE at 4°C. The concentration and quality (ratio of
absorbances at X = 260 and 280 nm) of plasmid DNA were determined using a
GeneQuant spectrophotometer (Pharmacia Biotech). Plasmid DNA was stored at -
20°C.
A 3.4 Polymerase chain reaction (PCR)- based methods
A 3.4.1 Competitive quantitative RT-PCR assay
(i) Construction ofsynthetic RNA competitors
RNA competitors for human GR mRNA and human 18S mRNA (used as an internal
control for variability in target RNA) were synthesised separately but under the same
conditions (Benchmarks 1994). Both competitors contain 83 base pair (bp) deletions
to distinguish the PCR products derived from endogenous and synthetic RNAs.
(i) a) Reverse Transcription (RT)
RT was performed using a kit (Amersham Pharmacia Biotech U.K. Ltd.). 200 ng
total RNA isolated from human liver (Appendix A 2.7) was incubated in a total
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volume of 8 pi at 65°C for 10 min, centrifuged briefly, and placed on ice. 7 pi of a
reverse transcription mix containing 5 pi reverse transcription buffer (contains
reverse transcriptase, RNAguard™, RNase/DNase-free BSA, dATP, dCTP, dGTP,
and dTTP in aqueous buffer), 1 pi 200 mM dithiothreitol (DTT) and 1 pi (0.2 pg)
random hexadeoxynucleotides were added (total volume of 15 pi), and the reaction
incubated at 37°C for 1 h.
(i) b) PCR
7.5 pi RT product was used in a 50 pi reaction mixture containing 5 pi Taq buffer
(contains 100 mM Tris-HCl, 15 mM MgCl2, 500mM KC1), 1 pi dNTP (lOmM of
each nucleotide), 10 pM primer 1 (hGR-1 or hi8S-1) (Appendix A 2.6b), 10 pM
primer 2 (hGR-2 or hl8S-2) (Appendix A 2.6b) and 0.5 pi Taq polymerase. The
reaction mixture was overlaid with 2 drops of mineral oil, and incubated at 94°C for
3 min before 30 cycles of PCR amplification (94°C 40 s; 54°C 40 s; 72°C 40 s) were
performed. The reaction was incubated at 72°C for 10 min following the last cycle
of PCR. A 5 pi aliquot of the reaction mixture was analysed by gel electrophoresis
(Appendix A 3.1a) to confirm the presence of one band of the expected size (635 bp
for GR, 613 bp for 18S).
To create the internal deletion 1 pi of the first PCR product was used as a template
for the first re-amplification step. PCR was carried out under the same conditions
but the 3' primer (primer 1) was replaced by the internal linker primer (hGR-3 or
hl8S-3) (Appendix A 2.6b). The 5' end of the internal linker primer is identical to
the 3' end of the 3' primer (match of 12 bases for GR and 10 bases for 18S) and thus
serves as a Tinker' between the 3' and 5' primers in the second re-amplification step.
A 5 pi aliquot of the reaction mixture was analysed by gel electrophoresis to confirm
the presence of one band of the expected size (531 bp for GR and 511 bp for 18S).
In the second re-amplification, lpl of the first re-amplification step PCR product
(containing the 531 bp GR or 511 bp 18S fragment) was re-amplified under the same
PCR conditions using the original 3' primer (primer 1). In both re-amplification
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steps the same 5' primer (primer 2) was used. A 5 pi aliquot of the PCR product was
analysed by gel electrophoresis to confirm the presence of only one band (543 bp for
GR, 521 bp for 18S). This PCR fragment thus contains an internal deletion (83 bp
for both GR and 18S), with identical 5' and 3' ends to the original fragment and the
same DNA sequence except for the missing 83 bp.
(i) c) Isolation ofPCRfragment andplasmidpreparation
The PCR product was run on a 2% low melting point gel, the fragment cut out and
the DNA purified (Appendix A 3.3b), ligated into pGEMT easy vector (Appendix A
3.3c(i)) and transformed into JM109 cells (Appendix A 3.3c(ii)). Small-scale
preparation of plasmid DNA was performed (Appendix A 3.3c(iii)a) and sequenced
using SP6 and 77 to check the orientation of the insert (Appendix A 3.4.5). Large-
scale plasmid DNA preparations were made so that there was sufficient competitor
for the whole experiment (Appendix A 3.3c(iii)b).
(i) d) Linearization of template
Linear GR/18S template was prepared by digesting 10 pg of the DNA from above in
a 50 pi reaction with 30 U restriction enzyme for 1 h (Sail at 37°C for GR, Ncol
40°C for 18S). Linearization was confirmed by agarose gel electrophoresis.
(i) e) In vitro transcription
In vitro transcription was carried out using a commercial kit (Promega U.K. Ltd.).
250 ng linearised template was incubated for 1 h at 37°C in a 50 pi reaction
containing 10 pi 5x transcription buffer (contains 200 mM Tris-HCl (pH 7.9), 30
mM MgCl2, 10 mM spermidine, 50 mM NaCl), 5 pi 100 mM DTT, 50 U RNasin, 10
pi rNTPs (ACGU 2.5mM), 30 U polymerase (77 or SPG according to orientation of
insert). 2 U DNase was added and incubated at 37°C for a further 15 min to digest
the DNA.
The synthesised competitor RNA was extracted with phenol/chloroform/isoamyl
alcohol (25:24:1) and then with chloroform/isoamyl alcohol (24:1) and then passed
through a microcon centrifuge filter YM100 to remove free nucleotides. RNA was
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precipitated overnight at -80°C by adding O.lx volume 3 M sodium acetate (pH 5.5)
and 2.5x volume absolute ethanol. This was spun at 12,000 rpm for 15 min, the
pellet washed with 75% ethanol, dried and re-suspended in 10 pi water.
RNA was quantitated on a GeneQuant spectrophotometer (Pharmacia Biotech) and
by agarose gel electrophoresis against an RNA mass ladder. The RNA competitors
were stored at -80°C.
(i) f) Calculation ofcompetitor concentration
The concentration of the competitor in moles (M) was calculated by dividing the
concentration of RNA (pg/pl) quantitated from GeneQuant by the molecular weight
of the competitor (where molecular weight = average molecular weight of nucleotide
(330) x number of nucleotides in fragment (calculated from final PCR product size +
number of base pairs from vector).
A 3.4.1 (ii) Competitive quantitative RT-PCR assay
The range of competitor concentrations for use in the assay was determined using
100 ng total RNA from liver (for assay methods see below), firstly by diluting
competitors over a 10-fold range, and then narrowing to a 4-fold range (see Figure A
3.1). The inter-assay coefficient of variation was 12%. As an additional internal
control to ensure inter-assay repeatability a liver sample was included after every 4th
muscle sample in the experiment.
(ii) a) RT
RT was carried out as above (Appendix A 3.4.1(i)a). For each sample, 4 separate RT
reactions were set up over a 4-fold range of serial dilutions of the two competitors
(for GR (2 x 10~nM, 1 x 10"nM, 0.5 x 10"nM, 0.25 x 10"nM); for 18S (2 x 10"7M, 1
x 10"7M, 0.5 x 10~7M, 0.25 x 10~7M)). Thus each reaction contained 100 ng target
RNA + 1 pi of each competitor (Tube 1, GR 2 x 10"UM, 18S 2 x 10"7M; Tube 2 GR




Target RNA (ng) 100 100 100 100 100
GR Competitor (M) 1 x 10"9 10"10 10"11 10"12 10"13
Figure A 3.1 Example of agarose gel from competitive-quantitative RT-PCR
assay on human liver
Gel shows increasing size of bands for the 100 ng target RNA used in the assay
against the decreasing band size of the serial 10-fold dilutions of GR competitor.
Band intensities are determined using a phosphorimager and AIDA package and the
ratio of target band to competitor band, corrected for size differences calculated. The
log ratio of band intensities is plotted against the log of competitor concentration and
the amount of target mRNA obtained at the equivalence point of 1.
(ii) b) PCR
PCRs for GR and 18S were performed separately using the same conditions as above
(Appendix A 3.4.1 (i)b). For GR 7.5 pi RT product was used with 10 pM primer 1
(hGR-1) and 10 pM primer 2 (hGR-2), and for 18S 5 pi RT product was used with
10 pM primer 1 (hl8S-l) and 10 pM primer 2 (hl8S-2).
(ii) c) Quantification ofdata
PCR products were size separated by agarose gel electrophoresis. The gel was
exposed to a Fuji phosphor screen and analysed using a FujiFilm FLA-2000
phosphorimager. Background was set by placing a linebox at the level of interest
and measuring the intensity (mm). Band areas were enclosed within a rectangle and
the intensity within the band determined by 3D densitometry (AIDA package),
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subtracting background. The ratio of target band to competitor band, corrected for
size differences, was calculated (using Sigma Plot 4.0). The log ratio of band
intensities was plotted against the log of competitor concentration and the amount of
target mRNA obtained at the equivalence point of 1.
A 3.4.2 5 '-RACE (RapidAmplification ofcDNA Ends) - PCR
a) First strand cDNA synthesis
5'-RACE-PCR was performed using a commercial kit (Life Technologies Ltd.)
according to the manufacturer's instructions with minor modifications. 2.5 pmol
GSP1 (Appendix A 2.6a), a primer complementary to human exon 2, was annealed
to 5 pg total RNA in a total volume of 15 pi by denaturing at 70°C for 10 min and
then placing on ice for 1 min. Lirst strand cDNA synthesis of GR cDNA was carried
out in a 25 pi reaction mixture containing 20 mM Tris-HCl (pH 8.4), 50 mM KC1,
2.5 mM MgCl2, 10 mM DTT, 400 pM dNTPs (all supplied with kit), incubating at
42°C for 1 min, adding 200 U Superscript II reverse transcriptase and incubating for
a further 50 min. Reverse transcriptase was inactivated by incubation at 70°C for 15
min, and adding 1 pi RNase mix before further incubation at 37°C for 30 min.
b) cDNA purification
cDNA was purified using a GlassMAX DNA Isolation Spin Cartridge. 100 pi of
ultrapure water was equilibrated to 65°C and the binding solution (6M Nal)
equilibrated to room temperature. 120 pi binding solution was added to the cDNA
and the mixture transferred to a GlassMAX spin cartridge. The spin cartridge was
centrifuged at 13,000 rpm for 20 s and the flow-through discarded. 400 pi cold
(4°C) lx wash buffer was added to the spin cartridge and centrifuged at 13,000 rpm
for 20 s. This wash step was repeated three times. The cartridge was then washed
twice with 400 pi cold (4°C) 70% ethanol and centrifuged at 13,000 rpm for 1 min
after the final wash. The spin cartridge was transferred into a sample recovery tube
and 50 pi of the pre-heated 65°C water added. cDNA was eluted by centrifugation at
13,000 rpm for 20 s. The purified cDNA was dried using a Speedvac (Savant) to a
volume of 10 pi.
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c) Terminal deoxynucleotidyl transferase (TdT) tailing ofcDNA
10 jul purified cDNA was tailed with dC in a 25 pi reaction containing 10 mM Tris-
HC1 (pH 8.4), 25 mM KC1, 1.5 mM MgCk (supplied as 5x tailing buffer with kit),
and 200 pM dCTP. The reaction mix was incubated for 2 min at 94°C, and chilled
on ice for 1 min. 10 U TdT was added and the reaction incubated for 10 min at 37°C.
TdT was inactivated by incubating at 65°C for 10 min.
d) PCR
Two rounds of PCR were performed to increase specificity. In the first round, 10 pi
dC-tailed cDNA was used in a reaction with 400 nM 'anchor' primer (5'-
CUACACUACUAGGCCACGCGGTCGACTAGTACGGG-IIGGGIIGGGIIG-3',
from kit), 400 nM GSP2 primer (Appendix A 2.6a), 20 mM Tris-HCl (pH 8.4), 50
mM KC1, 1.5 mM MgC^, and 200 pM dNTPs in a total volume of 50 pi. Reactions
were overlaid with 2 drops of mineral oil and incubated at 94°C for 5 min before
adding 2.5 U Taq DNA Polymerase. 35 cycles of PCR amplification (96°C, 45 s;
50°C, 40 s; 72°C, 1 min 30s) were performed, followed by incubation at 72°C for 10
min. A nested PCR was carried out on the products of the first PCR reaction, under
the same conditions but with 400 nM each of primers 'universal anchor primer' (5'-
CUACUACUACUAGGCCACGCGTCGACTAGTAC-3', from kit) and GSP3
(Appendix A 2.6.1).
A 3.4.3 RLM (RNA Ligase Mediated RapidAmplification ofcDNA Ends) -RACE
5'-RACE-PCR was also performed using a First Choice RLM-RACE kit (Ambion
Inc.) according to manufacturer's instructions.
(i) RNA processing
(i) a) Calf intestinal phosphatase (CIP) treatment
10 pg total RNA was incubated at 37°C for 1 h in a 20 pi reaction containing 2 pi
lOx CIP buffer and 2 pi CIP (supplied with kit). The CIP reaction was terminated by
adding 15 pi ammonium acetate solution and the RNA was extracted with
pheno 1: chloro form.
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(i) b) Tobacco acidpyrophosphatase (TAP) treatment
5 jliI CIP-treated RNA was incubated at 37°C for 1 h in a 10 pi reaction containing
lOx TAP buffer and 1 (0,1 TAP (supplied with kit).
(i) c) RNA adapter ligation
A synthetic RNA adapter was ligated to 2 pi CIP/TAP-treated RNA by incubating at
37°C for 1 h in a 10 pi reaction containing lOx RNA ligase buffer, 1 pi RNA adapter
and 2.5 U T4 RNA ligase (all supplied with kit).
(ii) RT
2 pi ligated RNA was reverse transcribed by incubating at 42°C for 1 h in a 20 pi
reaction containing 4 pi dNTPs, 2 pi random decamers, 2 pi lOx RT-PCR buffer, 10
U RNase inhibitor and 1 pi MMLV reverse transcriptase.
(iii) PCR
Two rounds of nested PCR were performed. In the first 'outer' PCR, 1 pi RT
product was used in a reaction containing 2 pi outer RNA adapter primer (from kit),
2 pi outer gene specific primer (GSP2, Appendix A 2.6a), 5 pi lOx RT-PCR buffer,
and 4 pi dNTPs in a total volume of 50 pi. Reactions were incubated at 94°C for 3
min before adding 1.25 U Taq DNA Polymerase. 35 cycles of PCR amplification
(94°C, 1 min; 60°C, 1 min; 72°C, 1 min) were performed, followed by incubation at
72°C for 7 min. A second 'inner' PCR was carried out on the products of the first
PCR reaction, under the same conditions but with 2 pi each of primers inner RNA
adapter primer (from kit) and inner gene specific primer (GSP3, Appendix A 2.6a).
A 3.4.4 Reverse Transcription (RT) - PCR
a) RT
RT was performed using a commercial kit (Promega U.K. Ltd.) on 5 pg total RNA in
a total volume of 40 pi containing 4 pi reverse transcription buffer (contains 100 mM
Tris-HCl (pH 8.8 at 25°C), 500 mM KC1, 1% Triton X®-100), 25 mM MgCl2, 10
mM dNTP, 40 U recombinant RNasin ribonuclease inhibitor, and 1 pg oligo(dT)
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primer, adding 40 U AMV reverse transcriptase and incubating at 42°C for 45 min.
RT was inactivated by incubation at 99°C for 5 min and 4°C for 5 min.
b) PCR
5 pi RT product was used in a 50 pi reaction mixture containing 5 pi Taq buffer
(contains 100 mM Tris-HCl, 500 mM KC1, Triton®X-100), 3 pi MgCh (25 mM), 1
pi dNTP (10 mM of each nucleotide), 40 pM 5'-primer (i.e. primers corresponding to
rat exons 14, 15, %, h, 110, Appendix A 2.6d) and 40 pM 3'-primer (GSP3 Appendix
A 2.6a). One 7b<yBead™ hot start polymerase wax bead was added, the reactions
overlaid with 2 drops ofmineral oil and incubated at 95°C for 4 min 10 s. 35 cycles
of PCR amplification (95°C 50 s; 50°C 45 s; 72°C 1 min 30 s) were performed,
followed by incubation at 72°C for 5 min.
A 3.4.5 Sequencing
DNA sequencing was performed using a Thermo Sequenase Radiolabelled
Terminator Cycle Sequencing Kit (Amersham Pharmacia Biotech UK Ltd.).
Termination mixes for each ddNTP were prepared by mixing 2 pi dGTP nucleotide
master mix and 0.5 pi [a-33P] ddNTP (G, A, T, or C; one of each per sequencing
reaction). A reaction master mix was prepared containing 2 pi reaction buffer
(contains 260 mM Tris-HCl, pH 9.5, 65 mM MgCy, 1 pi DNA, 0.05 pmol primer
(Appendix A 2.6.3), 13 pi distilled water and 8 U Thermo Sequenase polymerase.
4.5 pi reaction mix was added to each termination mix. 35 cycles of 95°C, 30 s;
55°C, 30 s; 72°C 1 min 30 s were performed and upon completion of the cycling
program, 4 pi 'stop' solution (contains 95% formamide, 20 mM EDTA, 0.05%
bromophenol blue, 0.05% xylene cyanol FF) was added and the reactions stored at -
20°C. Samples were resolved on 6% glycerol tolerant sequencing polyacrylamide
gels (Appendix A 3.1c).
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Summary
BACKGROUND The low dose dexamethasone sup¬
pression test (DST) has been used to detect subtle
variations in the feedback suppression of the
hypothalamic-pituitary-adrenal axis, which may con¬
tribute to the pathogenesis of several diseases includ¬
ing depression, the metabolic syndrome and coronary
artery disease. Little is known about the reproduc¬
ibility of this test, orwhether the test can be combined
with analysis of salivary Cortisol which would offer a
significant advantage over plasma in population
studies.
SUBJECTS AND DESIGN A low dose DST was carried
out in 29 healthy subjects (14 men, 15 women), aged
24-54 (mean 35-1) years, on two separate occasions
1-10 weeks apart. Following the administration of
0-25 mg dexamethasone (DXM) at 2200 h, plasma and
saliva were sampled at 0830 h the next day. Cortisol
was measured by radioimmunoassay in plasma and
time-resolved immunofluorescent assay ('DELFIA') in
saliva. Bland-Altman plots were produced for post-
DXM plasma and salivary Cortisol measures and used
to derive a coefficient of repeatability for each mea¬
sure, which describes the range of Cortisol measure¬
ments within which 95% of repeated measurements
will fall.
RESULTS The baseline, pre-DXM Cortisol concentra¬
tions were far more variable for saliva (mean 16-5,
Correspondence: Dr R. M. Reynolds, MRC Unit, Southampton
General Hospital, Tremona Road, Southampton SO 16 6YD, UK.
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range 4-4-34 nmol/l) than for plasma (mean 407-5;
range 232-958 nmol/l). Following DXM both measure¬
ments showed an approximately 30% suppression
from baseline but the variability of salivary Cortisol
was much greater. From the Bland-Altman plots the
95% range for the differences about their mean was
calculated and used as an indication of repeatability.
For plasma 95% of differences were within 0-78 log
units, indicating that a repeated measurement was
approximately half as small or twice as large as the
first. For saliva 95% of differences were within 1-64,
indicating that a repeated measurement was approxi¬
mately five times as small or five times as large as the
first.
CONCLUSIONS Assessment of dexamethasone sup¬
pression by salivary Cortisol measurement is far less
repeatable than the use of plasma Cortisol. In the
context of field studies of dexamethasone suppres¬
sion, salivary Cortisol measurements may only be
appropriate for large numbers of subjects.
Although the adverse health effects of excess glucocorticoids in
patients with Cushing's disease or during treatment with
exogenous corticosteroids are well known, subtle increases in
the circulating concentrations of these hormones have been
implicated in the aetiology of several common disorders
including central obesity, depression, the metabolic syndrome
and possibly coronary artery disease (Carroll et al., 1981;
Bjorntorp, 1993; Ljung et al., 1966; Brunner, 1997). These
changes in glucocorticoid exposure may be mediated by
alterations in the sensitivity of the central feedback control of
the hypothalmic-pituitary-adrenal axis (HPAA). These are
demonstrable by administration of the synthetic glucocorticoid,
dexamethasone (DXM), at night, which results in the suppres¬
sion of plasma Cortisol concentrations the following morning.
The conventional protocol for the overnight dexamethasone
suppression test (DST) (Liddle, 1960) depends on the
administration of between 1 and 2 mg DXM and is designed
to identify patients with Cushing's syndrome. However, the use
of a much lower DXM dose, e.g. 0-25 mg (Best et al., 1997)
may be more informative in distinguishing physiological
variations in HPAA activity. Recently it has been suggested
that the very low dose test could be further refined by measuring
© 1998 Blackwell Science Ltd 307
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the overnight suppression of salivary rather than plasma
Cortisol. Measurement of salivary Cortisol levels would offer
several potential advantages, enabling it to become a useful
epidemiological tool for population studies of HPAA function
(Landon et al., 1982). These include simplicity of sample
collection, allowing the test to be performed at home, the
avoidance of venepuncture which results in stress-induced
hypercortisolaemia and that salivary measurements reflect free
plasma Cortisol levels which are less influenced by changes in
corticosteroid binding globulin. Because of the interest in
studying the HPAA in large groups of subjects at risk of obesity
or the metabolic syndrome, we have assessed the reproduci¬
bility of the very low dose DST by comparing Cortisol
suppression in saliva and plasma in 29 healthy subjects.
weight (kg) divided by the height (m) squared. Waist and hip
circumferences were measured with a steel tape measure, at the
level of the umbilicus and the greater trochanters, respectively.
The waist to hip ratio was calculated as a measure of central
obesity. The subjects were also asked to complete the 10-item
General Health Questionnaire (cut-off score for depression=
score >5), a previously validated questionnaire for detecting
depression (Yesavage et al., 1983). Cortisol was measured in
plasma by radioimmunoassay (Guildhay antisera, Moore et al.,
1985). Cortisol and cortisone were measured in saliva by time-
resolved immunofluorescent assay ('DELFIA', Wood et al.,
1997). The coefficients of variation (CV) were 6-3% at
300nmol/l for plasma-based and 8-5% at 12 nmol/1 for
saliva-based assays.
Methods
The study group consisted of 29 healthy subjects, 14 men and
15 women. None of them had a history of endocrine disease.
They were taking no medication and none had received steroid
treatment systemically or topically within the previous 6
months. The study was approved by the Southampton and
South West Hampshire Health Authority and University of
Southampton Joint Ethical Committee.
In each subject two low dose DXM tests were performed at
least 1 week but no more than 10 weeks apart. On the first day
the subjects attended after fasting for 12 h and saliva and blood
samples were collected at 0830 h. Between 2 and 4 ml of saliva
was collected into a salivette tube (Sarstedt Ltd, Leicester, UK).
The subjects took 0-25 mg DXM at 2200 h the same night and
attended the following morning after a further 12-h overnight
fast for collection of saliva and blood samples at 0830 h. Plasma
and saliva samples were separated by centrifugation and stored
at —40°C until analysis. The subjects' height was measured
with a portable stadiometer (CMS weighing equipment,
Camden, London, UK) and weight with a SECA scale (SECA
Ltd, Birmingham, UK). Body mass index was calculated as the
Statistical analysis
As the distributions of Cortisol measurements were highly
skewed, logc-transformed values were used in all analyses.
Bland-Altman plots (the differences between two repeated
measurements for each subject against the mean of those
measurements) were produced for post-DXM plasma and
salivary Cortisol measures (Bland & Altman, 1986). From
these the 95% range for the differences about their mean was
calculated and this used as an indication of repeatability.
Fractional suppression of Cortisol in plasma and saliva was
calculated as (day 1 sample — day 2 sample)/day 1 sample (%).
Results
The subjects were aged 24-54 (mean 351) years with body
mass indices ranging from 17-9 to 31-3 (means 27-1 in men vs.
23-5 in women, P = 0 001 kg/m2 and waist to hip ratios ranging
from 0-82 to 1-2 (mean 0-94) in men and 0-67 to 0-81 (mean
0-74) in women. None of the subjects was depressed as
indicated by the General Health Questionnaire. Table 1 shows
the baseline and post-DXM suppression concentrations of
Table 1 Mean (95% confidence interval) fasting plasma Cortisol and salivary Cortisol concentration before and after suppression with 0-25 mg
dexamethasone in duplicate tests carried out in 29 subjects at least one week apart
Baseline First test Second test
Mean Range Mean Range Mean Range
(95% CI) (95% CI) (95% CI)
Plasma Cortisol 407.5 232-958 270.4 116-802 265.1 105-853
(nmol/1) (362.27, 458.33) (231.18, 316.33) (226.60, 310.07)
Salivary Cortisol 15.3 4.4-34.4 8.6 1.6-29.2 7.3 1.6-23.8
(nmol/1) (13.11, 17.94) (6.65, 110.08) (5.45, 9.82)
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Cortisol measured in plasma and saliva. The basal plasma
Cortisol concentrations ranged from 232 to 958 nmol/1 (mean
407-5 nmol/1) and tended to be lower in the men than the
women (371-4 vs. 485-6 nmol/1, P = 0-06). The mean
concentration of Cortisol measured after DXM suppression
was similar for both tests as assessed by plasma (270-4 vs. 265-1
nmol/1) or saliva measurements (Cortisol 8-6 vs. 7-3 nmol/1, total
Cortisol + cortisone, 37-6 vs. 29-4 nmol/1). Also the fractional
suppression of plasma Cortisol, which was similar on the two
occasions (30-6% and 30-4%), was somewhat but not
significantly greater than the fractional Cortisol suppression
measured in saliva (27-3% and 28-8%). Neither the fractional
suppression nor the post-DXM Cortisol measurements differed
according to sex, age, body mass index or waist to hip ratio.
The reproducibility of the post-DXM Cortisol concentrations
obtained from the two tests is illustrated by the Bland-Altman
plots in Figs 1 and 2 (showing the differences in Cortisol
concentration on the two occasions plotted against the mean).
For plasma (Fig 1), the mean difference did not differ
significantly from zero (mean 0-02, /, = 0-80); 95% of
differences were within 0-78 log0 units from the mean
(—0-76—1-0-80) indicating that a repeated measurement was
likely to be approximately half as small or twice as large as the
first. For saliva (Fig 2), the mean also did not differ significantly
from zero (mean 016, P = 0-29) but 95% of differences were
within l-641ogc units from the mean (—1-48—(-1-80), thus
indicating that a repeated measurement was likely to be
approximately five times as small or five times as large as the
first. Saliva repeatability was no better when cortisone was
considered, either alone, when as a total of salivary Cortisol and
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Fig-1 Differences in logc (post-DXM plasma Cortisol)
concentrations plotted against mean logc concentration, n =29.
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Fig. 2 Differences in log„ (post-DXM salivary Cortisol)
concentrations plotted against mean loge concentration, n —29.
Discussion
This study suggests that the use of salivary Cortisol measure¬
ment in the analysis of a very low dose overnight DST is less
reproducible than plasma Cortisol measurement. For saliva the
repeated measurement was as much as five times as small or
five times as large as the first for 95% of the time, while for
plasma a repeated measurement was only half as small or twice
as large as the first. Although the DST has gained increasing
importance in studies examining the role of abnormalities of the
HPAA in pathogenesis of several common diseases, there is
surprisingly little information on the reproducibility of the test.
Charles el at. (1982) showed similar levels of HPA axis
suppression in 17 of 19 depressed patients studied on two
occasions after the administration of 1 mg DXM. A similar
conclusion was reached by Greden et at. (1983), who showed
that nine of 13 subjects studied on two occasions had the same
abnormal response to 1 mg DXM, defined by a threshold level of
plasma Cortisol suppression. However, in these studies of
subjects with clear evidence of disease, no data was given on
the reproducibility of the test within individuals. Importantly,
the use of such a high dose of DXM would be expected to
completely suppress the axis and hence be more likely to result
in reproducibly undetectable Cortisol levels. This contrasts with
our study, where post-DXM Cortisol levels were well within the
detection limits of the assay, showing an approximately 30%
suppression and hence a greater within-subject variability. The
poorer performance of the 0-25 mg DST based on salivary
measurements is difficult to explain. It was not due to assay
imprecision, as the 'DELFIA' assay used in our studies has
been shown to be reproducible over a wide range of Cortisol
concentrations and the assays for saliva and plasma had similar
CVs. In addition, previous studies have shown that saliva
1998 Blackwell Science Ltd, Clinical Endocrinology, 49, 307-310
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quantitatively reflects free plasma Cortisol, and therefore might
be expected to be a better index of DXM suppression. Also,
although salivary Cortisol is converted to cortisone by 11/3-
hydroxysteroid dehydrogenase Type 2 (Walker & Best, 1995)
the salivary results were not significantly improved when the
total of Cortisol and cortisone concentrations were considered.
Thus the reason for the poor reproducibility of the saliva
measurement is unclear, but may include sampling problems
(e.g. variable salivary flow rates) or a poor correlation between
salivary and plasma Cortisol concentrations at low (post-DXM)
concentrations.
Our data imply that the intrinsic variation in salivary Cortisol
levels has been underestimated. The poorer repeatability of
measurements compared to plasma suggests that in the context
of field studies of dexamethasone suppression in normal
individuals, salivary Cortisol measurements may only be
appropriate for large numbers of subjects.
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ABSTRACT
It has been suggested that increased activity of the hypothalamic-
pituitary-adrenal axis may link low birth weight with subsequent
development ofcardiovascular risk factors and disease. Two hundred
and five men, aged 66-77 yr, who were born and still live in East
Hertfordshire underwent an overnight very low dose (0.25 mg) dexa-
methasone suppression test followed by a low dose l-/xgACTH-(l-24)
stimulation test. A 24-h urine sample was collected for analysis of
Cortisol metabolites by gas chromatography/electron impact mass
spectrometry. Men with lower birth weight had enhanced responses
ofplasma Cortisol to ACTH-(l-24) (P = 0.03), increased total urinary
Cortisol metabolite excretion (after adjustment for confounding effects
of increased obesity and lean body mass in high birth weight men; P =
0.04), but no difference in plasma Cortisol after dexamethasone. Fea¬
tures of the metabolic syndrome were independently associated with
enhanced adrenal responsiveness to ACTH-(l-24) (raised blood pres¬
sure, P = 0.02; glucose intolerance, P = 0.09; hypertriglyceridemia,
P = 0.02), with trends to increased urinary Cortisol metabolite ex¬
cretion, but not with differences in plasma Cortisol after dexameth¬
asone. Menwith low birthweight and/or the metabolic syndrome have
increased activity of the hypothalamic-pituitary-adrenal axis. This
may be an important mechanism underpinning the effects of events
in early life on later cardiovascular disease. (J Clin Endocrinol Metab
86: 245-250, 2001)
THE MECHANISMS underlying the association of type 2diabetes, raised blood pressure, and dyslipidemia (i.e.
the metabolic or insulin resistance syndrome) and their ex¬
acerbation by obesity are not known, but are important in our
understanding of the pathophysiology of atheromatous dis¬
ease. As patients with Cushing's syndrome develop these
clinical features, it is an attractive idea that less profound
disturbances of the hypothalamic-pituitary-adrenal axis
(HPAA) might underlie the metabolic syndrome and its link
with obesity. This idea is supported by case-control and
cross-sectional studies that show that high blood pressure,
glucose intolerance, insulin resistance, and hyperlipidemia
are associated with elevated Cortisol concentrations in blood,
saliva, and urine (1-6) or impaired peripheral inactivation of
Cortisol (7). Increased secretion of Cortisol also occurs in obe¬
sity, particularly if the obesity has a central distribution (8, 9).
In addition, increased Cortisol secretion could explain the link
between psychosocial deprivation and cardiovascular risk (10).
Recent observational studies have shown that low birth
weight predicts subsequent hypertension, insulin resistance,
glucose intolerance, and cardiovascular disease (11). Events
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in early life may have long-term effects on the HPAA. Ex¬
posure of pregnant rats to adverse influences during gesta¬
tion, including undernutrition, treatment with dexametha¬
sone, alcohol, physical restraint, or nonabortive maternal
infections, results in the birth of small offspring with hyper¬
tension and insulin resistance. These animals also have el¬
evated basal or stress-induced glucocorticoid secretion (12-
15). In studies of adult men, we recently reported that higher
fastingmorning plasma Cortisol concentrations, a crude mea¬
sure of Cortisol secretion, are associated with higher blood
pressure, plasma glucose and triglyceride concentrations,
and lower birth weight (16, 17). Children and adolescents
with lower birthweight have also been reported to excretemore
Cortisol or its metabolites in urine (18, 19). These studies have
led to the hypothesis that events in early life permanently alter
or program Cortisol secretion, and that this together with in¬
creased obesity leads to a high prevalence of the metabolic
syndrome and cardiovascular disease in adult life.
We investigated a group of men of known birth weight to
test this hypothesis by characterizing abnormalities of Cor¬
tisol secretion in relation to features of the metabolic syn¬
drome, obesity, and birth weight.
Subjects and Methods
Subject selection
We previously studied a cohort of 370 men born between 1920 and
1930 in East Hertfordshire, UK, for whom birth weights were recorded
by midwives. In 1991, blood pressure was measured, and 75-g oral
glucose tolerance tests were performed (20). In 1997 we approached the
surviving 245 men, of whom 205 were suitable and agreed to take part
245
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in the present study. Subjects with clinical evidence of pituitary or
adrenal disease and those who had received oral glucocorticoids in the
previous 3monthswere excluded. Subjects were invited to attend on any
convenient day between July and December. Ethical committee ap¬
proval and written informed consent were obtained.
Clinical protocol
At a preliminary interview, information about medical and social
history, family history of diabetes and hypertension, smoking habits,
alcohol consumption, and current medication was recorded, and sub¬
jects completed a 10-item General Health Questionnaire to measure
mood (21). On another occasion, subjects ingested 0.25 mg dexameth-
asone at 2200 h and fasted overnight. The following morning they
attended a local clinic at 0830 h, a 21-gauge butterfly cannula was
inserted in an antecubital vein, and, after 30 min rest, a baseline blood
sample was obtained before 1.0 /xg freshly diluted ACTH-(l-24) (tet-
racosactrin, Synaclhen, Alliance, Chippenham, UK) was injected as a
bolus with a 10 mL saline flush. Venous blood was sampled through the
cannula at 20, 30, 40, and 60 min after ACTH-(l-24) administration.
Samples were centrifuged immediately, and plasma was stored at —80
C. Height and weight were recorded, and waist and hip circumferences
were measured with steel tape at the level of the umbilicus and greater
trochanter, respectively. Finally, subjects collected a 24-h urine sample
at least a week before or a week after the dexamethasone/ACTH-(l-24)
test.
Dexamethasone (0.25 mg) and ACTH-(l-24) (1 /xg) doses were se¬
lected to provide an average 50-75% maximal suppression or stimula¬
tion, respectively, with a wide range (22, 23). More conventional doses
[e.g. 1 mg dexamethasone or 250 /xg ACTH-(l-24)] would be expected
to produce maximal effects in all of these otherwise healthy participants
and would not allow detection of subtle alterations in the control of
Cortisol secretion.
Laboratory methods
Measurements of glucose, triglyceride, and insulin concentrations
have been reported previously (20). RIAs were used to measure plasma
Cortisol with Guildhay antisera (24): corticosteroid-binding globulin
(Medgenics Diagnostics, Fleurus, Belgium), dehydroepiandrosterone
(Diagnostic Systems Laboratories, Inc., Webster, TX), 17a-hydroxypro-
gesterone (in-house RIA), progesterone (Immulite analyzer, Diagnostic
Products Ltd., Gwynedd, Wales), and dexamethasone (enzyme-linked
immunosorbent assay adapted from Cozart Biosciences Ltd., Abingdon,
UK). Urinary creatinine was measured using the Jaffe reaction on the
Bayer PLC (Newbury, UK) Advia analyzer.
Cortisol, cortisone, and their metabolites were measured in urine by
gas chromatography/electron impact mass spectrometry (22, 25). Total
Cortisol metabolite excretion was calculated as tetrahydrocortisols (THFs)
plus tetrahydrocortisone (THE) plus cortols plus cortolones. Ratios of uri¬
nary metabolites were used to infer relative activation of the principle
enzymesmetabolizingCortisol. Relative reduction by 5a- and 5/3-reductases
was inferred from the 5/3-THF/5a-THF ratio. Whole body equilibrium
between Cortisol and cortisone, determined by the balance of tissue-specific
activities of 11/3-reductase and 11/3-dehydrogenase activities, was inferred
from the ratio of THFs/THE. Renal 11/3-dehydrogenase activity was in¬
ferred from the urinary cortisol/cortisone ratio.
Statistical analysis
To obtain normally distributed variables, measurements of glucose,
triglycerides, urinary Cortisol metabolites, peak Cortisol after ACTH-(1-
24), and area under the curve after ACTH-(l-24) administration for
dehydroepiandrosterone and 17a-hydroxyprogesterone, were loge
transformed. Geometric means and sds are therefore presented for these
variables. Associations between continuously distributed variableswere
assessed by the Pearson correlation coefficient, and associations between
continuous and categorical variables were assessed by the Mann-Whit¬
ney U test or the two-sample t test as appropriate. Multiple linear
regression was then used to explore the relationship between continu¬
ously distributed response variables and possible explanatory variables,
with adjustment for confounding factors. Multiple logistic regression
was used to analyze binary response variables. In addition to analyzing
the peak Cortisol response to ACTH-(l-24) using the methods described
above, a longitudinal analysis of the Cortisol response to ACTH-(l-24)
was also conducted. The longitudinal approach considers the full series
of Cortisol data for each subject and models the average response during
the test in relation to the factors of interest, taking into account the effects
of time and the autocorrelation of Cortisol measurements within each
subject (26). All statistical analysis was carried out usingSTATA, release
5; the xtgee feature was used to implement the longitudinal analysis
(Statacorp 1997, Stata Statistical software release 5, Stata Corp., College
Station, TX).
Results
Subject characteristics and potential confounders
The men were aged between 66 and 77 (mean, 70.9; sd, 3.1)
yr, with a mean body mass index (BMI) of 26.9 (sd, 3.7)
kg/m2. Fifteen men had type 2 diabetes (2 h glucose, >11.1
mmol/L), and 33 had impaired glucose tolerance (IGT; 2-h
glucose, 7.8-11.0 mmol/L). Mean systolic blood pressure
was 161.5 mm Hg (sd, 22.1), and 73 men were receiving
treatment with antihypertensive drugs. Two subjects were
excluded from analysis of plasma Cortisol concentrations
because of extreme values; one had a vaso-vagal event after
iv cannulation, and the other was receiving ethinylestradiol
treatment. Six men had missing values for glucose measure¬
ments. None of the measurements of Cortisol in plasma or
urine correlated with age or differed in subjects receiving
topical or inhaled corticosteroid therapy (n = 16). None of the
differences in plasma Cortisol described below were ac¬
counted for by variation in plasma corticosteroid-binding
globulin or dexamethasone concentrations (data not shown).
Obesity, reflected in increased BMI, was associated with
higher blood pressure (r = 0.18; P = 0.04), hypertriglyc¬
eridemia (r = 0.28; P = 0.0001), and glucose intolerance
(r = 0.16; P = 0.02). Obesity was also associated with a
linear increase in total urinary Cortisol metabolite excre¬
tion (r = 0.19; P = 0.006), but did not predict plasma
Cortisol after dexamethasone or ACTH-(l-24) administra¬
tion. Central obesity, reflected in increased waist/hip ratio
(WHR), was associated with similar trends. In addition,
increased WHR predicted marginally lower plasma Cor¬
tisol after 0.25mg dexamethasone (r = -0.13; P = 0.06) and
disproportionately higher excretion of 5a- rather than 5/3-
reduced metabolites of Cortisol (r = —0.14; P = 0.05).
Obesity was not associated with altered ratios of Cortisol/
cortisone metabolites. Increased lean body mass, as judged
by urinary creatinine excretion (27), was also associated
with higher total urinary Cortisol metabolites (r = 0.23; P =
0.001). Neither obesity nor urinary creatinine was an in¬
dependent predictor of total urinary metabolite excretion
inmultiple regression analysis. Urinary creatinine was not
associated with plasma Cortisol concentration.
Men with a current or previous history of depression (n =
12) had greater peak plasma Cortisol concentrations after
ACTH-(l-24) [474.0 (sd, 1.1) vs. 428.7 (sd, 1.2) nmol/L; P =
0.03] and higher total urinary Cortisol metabolites [median,
22.4 (interquartile range, 16.3-48.2) vs. 17.8 (11.3-24.8)
mg/24 h; P = 0.04]. Men with manual occupations (class
IIIM—V; n = 134) had no difference in plasma Cortisol con¬
centrations, but excreted less total Cortisol metabolites than
menwith nonmanual occupations [class I—IIIN; n = 69; 15.9
(sd, 2.1) vs. 20.8 (sd, 1.8) mg/24 h; P = 0.008].
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Associations with birth weight
Table 1 shows relationships between birth weight and
Cortisol and its metabolites. A lower birth weight was asso¬
ciated with a greater rise in plasma Cortisol concentrations
after ACTH-(l-24) administration and a later peak time (Fig.
1), but no difference in plasma Cortisol after dexamethasone
administration. The inverse relationship between birth
weight and adrenal ACTH-(l-24) responsiveness remained
after exclusion of men with IGT and type 2 diabetes and/or
treated hypertension and was not confounded by obesity.
Differences in adrenocortical responses to ACTH-(l-24) in a
subgroup ofmenwith contrasting birth weight [>9.5 lb (4.31
kg) or s6.5 lb (2.92 kg); n = 12 in each group] were further
explored by measurement of other ACTH-dependent adre¬
nal steroids in plasma. Men with lower birth weight also had
higher levels of dehydroepiandrosterone [mean area under
curve: birth weight, S6.5 lb, 6.5 (sd, 2.2) nmol/L-h; >9.5 lb,
4.9 (sd, 1.5) nmol/L-h], 17a-hydroxyprogesterone [birth
weight, ^6.5 lb, 9.7 (sd, 1.3) nmol/L-h; >9.5 lb, 8.1 (sd, 1.3)
nmol/L-h], and progesterone [birth weight s6.5 lb, 3.6 (sd,
0.5) nmol/L-h; >9.5 lb, 3.1 (sd, 0.7) nmol/L-h], indicating that
no common biosynthetic defect, such as 21-hydroxylase de¬
ficiency, accounts for the difference in Cortisol response.
Total urinary Cortisol metabolite excretion was higher in
men with the lowest and highest birth weights (P = 0.03 for
quadratic trend). Although men with higher birth weight
were not more obese, they were taller and heavier as adults
(r = 0.23; P = 0.001) and excreted more creatinine in urine
(r = 0.20; P = 0.006), which could confound the relationship
with urinary glucocorticoid excretion. After adjustment for
urinary creatinine and obesity (either BMI orWHR), an inverse
linear relationship, rather than a quadratic trend, was evident,
such that low birth weight men excreted more urinary Cortisol
metabolites (r = -0.29; P = 0.04). Birth weight was not asso¬
ciated with Cortisol metabolite ratios (data not shown).
Associations with features of the metabolic syndrome
Table 2 shows relationships of plasma Cortisol and urinary
Cortisol metabolites to blood pressure, glucose tolerance, and
fasting plasma triglyceride concentrations after correction
for the potential confounding effects of obesity, depression,
social class, and urinary creatinine where appropriate.
Plasma Cortisol concentration at 0900 h after dexamethasone
treatment was not associated with cardiovascular risk fac¬
tors. However, the peak plasma Cortisol concentration after
ACTH-(l-24) was higher in men with higher blood pressure
and higher fasting plasma triglyceride concentrations and
tended to be higher in men with higher post-glucose plasma
glucose concentrations. Likewise, in a longitudinal analysis
of the Cortisol profiles, there were similar positive associa¬
tions between mean plasma Cortisol concentration and these
features, with orwithout adjustment for potential confound-
Time (minutes)
Fig. 1. Plasma Cortisol profiles during short Synacthen test accord¬
ing to birth weight. P = 0.03 from longitudinal analysis, interaction
of Cortisol response by birth weight with time. •, Birth weight of 6.5
lb (2.92 kg) or less; ▲, 7.5 lb (3.41 kg); T, 8.5 lb (3.86 kg); *, 9.5 lb (4.31
kg); •, >9.5 lb (4.31 kg).
TABLE 1. Relationships between birth weight and Cortisol and its metabolites








Post-dexamethasone , , ... Total urinary Cortisol Total urinary Cortisol
, ,. , Peak plasma Cortisol . . , , ... , ,. .plasma Cortisol / ■. r, \£,c motabolitos metabolites/creatinine
(nmol/LP nm0 (mg/24 h/ excretion (mg/mmol/
185.3 (88.7) 458.2 (1.2) 22.8 (1.7) 7.24(1.7)
208.2(92.9) 436.1(1.2) 15.4(2.2) 3.74(2.2)
202.0(94.9) 417.0(1.2) 17.3(2.2) 4.10(2.1)
210.2(98.2) 444.5(1.2) 14.1(1.9) 3.35(2.0)
189.3(80.2) 405.3(1.2) 23.6(1.7) 5.26 (1.7)




" Arithmetic mean (sd) for 0900 h plasma Cortisol after 0.25 mg dexamethasone.
6 Peak plasma Cortisol after 1 p.g ACTH-(l-24) calculated from individual maximums rather than mean data in Fig. 1. Geometric mean (sd).
c Unadjusted P value.
d P value adjusted for BMI, depression, and social class.
' Unadjusted P value for quadratic trend.
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Glucose tolerance Normal IGT/ 149 199.7 (91.0) 427.5 (1.2) 16.2 (2.0) 3.97 (1.97)
type 2
diabetes0
48 213.2(101.5) 442.3 (1.2) 19.7 (2.3) 5.00 (2.34)
P value NS 0.09d 0.05d NS NS
0.15 0.06
Blood pressure y 160 mm Hg 83 204.8(101.2) 415.7 (1.2) 17.1(1.8) 4.22 (1.78)
>160 mm Hg 120 200.5 (86.9) 442.2 (1.2) 17.0 (2.3) 4.17 (2.26)
or treatment
P value NS 0.02d NS NS NS
0.03°
Triglycerides y 1.4 mmol/L 102 196.8 (90.7) 418.0 (1.2) 15.6(2.1) 3.82 (2.09)
>1.4 mmol/L 101 207.8 (95.0) 445.3(1.2) 18.6 (2.0) 4.66 (1.54)
P value NS 0.02d 0.08d NS NS
0.04" 0.06°
Metabolic syndrome0 Absent 166 197.2 (90.5) 424.8 (1.2) 16.7 (2.0) 4.14(1.99)
Present 31 234.3 (104.9) 466.4 (1.2) 18.4 (2.5) 4.53 (2.49)
P value NS o.oH 0.007d NS NS
0.04° 0.006°
All 203 202.2 (92.8) 431.3 (1.2) 17.1 (2.1) 4.2 (7.8)
" Arithmetic mean (sd).
6 Geometric mean (sd).
c Defined in text.
d P value unadjusted.
° P value adjusted for BMI, social class, and depression.
ing factors. In men with all three features of the metabolic
syndrome [previously defined (28) as systolic blood pressure
>160 mm Hg or subject receiving antihypertensive therapy
(n = 120), the presence of impaired glucose tolerance or type
2 diabetes (n = 48), or fasting plasma triglyceride >1.4
mmol/L; n = 101], peak and mean plasma Cortisol concen¬
tration over time were significantly elevated. Total urinary
Cortisol metabolite excretion also tended to be greater in men
with these cardiovascular risk factors.
Predictors of the metabolic syndrome
Having examined individual features of the metabolic syn¬
drome, logistic regression modeling was then performed to
identify predictors of combined features of the metabolic
syndrome (as defined above). Potential variables included
age, social class, birth weight, WHR, BMI, plasma Cortisol
after dexamethasone, peak plasma Cortisol after ACTH-(1-
24), total urinary Cortisol metabolite excretion, and ratio of
5/3-/5a-reduced metabolites of Cortisol. The best fitting
model identified effects of BMI (P = 0.003), peak plasma
Cortisol after ACTH-(l-24) (P = 0.03), and birth weight (P =
0.02). The effect of birth weight was more significant when
peak plasma Cortisol was excluded (P = 0.008), and the effect
of peak plasma Cortisol was more significant when birth
weight was excluded (P = 0.02). The estimated odds ratios
for the metabolic syndrome are 1.18 (95% confidence inter¬
val, 1.06-1.32) for a unit increase in BMI, 1.55 (95% confi¬
dence interval, 1.09-2.21) for a 1-lb decrease in birth weight,
and 1.28 (95% confidence interval, 1.02-1.61) for a 50nmol/L
increase in peak Cortisol concentration. The effects of WHR
were similar to those of BMI.
Discussion
The hypothesis that Cortisol contributes to the pathogen¬
esis of essential hypertension and type 2 diabetes was re¬
jected bymany on the basis of small case-control studies with
very limited measurements of Cortisol secretion (29, 30).
More recently, a series of cross-sectional studies identified
associations between increased Cortisol levels and higher
blood pressure (1-4, 6), obesity (5, 8, 9), and lower birth
weight (16-18). The current report describes the most de¬
tailed assessment to date of the regulation of Cortisol secre¬
tion in a cross-sectional study ofmen inwhom the prevalence
of the metabolic syndrome and its antecedents, including
obesity and birth weight, have been carefully characterized.
The principal findings are that men with low birth weight
and features of the metabolic syndrome have enhanced re¬
sponsiveness of plasma Cortisol to ACTH-(l-24) and in¬
creased total urinary Cortisol metabolite excretion, but nor¬
mal plasma Cortisol after dexamethasone. Indeed, plasma
Cortisol after ACTH-(l-24) accounted for much of the effect
of birthweight on features of the metabolic syndrome. These
findings are consistent with the hypothesis that low birth
weight is associated with increased activity of the HPAA and
that this could contribute to the metabolic syndrome and the
attendant risk of cardiovascular disease.
The explanation for activation of the HPAA in men with
lower birth weight and features of the adult metabolic syn¬
drome remains unclear. Rats exposed to glucocorticoids in
utero have increased plasma glucocorticoid levels, which
have been associated with lower levels of glucocorticoid
receptors in brain and pituitary gland, which may impair
negative feedback control of CRH and ACTH secretion (14).
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If the same programming of glucocorticoid receptor expres¬
sion occurred in man, then suppression of plasma Cortisol by
dexamethasone would be expected to be impaired in men
with lower birth weight, but we found that it was preserved.
Indeed, as fasting plasma Cortisol was higher in low birth
weight men without dexamethasone (16, 17), but was not
different after dexamethasone administration, the incremen¬
tal effect of dexamethasone may be greater. However, dexa¬
methasone may not cross the blood-brain barrier adequately
at low doses in man (31), so this only tests the pituitary
component of the negative feedback loop. Alternatively, el¬
evated plasma Cortisol may result from enhanced drive to
CRH, ACTH, and Cortisol secretion from higher centers man¬
ifest as an increase in plasma Cortisol when stressed on first
sampling. Or increased Cortisol secretion could result from
increased adrenocortical sensitivity to ACTH. Our measure¬
ments of other ACTH-dependent steroids exclude variance
in Cortisol response due to subclinical 21-hydroxylase defi¬
ciency (32). Other corticosteroid biosynthetic defects that
have been proposed as being important in hypertension,
such as 11/3-hydroxylase deficiency, predict lower, rather
than higher, Cortisol responses. Finally, the pattern ofCortisol
response to Synacthen in low birth weight subjects with both
an increased peak and a slower decline suggests that they
may have impaired plasma clearance of Cortisol not revealed
by 24-h urinary Cortisol analysis.
Any of these possible mechanisms of altered Cortisol
secretion could be subject to programming by events in
early life. Alternatively, theremay be genetic determinants
underlying Cortisol secretion that also impact on fetal de¬
velopment. There are relationships between patterns of
Cortisol secretion and metabolism within families (33), and
increased Cortisol secretion has been shown to be inherited
together with higher blood pressure (4). As birth weight
is also at least in part inherited with higher blood pressure
(34), and as increased glucocorticoid exposure in utero can
lead to low birth weight (13), a genetic alteration in Cortisol
secretion could explain associations between birth weight
and subsequent hypertension without the need to invoke
programming.
By contrast with Cortisol measurements in low birth
weight men, our data show that obesity is associated with
lower plasma Cortisol after dexamethasone treatment and no
difference in responses to ACTH-(l-24) in the face of in¬
creased urinary Cortisol metabolite excretion, especially of
5a-reduced metabolites of Cortisol. The lower plasma Cortisol
may be explained by increased peripheral metabolism of
Cortisol by 5a-reductases (35). Indeed, increasing obesity and
its associated increase in lean body mass (reflected in higher
creatinine excretion) among high birth weight men con¬
founded the relationship between birth weight and urinary
Cortisol metabolite excretion. This confounding effect re¬
sulted in a U-shaped unadjusted relationship between birth
weight and Cortisol metabolites, as described previously (18).
Although obesity may amplify the metabolic syndrome and
its associationwith low birth weight (36), these data suggest
that primary changes in Cortisol in the lean insulin resistance
syndrome are not the same as those in primary obesity.
In conclusion, these data suggest that men with the cluster
of cardiovascular risk factors that includes low birth weight
and the adult metabolic syndrome have activation of the
HPAA. This may be a key mechanism to explain the rela¬
tionship between low birth weight and subsequent cardio¬
vascular disease and may offer novel therapeutic strategies
to reduce cardiovascular risk.
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Elevated Plasma Cortisol in Glucose-Intolerant Men:
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ABSTRACT
Recent evidence suggests that variations in Cortisol activitywithin
the physiological range contribute to associations between multiple
cardiovascular risk factors. Plasma Cortisol measurements during a
glucose tolerance test differ in men with hypertension, insulin resis¬
tance, and glucose intolerance, but it is unclear whether this reflects
altered responses of Cortisol to glucose, altered circadian rhythm, or
altered habituation to multiple sampling. We performed a single-
blind randomized cross-over study comparing 75 g oral glucose with
placebo in 39 fasted men (22 glucose intolerant and 17 controls) aged
68-77 yr. In all subjects, plasma Cortisol fell during the glucose tol¬
erance test. Subjects with glucose intolerance had significantly higher
plasma Cortisol following placebo (P = 0.001), suggesting an altered
circadian rhythm. Treatment with an oral glucose load blunted the
circadian fall in plasma Cortisol (P = 0.002), but this response was no
different in controls or glucose intolerant subjects. In addition, 0900 h
plasma Cortisol was higher in the first study phase in controls (P =
0.01) but not in glucose-intolerant subjects (P = 0.18), who showed a
lack of habituation to repeated plasma measurements. These data
support the hypothesis that alterations in central regulation of the
hypothalamic-pituitary-adrenal axis may be important in glucose
intolerance. (J Clin Endocrinol Metab 86: 1149-1153, 2001)
PATIENTS with high circulating Cortisol due to Cush-ing's syndrome develop glucose intolerance, insulin
resistance, and other risk factors for cardiovascular dis¬
ease including hypertension and dyslipidemia. There is
now increasing evidence that physiological variations in
Cortisol action could also contribute to development of
these risk factors. Plasma Cortisol and the Cortisol response
to the administration of corticotrophin are increased in
men and women with type 2 diabetes mellitus (1, 2). Fur¬
thermore, differences in activity of the hypothalamic-
pituitary-adrenal (HPA) axis have been demonstrated in
subjects with cardiovascular risk factors. These include
elevated morning plasma Cortisol (3-7), increased excre¬
tion of Cortisol metabolites (7, 8), abnormalities of diurnal
Cortisol secretion (9), and impaired peripheral inactivation
of Cortisol (7).
The mechanisms leading to variations in plasma Cortisol
action in subjects with glucose intolerance are unknown.
Differences in glucose and/or insulin concentrations may be
important: for example, insulin may modulate adrenal ste¬
roidogenesis by inhibiting 17,20-lyase, thereby favoring cor-
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tisol synthesis in preference to dehydroepiandrosterone and
androstenedione (10). Insulin may also affect Cortisol me¬
tabolism by decreasing the activity of 11 /3-hydroxysteroid
dehydrogenase type 1, which acts primarily as a reductase
mediating conversion of inactive cortisone to active Cortisol
(11). Such effects may be important determinants of acute
changes in plasma Cortisol, for example during a glucose
tolerance test. It is known that plasma Cortisol levels fall
during a glucose tolerance test (12, 13) and that this effect
may differ in subjects with cardiovascular risk factors (14,
15). However, it is not known whether this reflects the cir¬
cadian fall in circulating plasma Cortisol and whether inges¬
tion of glucose affects the response. We therefore performed
a placebo-controlled study of the effect of oral glucose on
circulating plasma Cortisol. To further explore the associa¬
tions between Cortisol and glucose tolerance,we studied both




We studied 40 men, aged 68 to 77 yr, selected from a well-charac¬
terized cohort from Hertfordshire who have participated in previous
investigations of the relationships between early life events and subse¬
quent Type 2 diabetes (16). The subjects were selected by their previous
glucose tolerance data from 1991 with the aim of studying equal num¬
bers with glucose intolerance and normal controls. None had a history
of endocrine disease or had received systemic or topical glucocorticoid
treatmentwithin the previous 6 months. Ethical approval was obtained
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from East and North Hertfordshire Local Research Ethics Committee
and written informed consent was obtained.
Clinical protocol
Following an overnight fast, subjects attended a local clinic at 0830 h
for oral glucose tolerance tests. A 21-g butterfly cannula was inserted in
an antecubital vein and after 30-min rest, a baseline blood sample was
obtained. Subjects then drank either 75 g oral glucose (as 389 ml Tra¬
ditional Lucozade Sparkling Glucose Drink) or placebo (identical in
appearance and taste to Lucozade but containing no glucose, supplied
by SmithKline Beecham). They returned a week later for a repeat test
with the alternative solution in a single-blind cross-over design. Twenty-
nine subjects (17 glucose intolerant, 12 controls) received glucose in the
first phase, whereas 10 subjects (5 glucose intolerant, 5 controls) received
placebo first. Venous blood was sampled from the cannula at 30,60,90,
and 120 min following the glucose or placebo load. Placebo and glucose
phases were separated by at least 1 week.
Laboratory methods
Blood samples were centrifuged, processed immediately and stored
at —80 C for subsequent hormone analysis. RIAs were used to measure
plasma Cortisol using Guildhay antisera (17) and corticosteroid-binding
globulin (CBG) (Medgenics Diagnostics, Fleurus, Belgium). Plasma glu¬
cose was measured by the hexokinase method.
Statistical methods
As the distributions of Cortisol measurements were skewed, log,,
transformed variables were used in all analyses. Independent two-
sample t tests were used to compare Cortisol concentrations for control
compared with glucose intolerant subjects. ANOVA for repeated mea¬
sures was used to analyze the plasma Cortisol measurements during the
glucose tolerance test.
Results
One subject completed only one phase of the study and
was therefore excluded from analysis. Using plasma glucose
measurements following the 75 g oral glucose load, we de¬
fined 22 subjects as glucose intolerant [either impaired glu¬
cose tolerance (2 h plasma glucose 7.8 to 11.0 mmol/L) or
Type 2 diabetes (2 h plasma glucose s 11.1 mmol/L)], and
17 subjects as normal controls.
Differences in plasma Cortisol between controls and glucose
intolerant subjects without glucose
In all subjects, plasma Cortisol concentrations declined .
over the 120 min of the test following placebo. Glucose in¬
tolerant subjects had significantly higher Cortisol concentra¬
tions following placebo than controls (P = 0.001) (Fig. 1). This
difference was most marked at baseline and during the first
90 min of the test but was no longer present at 120 min. The
differences in Cortisol between glucose intolerant subjects
and controls were not accounted for by variations in CBG
(data not shown).
Effect of treatment with glucose on plasma Cortisol
Figure 2 shows that treatment with an oral glucose load
blunted the circadian fall in plasma Cortisol in both controls
and glucose intolerant subjects (P = 0.002). There was no
significant difference in the effect of the glucose load
in controls compared with those with glucose intolerance
(controls P = 0.02, glucose intolerant P = 0.04, interaction
P = 0.50).
Order of test: habituation to venepuncture
0900 h plasma Cortisol concentrations were significantly
higher in the first phase of the study than in the second phase
in controls (P = 0.01) (Fig. 3). However, in glucose intolerant
subjects, 0900 h plasma Cortisol concentrations in the two-
study phases were not different (P = 0.18), as this measure¬
ment did not fall in the second study phase.
450 ->
Fig. 1. Differences in plasma Cortisol
between controls and glucose intolerant
subjects following placebo. P = 0.001
from ANOVA for repeated measures for
difference in plasma Cortisol following
placebo between glucose intolerant






































Fig. 2. Effect ofglucose on plasma Cortisol. plasma Cortisol following placebo. -O- plasma Cortisol following glucose. P = 0.002 from ANOVA
for repeated measures for effect ofglucose in raising plasma Cortisol in all subjects. No significant difference in effect ofglucose between controls
and glucose intolerant subjects (P = 0.02 for controls, P = 0.04 for glucose intolerant subjects).
Fig. 3. Effect oforder on 0900 h plasma
Cortisol effect of order of study phase
(first phase, black columns, second
phase, white columns) on 0900 h plasma
Cortisol in glucose intolerant and con¬
trol subjects. P = 0.01 for effect oforder
in control subjects; no significant order
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Effect of treatment with glucose and order of test on plasma
glucose and insulin concentrations
Both plasma glucose and insulin concentrations were higher
after treatmentwith glucose than placebo (P < 0.001) and were
significantly higher in glucose intolerant subjects than controls.
In contrast to the plasma Cortisol concentrations, plasma glu¬
cose and insulin concentrations were no different in the two
study phases in either glucose intolerant subjects or controls.
Discussion
We have shown that treatment with an oral glucose load
blunts the normal circadian fall in plasma Cortisol in subjects
with glucose intolerance and in normoglycaemic controls.
However, subjects with glucose intolerance had higher Cor¬
tisol concentrations following placebo, suggesting that their
normal diurnal fall in plasma Cortisol differed from controls.
We also found that baseline plasma Cortisol concentrations
were higher during the first phase of the study in control
subjects suggesting a stress response associated with the
novelty of first clinic attendance. In addition, subjects with
glucose intolerance had high plasma Cortisol concentrations
at the second clinic attendance suggesting a lack of habitu¬
ation to repeated measurement of plasma Cortisol.
Our findings accord with early reports showing that
plasma Cortisol concentrations fall during an oral glucose
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tolerance test (12,13). It was not known whether this reflects
the fall in circadian fall in plasma Cortisol or whether glucose
ingestion affects the response. We performed our studies in
the morning when any alterations in circadian rhythm
should be most clearly demonstrated. Indeed, we found
higher plasma Cortisol in subjects with glucose intolerance
than controls during the first 90 min of the placebo phase of
the study. Altered diurnal rhythms of salivary Cortisol in
subjects with glucose intolerance have been reported (9), and
our finding is consistent with the previously reported asso¬
ciations between 0900 h plasma Cortisol and glucose intol¬
erance (5, 6). However, the difference between subjects with
glucose intolerance and controls was no longer apparent at
120 min. This finding could explain why associations be¬
tween Cortisol measurements and glucose tolerance are still
evident at 120 min following glucose in some reports (14) but
to a lesser extent than the fasting measurements in others
(15). The current study, therefore, implies that where two
measurements of plasma Cortisol are separated by 2 h, during
which Cortisol will fall due to diurnal variation, the timing of
measurements is critical.
Despite the differences in circadian fall of plasma Cortisol,
the effect of glucose ingestion was to raise plasma Cortisol in
both normal and glucose intolerant subjects. Plasma and
salivary Cortisol concentrations rise following a meal (9),
particularly if the meal is of high protein content (18), as
protein ingestion stimulates pituitary ACTH secretion (19).
Although it has previously been suggested that carbohydrate
ingestion has little effect on the hypothalamic-pituitary-
adrenal (HPA) axis (20), we have now demonstrated that an
oral glucose load raises plasma Cortisol. It remains unknown
whether this is a consequence of the glucose load itself, or
whether the associated insulin release affects Cortisol me¬
tabolism (10, 11). Insulin may also act centrally on the HPA
axis regulating drive, although results of studies to date are
conflicting, either showing a decreased Cortisol response to
CRH following insulin infusion (21), or increased adreno-
corticotrophic hormone (ACTH) secretion following supra-
physiological hyperinsulinaemia (22). Likewise, the changes
in Cortisol induced by the glucose load could influence sub¬
sequent glucose and insulin metabolism. Manipulation of
Cortisol levels within the physiological range alters insulin
sensitivity (23). And although subject to the limitations of
measurement of hepatic glucose output in man, Cortisol has
been shown to impair insulin-dependent glucose uptake in
the periphery and enhance gluconeogenesis in the liver (24,
25). However, as the effect of treatmentwith the glucose load
did not differ between glucose intolerant subjects and con¬
trols, it would appear less likely that the hyperglycaemia or
changes in insulin concentrations associated with glucose
intolerance influenced the fall in Cortisol concentrations dur¬
ing the test.
One alternative hypothesis to explain the elevated plasma
Cortisol during the glucose tolerance test is a response to
stress. We attempted to reduce any effect of stress by con¬
ducting the study in familiar surroundings, with staff pre¬
viously known to the subjects. Yet we have found that fasting
plasma Cortisol measured at the first phase attendance, and
so arguably the most stressful visit, was significantly higher
than that at the second phase in control subjects. Elevated
plasma and salivary Cortisol concentrations are observed in
situations of increased perceived stress (9), and the stress of
venepuncture is known to raise plasma Cortisol (26). The
effect of psychosocial stress on raising Cortisol has also been
reported to be greater after a glucose load (27).
Most interestingly, we found that glucose intolerant sub¬
jects also had high baseline plasma Cortisol concentrations in
the second phase of the study, indicating a lack of habituation
to repeated stress. A similar lack of habituation of blood
pressure and heart rate responses to repeated restraint stress
is seen in spontaneously hypertensive rats compared with
normal controls (28). Subjects with glucose intolerance have
evidence of increased activation of the HPA axis (29), and so
elevated plasma Cortisol from stress of venous sampling
would be consistent with enhanced drive to CRH, ACTH,
and Cortisol secretion from higher centers in these subjects.
Lack of habituation to stress and increased activation of the
HPA axis in subjects with glucose intolerancewould support
the hypothesis that chronic stress in man leads to develop¬
ment of cardiovascular risk factors. Such variations in HPA
axis activity may also contribute to the observed relation¬
ships between psychosocial stress and subsequent cardio¬
vascular disease (30).
In conclusion, this study supports the hypothesis that al¬
terations in central regulation of the HPA axis may be an
important mechanism underlying the development of glu¬
cose intolerance and subsequent cardiovascular disease.
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tions did have a significantly longer duration of diabetes (14.2
vs 6.4 years; PC.001).
Of the 17 patients with CHF, 4 patients had a documented
New York Heart Association functional classification (class 11:
n = 2; class III: n=2). Of the 8 patients with renal dysfunction,
the mean serum creatinine was 1.8 mg/dL (159.1 pmol/L) and
mean blood urea nitrogen was 27 mg/dL (9.639 mmol/L). Only
2 patients had documentation in the medical record that pro¬
viders considered metformin contraindications.
Comment. In our review, almost one quarter of patients
with a prescription for metformin had 1 or more absolute
contraindications. Several recent studies in Europe have
documented similar rates of inappropriate metformin pre¬
scribing.2,5'6
Adverse event reports suggest the incidence of metformin-
associated lactic acidosis is between 1 in 10000 to 1 in 100000
patient-years.7 In the first 14months after its release in theUnited
States, the FDA received 47 confirmed cases of lactic acidosis
associated with metformin, with a 42% mortality rate. More
than 90% of patients had relative or absolute contraindica¬
tions to metformin.3
Because our assessment of the prevalence of contraindica¬
tions to metformin use relies on a chart review, it may under¬
estimate the frequency of contraindications and it is difficult
to determine whether clinicians are aware they are prescrib¬
ing metformin against a black-box warning. Nonetheless, our
results suggest that metformin frequently may be inappropri¬
ately prescribed despite black-box contraindications. Docu¬
mentation of this potential risk in the medical record is lim¬
ited and health care providers should consider improving the
documentation of the risk of lactic acidosis and provide ap¬
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Skeletal Muscle Glucocorticoid Receptor Density
and Insulin Resistance
To the Editor: In Cushing syndrome, elevated plasma Corti¬
sol levels cause insulin resistance, hyperglycemia, hyperten¬
sion, and dyslipidemia. In patients without Cushing syn¬
drome, these cardiovascular risk factors are associated with more
subtle elevations in plasma Cortisol concentrations1 and en¬
hanced tissue responsiveness to glucocorticoids.2 We ex¬
plored the possibility that insulin resistance in patients with¬
out Cushing syndrome involves dysregulation of glucocorticoid
receptor (GR) expression in muscle.
Methods. We obtained biopsies of vastus lateralis skeletal
muscle under local anesthesia from 23 menwithout fasting hy¬
perglycemia participating in the the Uppsala Longitudinal Study
of Adult Men.3 As previously described, participants under¬
went a 75-g oral glucose tolerance test, euglycemic hyperin-
sulinemic clamp, and ambulatory blood pressure recording.
Height, weight, and waist and hip circumferences were mea¬
sured. Glucocorticoid receptor messenger RNA (mRNA) lev¬
els were measured in muscle total RNA using a quantitative
reverse transcriptase (RT) polymerase chain reaction (PCR) as¬
say with synthetic RNA competitors for GR mRNA and 18S
mRNA as internal control. Both competitors contained 83 base
pair deletions to distinguish PCR products derived from en¬
dogenous and synthetic RNAs.1 The interassay coefficient of
variation was 12%. Stata v5.0 (Stata Corp, College Station, Tex)
was used for all analyses.
Results. Results are shown in the Table. After adjusting for
body mass index (BMI), higher levels of skeletal muscle GR
mRNA were associated with hypertension, higher insulin lev¬
els after a glucose load, and insulin resistance in a euglycemic
hyperinsulinemic clamp. Muscle GR mRNA was not associ¬
ated with plasma lipids, glucose, or BMI alone.
Comment. These data show that men with insulin resis¬
tance and hypertension have increased GR mRNA levels
and, by inference, increased numbers of GRs in skeletal
muscle. Glucocorticoid receptors mediate diverse effects on
insulin sensitivity (in liver, adipose tissue, and skeletal
muscle) and blood pressure (in kidney, blood vessels, and
brain). Increased numbers of receptors in these sites could
contribute to the association between features of the insulin
resistance syndrome, and explain enhanced responsiveness
to glucocorticoids.2 Glucocorticoid receptors also contribute
to negative feedback regulation of the hypothalamic-
pituitary-adrenal axis. If receptor expression were similarly
increased in central feedback sites, it might be expected that
lower circulating Cortisol levels would compensate for
peripheral hypersensitivity.
(Reprinted) JAMA, May 15, 2002—Vol 287, No. 19 2505
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Table. Associations of GR mRNA Levels With Cardiovascular Risk Factors*
Risk Factor Mean (SD) Partial Correlation Coefficient! P Value P Value Adjusted for BMI
Fasting plasma glucose, mg/dL4:§ 99.1 (16.2) -.05 .80 .58
Fasting plasma insulin, plU/mLf:§ 1.5 (1.2) 0.41 .06 .09
Insulin 1 h postglucose, plU/mLf§ 10.7(6,8) .53 .01 .02
Insulin sensitivity as M/l (mg-min",-kg~,[mU/1]-,)|| 5.2 (2.0) -.36 .10 .05
24-Hour systolic blood pressure, mm HgH 142 NA .05 .05
Triglycerides, mg/dLf:§ 106.2(79.6) 0.26 .24 .30
BMI, kg/m2 26.3 (3.3) 0.16 .46 Reference
Waist-hip ratio 0.95 (0.05) 0.14 .53 .91
*GR indicates glucocorticoid receptor; mRNA, messenger RNA; BMI, body mass index; and NA, not applicable.
|AII associations with GRs are adjusted for 18s mRNA.
tMedian and interquartile range are presented, but variables were log9 transformed for statistical comparisons.
§To convert mean (SD) glucose values to mM, multiply by 0.0555; to convert insulin values to pM, multiply by 6.945; to convert triglyceride values to mM, multiply by 0.0113.
||M/I = glucose infusion rate (g-mirr1) between 60 and 120 minutes of the euglycemic clamp divided by body weight (kg) and mean insulin level (mU-1-1).
^Associations with 24-hourmean ambulatory blood pressure were examined by censored normal regression to discount the effect of antihypertensive therapy. The 6 men receiving
antihypertensive therapy and the 3 with untreated values above 150 mm Hg were allocated to the top tertile; median is presented and no partial correlation coefficient can be
calculated.
However, dysregulation ofGR expression appears to be tissue-
specific. In an animal model of insulin resistance, dysregula¬
tion ofGR expression was associatedwith increased GR mRNA
in the liver but decreased GR mRNA in central negative feed¬
back sites.5 Further understanding of tissue-specific varia¬
tions in GR expression and function may offer fundamental in¬
sights into the pathophysiology of insulin resistance and its
association with hypertension.
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